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ABSTRACT
K-Agonists are no longer investigated for the treatment of pain, however there has recently been 
significant interest in the role of K-opioid agonists in cocaine abuse, alcoholism and the 
regulation of food intake. There is thus an interest in K-selective antagonist compounds both as 
pharmacological tools, to probe the function of the K-opioid receptor, and as potential 
therapeutic agents.
The K-selective antagonist presently in use is norBNI. The pharmacological profile of this 
bivalent ligand is however complicated due to poor solubility, slow onset and extremely long 
duration of action. Studies have shown that the second pharmacophore is not essential, but 
rather, it is the presence of the second basic nitrogen that is crucial in retaining good k -  
antagonist selectivity. It was believed that lower molecular weight, less lipophilic ligands would 
show an improved pharmacological profile. The synthesis of a variety of 5’-amino- and 
amidinosubstituted naltrindole analogues has afforded compounds displaying good K-selectivity 
and efficacy. By further probing the optimum distance between the two basic centres, as well 
as the level of basicity required, we sought to develop ligands with increased selectivity. We 
therefore synthesised further series of 5’-amido, amidino, imidazoline and urea substituted 
compounds for pharmacological evaluation. The highly basic amidino and imidazoline 
compounds displayed good affinity for the K-receptor. The affinity was somewhat lower for the 
non-basic amide compounds. The urea derivatives were slightly S-selective, a finding attributed 
to an interaction between a basic residue in the 5-receptor and the C=0 of the urea moiety. The 
most highly K-selective compound reported thus far is the 5’-guanidino-substituted, GNTI. 
Attempting to increase K-selectivity, we prepared substituted analogues of GNTI in the hope that 
the increased bulk would decrease affinity for the p- and 5- receptors.
In order to investigate the binding of the compounds to the K-opioid receptor, they were docked 
into a SYBYL generated model. Limited selectivity studies were conducted by docking 
compounds into the p-, 5- and K-receptor models and comparing the differences. By 
investigating the interactions between the receptor and the ligands, we were able to explain 
some of the trends observed in pharmacological assays such as the high affinity of the amidines 
and the low affinity of the urea derivatives. In addition, we were able to propose further 
synthetic targets that may display good K-selectivity and/or affinity.
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BOC f-butoxycarbonyl
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°C degrees Celsius
5 chemical shift (NMR spectra)
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h hour
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J coupling constant (NMR spectra)
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Rf retention factor (chromatography)
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The opioid compounds prepared in this thesis are named using 17-cyclopropylmethyl-6,7- 
didehydro-^Sa-epoxy-S.M-dihydroxyindoloP'.S'ie,?] morphinan as a base.
Agonist -  a substance that interacts with a receptor, causing a physiological response. 
Antagonist -  a substance that blocks the action of an agonist by binding to the receptor. 
Affinity -  the binding power of a compound.
Efficacy -  the degree of activation of the receptor.
Pharmacophore -  the core structure of a pharmacologically active series of compounds
Salt bridge -  electrostatic interaction formed between a negatively charged species and a 
positively charged species
Hydrogen Bonds -  dipole-dipole interactions between a non-bonding electron pair of a
heteroatom (donor) and an electron deficient hydrogen atom (acceptor).
Hydrophobic Bonds -  occur when non-polar sections of molecules are forced together by a 
lack of water solubility thus excluding water molecules and lowering the 




The analgesic properties of morphine (1) have been exploited since time immemorial. The 
adverse effects on the respiratory system and gastrointestinal tract, along with the addictive 
potential of the drug are, however, highly undesirable.1 Morphine was first isolated from the 
poppy, Papaver somniferum, in 1803 by the German pharmacist Serturner. The chemical 
structure was however only determined in the 1920’s by Gulland and Robinson,2 with the total 
synthesis following in 1952.3
'OHHO
Opioids such as morphine are known to interact with receptors in the central nervous system 
and periphery, causing analgesia.1 The existence of distinct types of opioid receptors was first 
proposed by Martin in 1967.4 Since then, a large amount of evidence supporting this theory 
has been reported5 and at least three receptor types (p, 8 and k )  have now been sequenced 
and cloned.6 Each of these three opioid receptors is coupled to a G-protein and consists of an 
extracellular N-terminal, seven transmembrane domains and an intracellular C-terminal portion 
(Fig. 1)6. The peptide sequence of the intracellular and transmembrane portions of the three 
receptor types is highly conserved,7 whereas the extracellular region varies significantly from 








Fig. 1 The seven transmembrane domains of an opioid receptor.
2Although each of the three receptors is able to mediate analgesia, additional pharmacological 
responses exist which are specific for the receptor types (Table 1.)
p K 8
Analgesia Analgesia Analgesia




Table 1. Pharmacological effects mediated by different opioid receptor types.
1.2 ENDOGENOUS LIGANDS
Peptidic substances displaying morphine like properties were isolated from brain tissue by 
various groups in the mid 1970’s.8 The active material was termed enkephalin by Hughes, et 
al.9 Enkephalin isolated from pig brain was found to consist of two pentapeptides, Tyr-Gly-Gly- 
Phe-Met(OH) and Tyr-Gly-Gly-Phe-Leu(OH) in a ratio of approximately 4:1. These two 
peptides differ only in their C-terminal amino acid and are generally referred to as methionine- 
enkephalin (Mef-enkephalin) and leucine-enkephalin (Leu-enkephalin).
In functional assays, these two enkephalins display good efficacy, with /Wef-enkephalin showing 
greater activity than morphine. In vivo, however, the endogenous ligands are less potent than 
morphine and have a shorter duration of action.10 This is due to the rapid deactivation of 
enkephalins by enzymatic cleavage of the Tyr-Gly and Gly-Phe bonds. Enzymes that 
preferentially act on enkephalins are localised in the vicinity of opioid receptors,11 possibly 
exerting physiological control over endogenous opioid peptide activity.
It was hoped that the discovery of endogenous peptide ligands would lead to a non-addicting 
analgesic, however, dependence upon these compounds has been shown.12
Various Met- and Leu-enkephalin based peptides displaying opioid activity have been isolated 
from the adrenal medulla. The pituitary gland has also yielded various opioid peptides, many of 
which are derived from p-lipotropin, a relatively large peptide which itself displays no opioid 
properties.14 It is notable that of all the p-lipotropin fragments, only those containing amino 
acids 61-65 (analogous to Mef-enkephalin) show opioid like effects.15 Dynorphin, a peptide 
derived from prodynorphin, has also been isolated from the pituitary gland.16
3Although endogenous peptide ligands are usually non-selective, certain inherent selectivities 
have been noted.17 p-Endorphin interacts mainly with p- and 5- receptors. Leu- and Met- 
enkephalin preferentially act on 5-receptors, while dynorphin displays a certain degree of k -  
selectivity.
Synthetically, exchanging one or more of the naturally occurring (L)-amino acids for the less 
common (D)-isomer produces peptide ligands with greater resistance to enzymatic cleavage. 
Exchanging one of the amino acids in the sequence for an alternative amino acid may also 
increase this resistance13 (see compounds 12-14, section 1.3). A good example of this is the 
synthetic peptide ligand, DAMGO (12, section 1.3), in which Gly2 of enkephalin has been 
exchanged for D-Ala2, Phe4 has been exchanged for MePhe4 and Gly-ol5 replaces the terminal 
Met5 or Leu5 residue.
1.3 AGONISTS
Opioid agonists elicit analgesia by acting within the central nervous system. The primary areas 
of action are those concerned with the perception of pain and respiratory control. In contrast to 
anaesthetics therefore, opioid analgesics cause no loss of consciousness.
Although clinically the most beneficial property of morphine is its ability to relieve severe pain, 
undesirable side effects such as respiratory depression, altered mood, physical dependence, 
constipation and vomiting are experienced.18,19 The naturally occurring opioid codeine (2), 
which has lower potency but is also less addictive,1 is found in many commercially available 
pharmaceutical products. Heroin (3), an acylated derivative of morphine, was synthesized in an 
attempt to find a compound possessing the analgesic properties of morphine without the 
undesirable side effects. Although heroin is a marginally better analgesic than morphine, it has 




The search for analgesics devoid of addictive properties lead to the development of various
totally synthetic compounds, originally focussing on four main classes,19 namely; 4-
phenylpiperidines [eg. pethidine (4)], diphenylpropylamines [eg. methadone (5)], morphinans
4[eg. levorphanol (6)], and 6,7-benzomorphans [eg. metazocine (7)]. The majority of A/-methyl 




Two semi-synthetic compounds from the orvinol series, etorphine (8) and buprenorphine (9), 
have found wide applicability in animal20 and human21 use respectively. While etorphine 
displays high agonist potency, particularly in animals, buprenorphine is a p-partial agonist/ic,8- 
antagonist. The key step in the synthesis of these compounds is a Diels-Alder reaction 
between methyl vinyl ketone and the naturally occuring epoxymorphinan, thebaine (10).
8 9
510
Since the discovery of endogenous ligands and distinct receptor types, a challenge has been to 
synthesise not only compounds which show selectivity due to relative efficacy (eg. 
buprenorphine, 9), but also agonists that show p-, 5- and K-selectivity in binding. Such ligands 
would allow the pharmacological roles of the individual receptors to be determined. The 
synthesis of selective radiolabelled ligands would provide further insight into receptor-ligand 
interactions.
The original p-agonist, against which other compounds were measured, was morphine. 
Although morphine did not show selectivity in binding assays, p effects dominated in vivo 
assays. In the 1960’s, fentanyl (11 )22, a p-agonist showing short duration of action and almost 




The endogenous peptide ligands, endomorphin-1 and -2 also show p-selectivity.17 The p- 
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Most 5-selective agonists are derived from the endogenous peptide ligands Met- and Leu- 
enkephalin, which act predominantly with 8-receptors. Incorporation of unnatural D-amino acids 
in the peptide sequence offers greater resistance to enzymatic hydrolysis. DADLE (13, D-Ala-
6D-Leu enkephalin), and more recently DPDPE (14, D-Pen-D-Pen enkephalin) have been used 
as standard 5-selective agonists in binding assays.24 It was only in the 1990’s that (±)BW 373 
U86 (15), the first non-peptide 8-agonist was discovered 25 The racemic compound has since 
been resolved and modified to give the methyl ether, (+)SNC 80 (16),26 which displays high 






The first K-selective agonist to be developed was the non-peptidic, arylacetamide ligand 
U50488 (17).27 Subsequent modification of this compound has lead to other K-selective 
agonists, including U69 593 (18) and C1 977 (19).7 Although most K-selective agonists belong 
to the arylacetamide class, agonist properties have also been reported for various














In the early 1940’s it was discovered that the effects of morphine in dogs (drowsiness, 
uncoordination and vomiting), could be reversed by treatment with A/-allylnorcodeine (22) or N- 
allylnormorphine (23, nalorphine).30 By administering nalorphine prior to morphine, the 
respiratory depression and analgesic effects usually induced by morphine could not be 
detected. Nalorphine was hence antagonising the effects of morphine and could therefore be 
used in the treatment of morphine overdose and resultant respiratory depression. Reports later 
emerged, however, in which nalorphine displayed analgesic properties,31 which were later 
attributed to an agonist response at the K-opioid receptor.
OH OHHO
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A compound that displays antagonist properties will cause a shift to the right in the dose- 
response curve of a standard agonist. If compounds are competitive antagonists, interacting 
reversibly with the receptor, a parallel shift will be seen. Selective opioid antagonists are 
primarily used as pharmacological tools to gain a better understanding of the interaction of 
endogenous opioid peptides and newly discovered agonists with the various receptor types.
The first pure opioid antagonist to be discovered was naloxone (24). Apart from its usefulness 
as a pharmacological tool, naloxone is now used in the treatment of opioid induced respiratory 
depression as well as CNS injuries, and the regulation of blood pressure in various forms of 
shock.32 Naltrexone (25), the A/-cyclopropylmethyl analogue of (24) is a pure opioid antagonist
8which displays higher oral activity and longer duration of action than (24).33 Naltrexone has 
proved useful in the treatment of opioid dependence and alcoholism.
Both naloxone (24) and naltrexone (25) are competitive antagonists at p-, k- and 6-receptors, 
although p-selectivity has been shown at low dose concentrations in vivo.
If the compounds are non-competitive antagonists and form an irreversible interaction/bond with 
the receptor, the dose-response curve will be shifted to the right and down (ie. a lower 
maximum response will be achieved.)
Irreversible antagonists are useful in the assessment of agonist efficacy since they immobilize 
the receptor reserve in a preparation, hence increasing the efficacy demand on ligands to 
produce a response.34 The apparent efficacy of the ligand is therefore reduced and less than 
maximal response is observed. The efficacy of the ligand is directly related to the concentration 
of irreversible antagonist required to produce such an effect. Selective non-competitive ligands 
have proved particularly valuable since they permit complete knockout of one particular 
receptor, allowing the role of each of the individual receptor types to be more easily determined.
1.4.1 p-SELECTIVE ANTAGONISTS
The first non-peptidic, competitive, pure opioid antagonist to show p-selectivity in vitro and in 
vivo, was cyprodime (26).35 Although (26) displays a high degree of p-selectivity, it shows lower 
p-affinity and lower antagonist potency than naloxone (24).
HO O O
24 R = ally!
25 R = cyclopropylmethyl
26
9In the late 1970’s it was shown that A/-substituted 4-phenylpiperidines displayed non-selective 
antagonist activity at opioid receptors.36 It was not, however, until much later that ^-selectivity 
was shown for a compound of this type. Since A/-substitution did not influence the antagonist 
nature of the compounds, various changes were made to this region of the molecule, in the 
hope of increasing ^-selectivity. The most selective compound thus far, which employs a 
cinnamyl group as the N-substituent, has been disclosed by Thomas et. al. (27).37
p-CNA (28), a non-competitive opioid antagonist, binds irreversibly to all three opioid receptor 
types via the alkylating function at C-6.38 p-FNA (29) is a p-selective, irreversible opioid 
antagonist,39 based on the structure of p-CNA. It was thought that replacing the nitrogen 
mustard with a less reactive Michael acceptor, such as a fumarate group, would confer greater 
selectivity during covalent bond formation. Although p-FNA showed good selectivity during 
both in vivo and in vitro assays, agonist properties were initially displayed, after which the 
antagonist properties became dominant.39,40 The agonist properties were attributed to an 
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Lewis et a i, developed the compound C-CAM (30), a p-selective antagonist showing long 
duration of action.41 This compound is particularly noteworthy since it displays only antagonist 
properties without initial agonist effects.42 Initially, it was thought that the cinnamoylamino 
substituent served as a Michael acceptor for nucleophilic addition 43 However, it has since 
been shown that no covalent bond is formed and the interaction is hence pseudo-irreversible.44 
The observed binding can be explained in terms of a strong lipophilic interaction. The apparent 
anomaly which exists, in that C-CAM is highly p-selective in behavioural assays but only 
moderately selective in binding assays, can be explained by C-CAM binding reversibly to all 
three receptor types, while only the interaction with p-receptors is wash-resistant.44 This is an 
example of selectivity amplification. M-CAM (31 ),45 the methyl analogue of C-CAM has since 





30 (R = Cl)
31 (R = CH3)
Following on from the work on C-CAM, Derrick et at. have now reported 3-deoxy C-CAM 46 
This compound is noteworthy in that it only displays reversible high affinity, p-antagonism. Why 
the removal of a phenolic substituent should result in a loss of irreversibility, but not affinity or 
selectivity, however, remains to be determined.
1.4.2 8-SELECTIVE ANTAGONISTS
Reasonable success has been achieved in obtaining 8-selective competitive opioid antagonists 
through the modification of endogenous peptide ligands 47 Two peptide based 8-antagonists 
which show good selectivity are H-Tyr-Tic-Phe-Phe-OH (TIPP) and H-Tyr-Tic-Phe-OH (TIP)48 
where Tic represents a 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid residue. Currently, the 
dipeptide DMT-Tic (32) shows the highest selectivity and affinity of the 8-selective peptide 
antagonists,49 and has been reported to be active after both central and peripheral 
administration.
The first 5-selective non-peptide competitive antagonist was naltrindole (33). This compound 
was designed by Portoghese et al.,50 and was based on the “message-address” concept, in 
which it was postulated that there are two recognition subsites. Interaction at the “message” 
subsite relates to opioid activity, while interaction at the “address” subsite controls selectivity.51 
The naltrexone pharmacophore provided the message portion of the molecule (opioid 
antagonist activity), while the indolic phenyl group, mimicking a key element in Phe4 of Leu- 
enkephalin, conferred 8-selectivity.52 The address portion of the molecule was held in the 
correct orientation with respect to the message portion by the pyrrole spacer. Administration of 
naltrindole decreases physical dependence in patients who receive morphine regularly. 
Naltrindole was also found to exhibit immunosuppressant properties in rat models, without the 
cytotoxic effects experienced with cyclosporin.53 Several ligands closely related to naltrindole 
have since been synthesized and display good 8-selectivity. Substitution at the 7'-position, for 
example with a bromine, hydroxyl, or benzyloxy-group has been particularly well tolerated; 




More recently, 8-selective compounds, incorporating only the essential portions of the 
naltrindole structure, have been prepared (34).55 These indolo- and
benzofurooctahydroisoquinoline compounds are generally more selective but less potent than 
naltrindole.
FIT (35J56 and SUPERFIT (36)57 were two of the earliest 8-selective irreversible antagonists 
discovered. Both of these ligands however displayed partial agonist properties during in vivo 
assays.
By designing an irreversible antagonist based on the structure of the known reversible 
antagonist, naltrindole (33), Portoghese et a/, were able to report the compound NTII (37),58 
which showed 8-selective irreversible antagonism in the absence of initial agonism. A more 
recently disclosed 8-selective irreversible antagonist, BNTII (38),59 is similarly based on the N- 
benzylnaltrindole (BNTI) structure with an isothiocyanate group again providing the means for 
an irreversible interaction.
Interestingly, BNTI (39)59,60 shows a similar profile to BNTII (38), although there exists no 
means for covalent bond formation. At present this is explained by a strong lipophilic 







37 38 (R = NCS)
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1.4.3 k-SELECTIVE ANTAGONISTS
Until very recently, attempts to synthesize a peptidic K-selective, reversible antagonist based on 
the structure of the K-selective endogenous peptide ligand, dynorphin A, have been 
unsuccessful.17 Schiller et al., have now reported dynantin, the first highly potent dynorphin A 
derived antagonist showing good K-selectivity.61
The prototype K-selective antagonist, norbinaltorphimine (40, norBNI), is a non-peptidic, 
bivalent ligand showing a high degree of selectivity both in vitro and in vivo.62 There is however 
a delay between the administration of norBNI and the peak K-selective antagonist effect63 Poor 
solubility and extremely long duration of action further complicate the pharmacological profile of 
this drug. Literature reports show the effects of norBNI lasting up to 7 weeks in mice and 11 
weeks in pigeons.64
HC O'" ™ OH
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The long duration of action could be explained in terms of an irreversible interaction with the 
opioid receptor, however the fact that effects of norBNI are surmountable,65 suggests this is not
14
the case. A more plausible explanation would be that the large size of the bimorphinan 
structure impedes the diffusion of the drug through the blood-brain barrier, causing slow onset 
of action. Poor elimination of the drug from the brain would account for the long duration of 
action.
Studies have shown that the second pharmacophore is not essential, but rather, it is the 
presence of the second basic nitrogen which is crucial in retaining good K-antagonist 
selectivity.66 It has been postulated that this basic nitrogen mimics the guanidine moiety of the 
basic Arg7 residue of the endogenous, K-selective peptide, dynorphin.51 At the same time, the 
basic nitrogen group decreases 8-antagonist potency.67 With the recent cloning of opioid 
receptors, it has become possible to examine these postulates by means of site-directed 
mutagenesis and chimera studies. Using various p/K chimeras, K-selectivity for morphinan-type 
antagonists was shown to reside in extracellular loop (EL) 3 of the K-opioid receptor.68 Glu 297, 
an acidic residue in EL 3 which could interact with a basic "address" moeity of the morphinan 
ligand was identified,69 and its role in conferring K-selectivity was further confirmed by site- 
directed mutagenesis studies.69,70 This acidic residue is unique to the K-receptor, the 
analogous position being occupied by a bulky Trp (Trp 284) and basic Lys (Lys 303) residue in 




In an effort to improve the in vivo properties of norBNI, Portoghese et ai. synthesised the 
piperidine (41 ),66 which has a basic nitrogen held by a pyrrole spacer m a position similar to that 
of the second basic nitrogen in norBNI, but which lacks much of the second bulky morphinan 
group. In vitro, (41) showed slightly better selectivity than nor-BNI, however the 2% overall yield 
prevented in vivo evaluation. A readily accessible method for preparing this, or closely related 
compounds would be highly desirable. Furthermore, derivatives of the secondary amine could 
be prepared and their antagonist properties evaluated.
The interatomic distance and spatial arrangement of the two basic centres is crucial in 
conferring K-selectivity in morphinan-type antagonists. This distance, as measured for norBNI, 
is approximately 11 A.71 Additionally, it has been found that substituting naltrindole (33) with a 
basic group at the 5' position decreases 8-affinity.67 With this in mind, compounds with an
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amidine67 (42), amide-amine72 (43-44) or amidine-amine group72 (45) attached to the 5’-position 
of naltrindole were synthesised, showing good K-selectivity.
Results for the amidines indicated that selectivity increased as the length of the side chain 
increased, however, the chain length was not extended beyond the most selective compound 
(n=1, m=3). Jales et a lP  then went on to report the most selective amidine compound thus far 
(42, n=2, m=3), as well as a series of 5'-amido-substituted compounds74 (46) which showed 
modest selectivity, despite the lack of a second basic centre.
HO
42 R = CHnNHC(=NH)(CH2)mCH3 (n=1,2m
43 R = CONHCH2CH2N(CHnCH3)2 (n=0,1)
44 R = CH2NHCO(CH2)3N(CH3)2
45 R = CH2NHC(=NH)(CH2)nN(CH3)2 (n=1,3)
46 R = CH2CH2NHCOCHnCH3 (n=1,2,3)
47 R = NHC(=NH)NH2
Substitution of the 5-position of naltrindole with a basic guanidine group gave the highly k -  
selective anatgonist GNTI (47).75 It is noteworthy that a 5-selective compound has been 
changed into a K-selective compound, simply by the addition of a basic group. Interestingly, 
Sharma et a l.p  have shown that moving the guanidine substituent to the 6-position gives a 
selective K-agonist. With the guanidine group in the 7-position, the compound becomes a 
selective 8-antagonist. This is consistent with previous findings that substitution at the 7'- 
position of naltrindole does not affect 8-selectivity (section 1.4.2).
Portoghese recently published77 a comprehensive range of 5'-substituted indolo-morphinan 
ligands, allowing investigation into the optimum distance between the second basic centre and 
the core naltrindole structure, as well as the effect of various substituents. Guanidine, amidine, 
quaternary ammonium and amine side chains all displayed K-antagonism with potency 
decreasing in this order. He concluded that K-antagonist efficacy appeared to be related to 
both the pKa of the side chain and the distance between the two cationic centres. Thus far, 
GNTI (47) is the most potent and selective K-antagonist to have been reported. Preliminary 
data reported at the 2001 Annual Scientific Meeting of the College on Problems of Drug Abuse
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(CPDD),78 would indicate that the in vivo effects of GNTI are long lasting; a situation similar to 
that found for norBNI.
The phenyl piperidines, an unrelated class of compounds which have previously been 











UPHIT (50), one of the first K-selective irreversible antagonists was disclosed by Rice et. al.80 
The compound was designed by the addition of an acylating isothiocyanate group into the 
structure of the known K-agonist U50488 (17). A more recently reported compound, DIPPA 
(51 ),81 which also makes use of an isothiocyanate acylating group, is based on the finding that 
IC1199411 (52) shows potent K-selective agonism.
50 51 (R = NCS)
52 (R = H)
Both UPHIT (50) and DIPPA (51) display short term agonism, followed by long term 
antagonism. This can be seen as a consequence of their design, since both compounds are 
based on the structures of known agonists. This problem has restricted the use of these two 
ligands in investigating K-receptor function.
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Similar problems were encountered in the early irreversible antagonists selective for the 8- 
opioid receptor. This problem however, was overcome by designing non-competitive ligands 
based on competitive 8-antagonist structures. A possible reason why this was not exploited in 
the design of early irreversible K-antagonists is the limited opportunities in the structure of the 
original K-selective antagonist, norBNI (40), for the introduction of an electrophilic group.
The only viable position is the pyrrole N-atom, which could be substituted with a benzyl group 
(into which an electrophile could be introduced), in a manner analogous to that used in the 
design of BNTI (39) and BNTII (38), irreversible 8-antagonists based on the reversible 8- 
antagonist naltrindole.
More recently, however, 5’-substituted naltrindole derivatives, and particularly guanidinium 
compounds, have shown substantially greater selectivity than that of norBNI. Basing the design 
of an irreversible K-antagonist on these structures would therefore seem more favourable. This 
could be done either by introducing a benzyl group at the indolic nitrogen (again with the 
possibility of substituting with an electrophile such as isothiocyanate) or by introducing an 
electrophilic group into the 5-basic side chain.
As mentioned previously, irreversible antagonists can also be used in the assessment of 
agonist efficacy. While p-FNA (29) and C-CAM (30) have been used both in vivo and in vitro to 
assess p-efficacy, no such procedures have been undertaken with the available K-irreversible 
ligands, UPHIT (50) and DIPPA (51). A K-selective irreversible ligand, solely displaying 
antagonism would prove an extremely valuable tool in assessing the relative efficacy of 
standard agonists, both those displaying selectivity for the K-receptor, as well as those with 
affinity for more than one opioid receptor type.
1.5 THE SIGNIFICANCE OF THE k-OPIOID RECEPTOR
Originally, research into K-selective opioid ligands focussed on potential analgesics.82 Since k -  
agonists do not cause euphoria, it was hoped that this class of compounds could provide a 
potent, non-abusable analgesic. The dysphoric side effects, however, have precluded the use 
of pure K-agonists in the treatment of pain.
Although the analgesic properties of opioids have long been recognised, it has become 
increasingly apparent that they have a significant role to play in a wider range of clinical 
situations.
Cocaine administration has been shown to up-regulate K-opioid receptors, causing an increase 
in the levels of both dynorphin and dynorphin mRNA.83 It is therefore conceivable that K-opioid
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systems play a role in modulating the effects of cocaine. Recently there has been significant 
interest in the role of K-opioid agonists in cocaine abuse. In rodents, K-opioid agonists were 
found to block cocaine-induced place preferences and hyperactivity.84 Acute administration of 
the K-agonists, U50 488 and spiradoline, has also been reported to reduce self-administration 
of an intermediate dose of cocaine in rats.85 Additionally, the K-antagonist norBNI, potentiates 
the discriminative stimulus effects of cocaine.86
In post-detoxification treatment of heroin addicts, Rothman et al.B1 have shown that a 
combination of buprenorphine (|i-partial agonist/K-antagonist) and naltrexone (p-antagonist) 
produced a greater positive response to treatment than with naltrexone alone, indicating a 
possible role for K-antagonists in the treatment of drug addicts. It is still unclear, however, if the 
presence of a p-partial agonist contributes to the positive response. This can be supported by 
the fact that in rat models, administration of norBNI has no effect on morphine or heroin self- 
administration.88
The use of K-agonists as alternatives to hyperosmotic agents in the treatment of cerebral 
edema of the focal ischemia type, has also been postulated.89
Newman et al?° have suggested a role for K-antagonists in determining the underlying 
mechanisms that cause the motor fluctuations that develop during treatment of Parkinson’s 
disease, while norBNI (1) has been reported to improve recovery after traumatic brain injury in 
rat models.91 During feeding studies using rats, administration of norBNI has been shown to 
reduce deprivation intake and suppress other forms of food intake. The K-receptor has also 
been implicated in polydipsia (alcohol dependence), since norBNI was able to decrease 
drinking in genetically polydipsic mice.92
1.6 SPECIFIC AIMS
While norBNI (40) has proved a useful ligand for the study of K-receptors, there is still 
significant interest in the development of alternative ligands, with, for example improved 
pharmacokinetic properties. It was believed that less lipophilic, lower molecular weight ligands 
might display a more favourable pharmacological profile.
In order to extend the range of ligands available, it was decided to synthesise further series of 
5’-amido, amidino, imidazoline and urea substituted compounds, and to submit these 
compounds for pharmacological evaluation. In this way, it would be possible to further probe 
the effects of varying the distance between the two basic centres. Since urea derivatives are 
less basic than amidine derivatives, and amido derivatives are non-basic, it would also be 
possible to investigate the level of basicity required for K-selectivity. The most highly k -
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selective compound reported thus far is the 5’-guanidino-substituted, GNTI (47). It was 
envisaged that further substitution of the guanidine functionality might reveal compounds with 
increased K-selectivity and/or affinity and allow the introduction of new functional groups. In this 
regard, a terminal amine group was particularly desirable, since this can readily be converted to 
an isothiocyanato group which could confer irreversible properties to these ligands.
It was hoped that molecular modelling studies would allow us to investigate the interactions 
between the synthesised ligands and the K-receptor. In addition, selectivity could be 
investigated by docking the various ligands into all three opioid receptors. This would allow us 
to design new, potentially selective ligands for the K-opioid receptor.
2 0
2. SYNTHESIS
2.1 AMIDE SUBSTITUTED LIGANDS
2.1.1 DESIGN RATIONALE
In a 1995 patent72 Portoghese and Olmsted disclosed a series of aminoamide compounds (53- 
55), showing selectivity for the K-opioid receptor. Although the amide group is not a basic 
functionality, due to delocaljsation of the lone pairs across the carbonyl, selectivity was 
demonstrated for these compounds. This could however be attributed to the basicity of the 
distal amine in the side chain. At first glance this amine group would not appear to be in a 
suitable position for interaction with the receptor. It is feasible however, that the alkyl chain 
could fold back upon itself, thereby placing the nitrogen in close proximity to the acidic Glu 297 
residue.
Within our group,74 a series of amide derivatives (56-58) have also been prepared. These 
compounds again show a degree of K-selectivity -  albeit lower than that reported for the 
aminoamides (53-55). In this case, however, there is no basic group in the side chain.
For ligands (56-58), an increase in the acyl chain length was accompanied by an increase in k -  
selectivity, seemingly confirming our belief that lipophilic interactions are also important in the k -  
address. If hydrophobic interactions are important, an obvious extension of this work would be 
to synthesise a series of amides with a longer alkyl group (59) or an aryl ring in the side chain 
(60-63). The resultant increase in lipophilicity and potential for strong hydrophobic interactions 
could further increase K-selectivity. Whereas for compounds (53-54), the amide functionality is 
attached directly to the naltrindole core, for compound (55) there is a methylene spacer before 
the amide group. Since receptor binding data for compounds (53-55) were highly similar,72 it 
was decided to attach the amide group directly to the 5-position of naltrindole as in compounds
H H
53 R = CONH(CH2)2N(CH3)2
54 R = CONH(CH2)2N(CH2CH3)2
55 R = CH2NHCO(CH2)3N(CH3)2
56 R = CH2CH3
57 R = (CH2)2CH3
58 R = (CH2)3CH3
(53-54).
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59 60 n = 1, R = H
61 n = 2, R = H
62 n = 4, R = H
63 n = 1, R = OMe
2.1.2 SYNTHESIS
Amides are commonly formed via the acylation of amines, by activated carboxylic acid 
derivatives, such as acyl halides,93 anhydrides,94 or carboxylic esters.95 Perhaps the most 
widely used method is the reaction of a carboxylic acid with a coupling agent (eg. DCC), 
followed by displacement with an amine.96 Carbodiimide derivatives are most commonly used 
for this purpose, although the reaction may also be promoted by reagents such as ArB(OH)297 
and POCI3.98
Compounds (53-54) were synthesised via the benzotriazoM-yloxytris(dimethylamino)- 
phosphonium hexafluorophosphate (BOP)99 assisted coupling of (64) with the required amine.72 
Accordingly, we accomplished the synthesis of (59) using (64), BOP and heptylamine in the 
presence of triethylamine (scheme 1). The reaction proceeded well, giving 17- 
cyclopropylmethyl-e.Z-didehydro^.Sa-epoxy-SXN-heptyOamido-S.M-dihydroxyindoloP'.S'ie,?]- 
morphinan (59) in a yield of 83%. The carboxylic acid precursor (64) was significantly easier to 
prepare than the amine precursor used in the preparation of (56-58).
2 2
Scheme 1
The synthesis of compounds (60-63) was then attempted using the above methodology. The 
results however, were unsatisfactory, giving yields of less than 10%. Since numerous amide 
coupling reagents exist, we decided to investigate some alternatives. 1-[3-(Dimethylamino)- 
propyl]-3-ethylcarbodiimide hydrochloride (EDCI)100 is particularly useful since it yields a water 
soluble side-product which can easily be separated from the product after the reaction. The 
yields of these reactions can often be increased by the addition of a catalytic amount of an 
aminopyridine, such as 4-(dimethylamino)pyridine (DMAP).
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We therefore attempted the synthesis of compounds (60-63) by stirring carboxylic acid (64), 
EDCI, DMAP and the required amine in the presence of triethylamine at room temperature for 
12 hours (scheme 2). The crude products were further purified by preparative thin layer 
chromatography [CH3OH/CH2CI2/NH4OH (20:80:1)] with typical yields of 9-22%. Unreacted 
amine and decomposition products could also be identified from the reaction mixture. Although 
the yields are very poor for this series of compounds, the reactions were not optimised since in 





60 n = 1, R = H
61 n = 2. R = H
62 n = 4, R = H
63 n = 1. R = OMe
Scheme 2
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2.2 AMIDINE SUBSTITUTED LIGANDS
2.2.1 DESIGN RATIONALE
As mentioned in the Introduction section, Portoghese et al.,72 described a series of amidine 
compounds which showed good selectivity for the K-receptor (65-69). It was shown that k -  
selectivity increased as the length of the alkyl side chain increased. Additionally, as a result of 
decreased affinity for the 5-receptor, greater ic/S-selectivity was shown for the branched alkyl 





N — C— R
HO
H H
65 R = CH3 70
66 R = CH2CH3
67 R = (CH2)2CH3
68 R = (CH2)3CH3
69 R = CH2CH(CH3)CH2CH3
Jales et atP  were able to demonstrate increased affinity for compounds in which the basic 
nitrogen was one carbon atom further away from the "message" scaffold (70). It was not certain 
whether the observed increase in affinity was as a result of the greater N-N distance or as a 
result of the greater overall chain length. We decided to synthesise compound (71), where the 
basic nitrogen was in the position used by Jales, but branching was introduced into the alkyl 
side chain via incorporation of an isobutyl group. This we hoped, would combine the best 
features of (69) and (70), and give us greater insight into receptor/ligand interactions in the 
address portion of the molecule.
s - cU
71
For unsymmetrically substituted amidines, the two compounds R1NH(C=NH)R2 and 
R1(C=NH)NHR2 are not equivalent. It was therefore of interest to see what impact this "amidine 
reversal" would have on the selectivity and affinity of these compounds. We decided to
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synthesise a series of "reverse amidines" (72-74), which were otherwise analogous to the series 
reported by Portoghese et al. (65-69). In effect, the N-N distance for these compounds would 
be shorter than for the series reported by Jales. Compounds with a longer alkyl side chain were 
focussed on, as this was expected this to give compounds with the greatest K-selectivity. The 
longest chain studied thus far was "Bu, we therefore wanted to test whether longer chains would 






72 R = (CH2)2CH3
73 R = (CH2)4CH3
74 R = (CH2)6CH3
2.2.2 SYNTHESIS
Amidines can be formed directly from the reaction of nitrile containing compounds with amines. 
This reaction however is limited to nitriles which are substituted by electron-withdrawing 
groups.101 Alternatively, unreactive nitriles can be reacted in the presence of Lewis acids,102 or 
with metal amides or amines.103 Amidines can also be formed by the condensation of amides 
with amines in the presence of halogenating agents104 or triflic anhydride.105
The classical approach to the synthesis of amidines, the Pinner synthesis,106 involves the 
transformation of the nitrile to the alkyl imidate, which is subsequently reacted with the amine. 
Modifications to this reaction include the use of thioimidic esters107 and thiophenylimidic 
esters108. Since thiols are both better nucleophiles and better leaving^groups than alcohols, the 
preparation of thioimidates should be possible under milder conditions. Additionally, 
thioimidates should be more reactive towards nucleophiles than the analogous imidates.
Our target compound (71) was very similar to that prepared by Jales (70) and it was decided to 
follow the protocol he reported. The required nitrile (75) and amine (76) intermediates were 
synthesised by a Fischer indole reaction between 4-hydrazinobenzylcyanide and naltrexone 
(77), followed by a Raney nickel catalysed hydrogenation (scheme 3).72,73
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Although glacial acetic acid has previously been used as the solvent for the Fischer indole 
cyclisation, we found the yield to be both higher (82% vs. 46%) and more reproducible when a 
mixture of ethanol and 2N hydrochloric acid (5:1) was used. Raney nickel catalysed 
hydrogenation usually produced good yields for the reduction of nitrile (75) to amine (76), 
however, the yields obtained with a Raney nickel catalysed transfer hydrogenation - formic acid 
being the solvent - were found to be slightly superior and more reproducible. Portoghese's 
group later found that the addition of hydrazine hydrate to the hydrogenation mixture gave 
improved reproducibility.77
Isovaleronitrile was treated with dry ethanol and HCI gas, to give the crude imidic ester 
hydrochloride. The white precipitate was washed with diethyl ether, dried under nitrogen and 
subsequently reacted with amine (76) in ethanol at room temperature for 72 hours (scheme 4). 










In order to synthesise the "reverse amidine" series (72-74) discussed above, the imidate of 
nitrile (75) had to be prepared before reaction with an alkylamine. Due to the reported 
advantages of thioimidic esters over imidic ethers,108 it was decided to react nitrile (75) with 
thiophenol in methanol, under an atmosphere of HBr, to form the thiophenylimidic ester 
derivative (78) (scheme 5). The crude compound (78) was reacted with the appropriate amine 
in methanol at room temperature for 12 hours, and the product purified by preparative thin layer 
chromatography, giving the corresponding amidines (72-74) in yields of 20-30% (scheme 5). 
Apart from the desired products (72-74), the disubstituted amidines (79-81) were detected as 
minor products (5-10%) in each of the reactions. Additionally, unreacted nitrile (75) could be 
identified in the reaction mixture (ca. 10%).
72 R = (CH2)2CH3
73 R = (CH2)4CH3
74 R = (CH2)eCH3
79 R = (CH2)2CH3
80 R = (CH2)4CH3
81 R = (CH2)6CH3
75
Scheme 5
2.3 4,5-DIHYDROIMIDAZOLE SUBSTITUTED LIGANDS
2.3.1 DESIGN RATIONALE
Previously, within our group, the 4,5-dihydroimidazole (imidazoline) derivative (82) had been 
synthesised.74 Since this is essentially a ring constrained analogue of the amidine series (72- 
74) described in the previous section, it was of interest to compare the pharmacological 
activities of the imidazoline and the amidines.
HH
82 72 R = (CH2)2CH3
73 R = (CH2)4CH3
74 R = (CH2)eCH3
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In the amidine series, however, the presence of an aliphatic side chain could contribute to the 
binding via lipophilic interactions. For this reason, we decided to synthesise the 4-methyl- and 
4,4-dimethylimidazoline derivatives (83) and (84), the methyl groups of which could interact with 
any lipophilic binding sites available, in a manner analogous to that of the shorter aliphatic side 
chain. (83) and (84) can be considered constrained "propyl and 'butyl amidines, respectively.




The synthesis of 2-alkyl substituted imidazoline compounds can be achieved either by an 
intramolecular cyclisation reaction, or a condensation reaction. Cyclisation reactions occur with 
substituted (N-2-aminoethyl)amides.109 Condensation reactions typically occur between 
ethylenediamine and a substituted nitrile,110,111 carboxylic acid112 or carboxylic acid alkyl 
ester.113 Reactive nitrile groups undergo the condensation reaction with boiling 
ethylenediamine. Less reactive nitriles, however require temperatures higher than the boiling 
point of the diamine (118 °C). For this reason, the mono-acid salt of the diamine is often used. 
Sulfonic acid salts are favoured since they form a homogenous melt, while the reaction mixture 
formed with chloride salts is often heterogenous at first and the reaction consequently slower.110
4-Methyl- and 4,4-dimethylimidazoline derivatives reported in the literature thus far have been 
synthesised via an exchange reaction between substituted diamines and imidazolines.114 This 
approach would involve two steps; first the preparation of the imidazoline (82), followed by the 
exchange reaction (scheme 6 ). Since the imidazoline compound was not prepared in a high 
yielding reaction (38%), this was not a favourable approach.
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83 Ri = H, R2 = Me
84 Ri = R2 = Me
Scheme 6
Imidazoline (82) was previously synthesised via the reaction of nitrile (75) with the p- 
toluenesulfonic acid salt of ethylenediamine.74 It has been reported that the production of 
amidines/imidazolines is dependant on structural factors influencing the cationic properties of 
the carbon atom of the cyano group and on the strength of the basic reagent.110 Since the nitrile 
containing reagent would be unchanged, and methyl substituents would not be expected to 
have a large influence on the basicity of the diamine, it was decided to attempt a direct 
condensation using substituted diamines. Preparation the 4-methyl- and 4,4- 
dimethylimidazoline derivatives was envisaged via the reaction of nitrile (75) with the p- 
toluenesulfonic acid salts of 1,2 diaminopropane and 1,2  diamino-2 -methylpropane, 
respectively.
HjN NH3+ O -S — \ -----
♦ ^
-N-'X]
75 83 R1 = H, R2 = Me
84 Ri = R2 = Me
Scheme 7
The respective diamino compounds were added to p-toluenesulfonic acid in 'PrOH and stirred at 
room temperature for 30 minutes.74 The salts were then isolated and recrystallised from 
petroleum ether/CH2CI2, before being stirred with nitrile (75) (in the absence of solvent) at 160 
°C for 3 hours. In each case, the crude reaction mixture was purified by preparative TLC, to 
yield the required products (scheme 7) in 5-6% yield. At the time of purification, approximately
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60% starting material (nitrile compound) remained. By TLC analysis however, decomposition 
products were starting to appear and it was thought better to end the reaction and isolate the 
desired product in a low yield rather than risk further decomposition.
2.4 UREA SUBSTITUTED LIGANDS
2.4.1 DESIGN RATIONALE
GNTI (47), the most selective K-antagonist to date, is believed to derive some of its selectivity 
from the highly basic guanidine moiety.75 Although the urea functionality (pKa ca. 7) is 
significantly less basic than the guanidine group (pKa ca. 11 ), the relative positions of the 
nitrogen atoms are similar since both functionalities are necessarily planar. At this stage we 
were still investigating a previous finding in our group that the insertion of two methylene groups 
between the naltrindole "message" and the basic nitrogen "address" might improve selectivity.74
We aimed therefore, to synthesise a series of 5-ethylurea substituted ligands (85-87). These 
ligands, we hoped, would provide further information on the nature of the binding site and the 
level of basicity needed to provide selectivity. In a patent report by Portoghese,72 
amidinoamines and amidoamines, having the amino group e to the message scaffold, showed 
greater selectivity than the analogous amidino and amido ligands. The second nitrogen atom of 
the urea moiety is also e to the message scaffold. Alkyl substituents of differing lengths could 
be used to further probe the role of lipophilic interactions.
2.4.2 SYNTHESIS
Since we desired a urea compound substituted at one nitrogen with 17-cyclopropylmethyl-6,7- 
didehydrcM.Sa-epoxy-S’-ethyl-S.M-dihydroxyindolo^'.S'rejJmorphinan (8 8 ), and at the other 
nitrogen with an alkyl group, we were interested in procedures for the synthesis of asymmetric 
ureas. These include the reaction of amines with isocyanates,115 the reaction of a carbocation 
with a cyanamide,116 the reaction of an electrophile with a monosubstituted urea117 and the 
reaction of an amine with an activated carbamate.118
HH
47 85 R = CH2CH3
86 R = (CH2)3CH3
87 R = (CH2)sCH3
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Since we had amine (76) in hand, and alkylisocyanates were commercially available, this 
methodology was the most attractive.
Isocyanates are able to react with both amines and alcohols. While the reaction of isocyanates 
with amines is fairly rapid, the reaction of alcohols is relatively slow and that of phenolic 
functionalities is slower still.115 We decided to react amine (76) with the required isocyanates 
without protecting the free hydroxyl groups, since the 14-OH position is relatively hindered and 
the 3-OH is a phenolic hydroxyl group.
Amine (76) was therefore stirred with ethyl isocyanate in CH2CI2 at room temperature for 5 
hours (scheme 8 ). The desired urea (85) was isolated and purified by preparative TLC. 
Additionally, the urethane derivative (89), resulting from the reaction of the 3-OH group with 
ethyl isocyanate, was isolated as a by product from the reaction. Amine (76) was reacted with 
butyl and hexyl isocyanate in a similar manner, yielding typically 30-40% product (85-87) and 
approximately 10% urethane derivative (89-91) in all three cases. The urethane derivative 
could be hydrolysed to the desired product by stirring overnight with an excess of potassium 









85 R = CH2CH3
86 R = (CH2)3CH3








89 R = CH2CH3
90 R = (CH2)3CH3
91 R = (CH2)5CH3
Scheme 8
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The mechanism of this reaction is analogous to an acylation in an aprotic solvent. The opening 
of the N=C bond can be viewed as equivalent to the departure of a leaving group.115 Since the
solvent is not able to play a role in proton transfer, a second or even third molecule of the amine 
is able to assist in proton transfer via a cyclic intermediate (scheme 9). Both tertiary amines 
and bifunctional catalysts, such as carboxylic acids (which can increase the nucleophilicity of 
the amine and assist in proton transfer), are able to catalyse this reaction. Tertiary amines are 
more successful at catalysing urethane formation while carboxylic acids are good catalysts for 
the synthesis of ureas. If the above reactions were to be repeated, the addition of a carboxylic 
acid catalyst may improve the yields
2.5 SUBSTITUTED DIAMINES
2.5.1 DESIGN RATIONALE
In a patent report by Portoghese et al.72 amidinoamines (eg. 92) displayed approximately 2 fold 
greater selectivity than the analogous amidine compounds (eg. 6 8 ) and significantly higher 
selectivity than norBNI. Since we had seen a certain degree of kappa selectivity displayed by 
amine (76) in GTPyS functional assays, we were interested in the effect of an alkylamino- 
substituent (eg. 93) on this ligand. We hoped that these substituents would increase selectivity 
in a manner similar to that demonstrated in the amidinoamine series.







That the terminal amine functionality could be used as a precursor to an irreversible ligand, for 
example by reaction with thiophosgene to form the isothiocyanate derivative, was of additional 
interest to us.
2.5.2 SYNTHESIS
The initial approach involved the nucleophilic attack of amine (76) on an electrophile. Since the 
phenolic 3-OH group could also be expected to react with electrophiles, it was protected with a 
trityl group. This could easily be removed at a later stage under acidic conditions. Since the 
protection of a phenol in the presence of a primary amine could prove problematic, it was 
elected to protect at the nitrile stage (75) and then reduce to the corresponding amine (94). The 
trityl protecting group was introduced by stirring with trityl chloride in the presence of 4- 
dimethylaminopyridine.119 Reduction of the trityl protected nitrile (95) was achieved by transfer 
hydrogenation using Raney nickel catalyst in 50% MeOH/cyclohexene at ca. 50 °C (scheme 
10). Methanol is present in order to dissolve the compound, while cyclohexene provides the 
hydrogen for transfer hydrogenation. This solvent was chosen in place of formic acid (used 







The reactions of amine (94) with the commercially available alkyl chloride electrophile, 3- 
(dimethylamino)propyl chloride (as both the hydrochloride salt and the free base), and an alkyl 
tosylate (96) were investigated. (96) was prepared by first reacting 3-aminopropan-1-ol with
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BOC-anhydride, giving 3-(N-BOC-amino)propan-1-ol.120 Subsequent reaction with tosyl 
chloride and 4-dimethylaminopyridine gave 3-(N-BOC-amino)propan-1-yl tosylate (96).121 Amine 
(94), the desired electrophile and potassium carbonate were combined in dimethylformamide 
and stirred at RT, ca. 50 °C or reflux for 12 h (scheme 11). In each case, analysis of the 
mixture showed only unreacted starting material at RT, trace amounts of the desired product but 
mostly degradation products at 50 °C or degradation products at reflux. It was therefore 
decided that direct aikylation would not be the most favourable approach to this synthesis.
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Scheme 12
Introduction of a methyl group was then attempted via a reductive aikylation approach. This 
could be followed with an acylation, the amide group later being reduced to give the desired 
disubstituted amine derivative.
Reductive alkylations122 involve the reaction of aldehydes or ketones with an amine, giving an 
imminium moiety, which can then be reduced to the secondary or tertiary amine (scheme 13). 
Formation of the imminium is the relatively slow, rate determining step, whereas the reduction 
reaction usually occurs rapidly. A successful reducing agent should reduce the imminium 
moeity without reducing the ketone or aldehyde groups. Although sodium cyanoborohydride is 
most often chosen as the reducing agent in reactions of this type, a wide variety of other hydride 
reducing agents and catalytic hydrogenation have been equally successful.123 The amine is 
usually used in about five fold excess to avoid competition from the product amine.
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Since amine (76) was the most valuable reagent, it was decided to attempt the synthesis 
without using an excess. Instead a little over one equivalent of formaldehyde was used, with 
sodium cyanoborohyride as the reducing agent. Analysis of the crude reaction mixture showed 
none of the required product (97). Unreacted starting material was however detected, as well 
as approximately 20% of the dimethyl derivative (98) (scheme 14).
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Since amine (76) had displayed a degree of kappa selectivity,74 we decided to prepare 
derivative (98) in greater quantity for pharmacological testing. Reacting amine (76) with three 
equivalents of formaldehyde, we were able to isolate the required product (98) in 57% yield.
At this stage, a report appeared in the literature in which Jones et al. synthesised (98) in good 
yield.77 The major difference in our procedures was their use of methanol as solvent, the 
presence of excess acetic acid and allowing the reaction to proceed for 24 hours. We repeated 
the published procedure and found the results to be superior to our previous attempts. It is 
likely that the presence of the acid helps polarise the carbonyl group and generate the positive 
imminium species.
An alternative approach towards mono- and longer chain dialkylated products was then 
attempted. In the previous section, the synthesis of amide derivatives (59-63) is described.
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Reduction of the amide functionality should yield the corresponding N-alkylamino compound. It 
was decided to synthesise an ethylamide derivative (99) using the procedures described in the 
previous section (scheme 15). If the reduction reaction proved successful, we could then 
synthesise the required amido amines (also mentioned in the Portoghese and Olmsted patent) 
and subsequently reduce them to the corresponding diamines.
Classically, amides have been reduced to the corresponding amines with lithium aluminium 
hydride (LAH) or catalytic hydrogenation.124 Catalytic hydrogenation, however, usually requires 
high temperature and pressure. Since our compounds contain an indole functionality, which 
could be reduced under these forcing conditions, the LAH approach was preferred (reduction of 
an indole with LAH is much rarer).
LAH reductions are required to be performed in an aprotic solvent such as ether, 
tetrahydrofuran or diglyme. Even though the compound may not completely dissolve in the 
solvent, the reaction will usually occur as long as it is partially in solution.
Since some alkoxide formation was expected due to reaction between hydride and the hydroxy 
groups on (99), it was decided to use excess LAH for the reduction. One equivalent of 
ethylamide derivative (99) was therefore reacted with an excess of LAH in tetrahydrofuran for 
12 h, at both RT and reflux (scheme 16). TLC analysis of the product mixture however, 












The ethylamide (99) did not appear to dissolve in tetrahydrofuran and it was decided to attempt 
the reduction using a different solvent. One equivalent of (99) was therefore added to one 
equivalent of LAH in diglyme (scheme 16). Once again, the starting material did not appear to 
be soluble in the solvent, however, the mixture was heated at reflux for 12 hours. Subsequent 
TLC and mass spectrometric analysis confirmed that no reaction had taken place.
Although sodium borohydride (NaBH4) alone is not able to reduce the amide group, a stronger 
reducing agent (B2H6), is formed when NaBH4 is used in conjunction with other reagents such 
as aluminium chloride,125 borontrifluoride126 or iodine.127 The reduction of (99) was therefore 
attempted with a combination of NaBH4 and borontrifluoroetherate in tetrahydrofuran. The 
reaction was heated to reflux for 12 hours. Once again, however, TLC and mass spectrometric 
analysis showed only unreacted starting material.
Since a degree of success had been achieved using reductive aikylation methodology (see 
above), we were interested in attempting the reverse reaction, ie. using aldehyde (1 00 ) 
(scheme 17). Aldehyde (100) could be synthesised via reduction of the corresponding nitrile 








Since nitrile (75) had previously been synthesised (section 3.2.2), the reduction of this
compound was the favoured route to the aldehyde (100). Procedures for the reduction of nitrile
128containing compounds to the corresponding aldehydes fall essentially into two main classes.
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The reaction can either be achieved via a Stephen reduction, or via a metal hydride reducing 
agent and subsequent hydrolysis.
The Stephen reduction,129 however, requires the presence of acid in ether or dichloromethane. 
Since our compound would form the salt in the presence of acid, it would not be expected to 
dissolve in either dichloromethane or ether and hence the reaction would not be expected to 
proceed satisfactorily.
The reduction of both (75) and (95) was therefore attempted using DIBAL-H.130 One equivalent 
of DIBAL-H was added to one equivalent of nitrile (75) or (95) in dichloromethane and left to stir 
at RT (repeated at reflux) for 12 h (scheme 18). Analysis upon work up however showed 













Nitriles have also been converted to the corresponding aldehydes using Raney nickel catalysed 
transfer hydrogenation.131 In an effort to ensure isolation of the aldehyde, we stirred nitrile (75) 
with a catalytic amount of Raney nickel in 47:47:6 MeOH/cyclohexene/H20  at room temperature 
for 5 days. Water was added to the reaction mixture in order to promote hydrolysis of the imine. 
TLC and mass spectrometric analysis showed the formation of approximately 50% aldehyde 
(spot turns orange with 2,4-dinitrophenylhydrazine) and 50% unreacted starting material. If 
however, the reaction was left for a longer period of time, side reactions started occurring.
Attempted purification by preparative thin layer chromatography lead only to decomposition 
products. It was therefore decided to react the reaction mixture with pentylamine, in an attempt
132to isolate the required amine product (102). The reducing agent chosen was decaborane, 
since this allowed the use of methanol as solvent. From the reaction mixture, we were able to 
isolate unreacted pentylamine, unreacted nitrile (75) as well as amine (76), formed via the 
decaborane reduction of nitrile (75). We were unable however, to isolate any of the desired 




The oxidation of alcohol (101) to the desired aldehyde (100) was then attempted. Alcohol (101) 
was synthesised by reacting 4-hydrazinophenethylalcohol, prepared from 4-aminophen- 
ethylalcohol, with naltrexone under Fischer indole cyclisation conditions (cf. section 2.2.2). We 
were able to isolate the desired alcohol (101) in 8 % yield (scheme 19). The low yield was 
predominantly due to poor extraction during the work up procedure and not due to competing 
reactions or by-product formation. Although this yield was not optimised, it would seem that this 
reaction would not be particularly useful as the beginning of a synthetic scheme. Nevertheless, 











Primary alcohols can be converted to aldehydes with strong oxidising agents, such as 
permanganate,133 osmium tetroxide134 or chromium(VI) reagents;135 by catalytic 
dehydrogenation, for example with copper chromite120 or Raney nickel;136 with 
dimethylsulfoxide based reagents137 or with hypervalent iodine reagents such as the Dess- 
Martin Periodinane.138 The Oppenauer oxidation has also been used in the preparation of 
aldehydes, but it is more commonly used to oxidise secondary alcohols to the corresponding 
ketones.120
The oxidation of alcohol (101) was attempted using both pyridinium chlorochromate (PCC) and 
Swern conditions139 (scheme 20). In neither case (at RT or reflux) could product be detected.
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Swern conditions at RT or reflux, as well as PCC at RT gave only starting material, while PCC 
at reflux lead to the formation of degradation products.
N -X l
v OH ,n^ ov OHN^XI\ OH O
DMSO / = \







At this point in the project, greater success was being achieved in the synthesis of substituted 
guanidines (section 2.6). The decision was made to concentrate on this new series of ligands 
and further attempts to reach the aldehyde were not made.
2.6 GUANIDINYL SUBSTITUTED LIGANDS
2.6.1 DESIGN RATIONALE
As discussed previously, GNTI (47), is the most selective K-antagonist published to date.75 
Since amidine (70)73 appeared to show greater selectivity than the analogous amidine (6 8 )72 









As a highly potent, highly selective ligand, GNTI (47) was an obvious candidate for further 
modification. Since a degree of selectivity had previously shown in the non-basic amide 
series,74 we were aware that hydrophobic interactions could potentially play a role in conferring 
selectivity. The unsubstituted guanidinyl group provided the opportunity for introducing further 
substituents in the hope that greater potency and selectivity could be achieved.
With this in mind, it was also decided to investigate the influence of a benzylic substituent on the 
selectivity and affinity of these ligands (105-106). To allow a preliminary study of substituent 
effects on the benzyl group, para-substituted analogues (107-112) were also targeted.
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105 R = H
107 R = CI
108 R = N02
109 R = NH2
106 R = H
110 R = CI
111 r  = no2
112 R = NH2
At this stage, a molecular modelling study was undertaken (section 3) and the ligands docked 
into a model of the kappa opioid receptor in order to identify key interactions and possible 
improvements that could be made. As discussed in the modelling section (3.2.7), two 
hydrophobic pockets for interaction between the K-opioid receptor and the side chain of these 
ligands, were identified. It was thought that by adding two substituents to the guanidinyl group, 
we could achieve interaction with both of these pockets, thereby increasing affinity and/or 
selectivity for the K-receptor. Preparation of a series of N.N'-disubstituted GNTI derivatives, for 
evaluation as K-selective antagonists, was planned (113-117).








113 R1 = R2 = (CH2)3CH3 114 R1 = R2 = (CH2)3CH3
115 R1 = R2 = (CH2)2CH3
116 R1 = (CH2)2CH3l R2 = cyclopropylmethyl
117 R1 = CH2C6H5, R2 = cyclopropylmethyl
Both aromatic and aliphatic substituents were chosen in order to probe this hypothesis. Of 
particular interest, was the preparation of compound (117) with a guanidinyl group possessing 
both a benzylic and a cyclopropylmethyl substituent. This can be seen as a stripped down 
version of norBNI (40) and comparison of the pharmacological results with those of norBNI 






The classical approach to the synthesis of guanidines has been the reaction of primary amines 
or ammonia with S-alkylisothioureas,140 via the nucleophilic displacement of the alkyl mercaptan 
anion. The by-products formed are however often foul smelling and toxic.
Alternative procedures which have been reported include the use of carbodiimides, cyanamides 
and aminoiminomethanesulfonic acid derivatives.140,141 More recently, the use of protected 
thiourea derivatives has greatly increased.142 These derivatives are usually used in combination 
with Mukaiyama's reagent (118) or a thiophile such as a mercury, copper or lead salt. The solid 
phase application of certain of the above methods has been investigated with varying degrees 
of success.143 The conversion of alcohols to protected guanidines has also been reported using 
Mitsonobu conditions.143
Guanidinylations are often carried out in polar solvents such as DMF or methanol, however the 
rate of these reactions has been reported to increase with the use of nonpolar solvents.142
At this stage, GNTI (47) had only appeared in a literature communication which did not include 
full experimental details.75 The formation of the guanidine group had however been based on a 
previously reported procedure, in which acyl guanidines had been prepared from 
acylthioureas.144 Rather than a simple acyl derivative, groups such as terf-butoxycarbonyl 
(BOC) are extremely useful since they can easily be removed at a later stage.
We decided to attempt the synthesis of guanidine (104) using the mercury(ll) chloride promoted 
addition of bisBOC-thiourea to amine (76) (as indicated for GNTI).75 The mechanism of this 
reaction is not well understood. Mercury is able to form a complex with the sulfur atom, thereby
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activating the carbon atom towards nucleophilic attack by the amine. Reports have been 
published supporting both a tetrahedral intermediate,145 which subsequently collapses to 
eliminate mercury sulfide; and a carbodiimide intermediate,146 in which the sulfur group leaves 
prior to nucleophilic attack by the amine. Carbodiimide intermediates have been isolated in the 
absence of amine (or less than 1 eq of amine). These intermediates were subsequently reacted 
with an amine to provide the expected guanidine.
Apart from functioning as a protecting group, the BOC group has been shown to influence the 
progress of the reaction - bisBOC reagents showing greater reactivity than monoBOC 
reagents.146 This can be seen as a consequence of the electron withdrawing nature of the BOC 
group, which would promote addition of the amine. With this in mind, a variety of conjugated 
substituents have been investigated and found to promote guanylation. Simple N,N'-dialkyl 
substituted thioureas have been found to be unreactive under these conditions,146 seemingly 
confirming the importance of the electron withdrawing group. Further investigations showed 
that a proton on each of the nitrogen groups is required for reactivity.146 These findings would 
support the formation of a carbodiimide intermediate.
Adding 1.1 eq of bisBOC-thiourea and mercury(ll)chloride to 1 eq of amine (76) and 
triethylamine in dimethylformamide, and stirring at room temperature for 2 hours, resulted in the 
formation of the desired bisBOC-protected guanidine (119) in 67% yield. Subsequent 
deprotection with trifluoroacetic acid afforded (104) (scheme 21). Purification of the 
deprotected product was then attempted by column chromatography. This was unsuccessful, 
giving a range of decomposition products. It was found however, that trituration with diethyl 










At this stage, Portoghese published a full paper77 detailing the experimental procedure for the 
synthesis of both GNTI (47) and (104). Although our methods were essentially the same, slight 
differences in stoichiometry and reaction time existed (he added more triethylamine and used 
half the reaction time). It was decided to repeat the procedure reported by Portoghese, in order 
to compare the yields. Although no yield was quoted in the literature for compound (104), in our 
hands, more reproducible results were achieved using our procedure.
The desired benzyl-substituted guanidines (105,107-109) could either be synthesised via N- 
alkylation of the above guanidines (47) and (104)147, or by the reaction of a substituted 
guanylating agent with amines (76) and (120) (Scheme 22).
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47 n = 0 
104n=2
105 n= 0, R = H
107 n= 0, R = Cl
108 n= 0, R = N02
109 n= 0, R = NH2
106 n= 2, R = H
110 n= 2, R = Cl
111 n= 2, R = N02
112 n= 2, R = NH2
Scheme 22
Benzyl-substituted guanidinylating agents which have appeared in the literature include an N- 
BOC-N'-benzylthiourea144 and N,N'-bisBOC-N-benzyl-2-methylthiopseudourea.148 It was 
decided to follow the procedure using N.N'-bisBOC-N-benzyl^-methylthiopseudourea, since the 
yields published were considerably higher than with N-BOC-N'-benzylthiourea, and the use of 4- 
substituted benzyl groups had also been investigated.
The reported synthesis of amine (120)77 involved a Fischer indole reaction between naltrexone 
(77) and 4-nitrophenylhydrazine, in acetic acid at 110 °C for 7 days, giving the nitro derivative 
(121) which was then reduced to amine (120). Although repeating the Fischer indole procedure 
as described, it was found that extraction of the black, gummy residue required copious 
amounts of solvent and yields were consistently below 15%. The cyclisation reaction was 
therefore carried out in 50% EtOH/cHCI at reflux for 18 hours. Although the residue was still
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found to be a black gum, compound (12 1 ) could be isolated, achieving consistent yields of ca. 
30% (scheme 23).







In the literature,77 the reduction of the nitro group to the amino group was achieved via Raney 
nickel catalysed hydrogenation in the presence of hydrazine hydrate (69% yield). Since we had 
previously found Raney nickel catalysed transfer hydrogenation to give more reproducible yields 
than standard Raney nickel hydrogenation procedures (section 3.1 and 3.2), this approach was 
again taken. (121) was stirred at ca. 50 °C for 7 hours in 50% MeOH/cyclohexene, with a 
catalytic amount of Raney nickel. The crude reaction mixture was purified by column 
chromatography, affording (120) in 44% yield (scheme 23).
Although amine (76) had previously shown lower reactivity than would be expected for a 
primary amine, and was considerably more hindered than the simple alkylamines used in the 
published procedure, we were confident that reaction with the substituted guanylating agents 
would be possible. The amine group in compound (120) can be viewed as an aniline-type 
moiety and would be expected to react more slowly since the electron density is delocalised 
over the aromatic ring.
Reaction of the appropriately substituted benzylbromide with sodium hydride and 1,3-bisBOC-2- 
methyl-2-thiopseudourea in DMF afforded the required 4-substituted benzylguanylating agents 
in good yield.
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1 equivalent of 1,3-bisBOC-1-(benzyl)-2-methyl-2-thiopseudourea was added to 1 equivalent of 
amine (76) in DMF. The solution was then stirred at 60 °C for 3 hours, at which point analysis 
by TLC showed no conversion to the desired product. A second equivalent of the guanylating 
agent was added and the solution stirred at 80 °C overnight. Again, TLC analysis of the 
reaction solution showed only starting materials. At this stage 1.1 equivalents of 
mercury(ll)chloride were added and the reaction stirred for a further 4 hours. TLC analysis then 
showed that most of the amine had been converted to the bisBOC-guanidine derivative and the 
reaction was quenched and worked up (scheme 24). The product was purified by column 
chromatography. Stirring the bisBOC-protected product for 12 hours in trifluoroacetic acid 
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108 n = 0, R = NO2
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111 n = 2, R = N02
112 n = 2. R = NH2
Scheme 24
Reaction of amine (76) with 4-chloro- and 4-nitrobenzylguanylating agents proceeded smoothly 
using 2 equivalents of both the guanylating agent and triethylamine, and 1 equivalent of both 
the amine and mercury(ll)chloride. The reaction of amine (120) with the guanylating agents 
was, as expected, more sluggish and required stirring at 60 °C for 48 hours under the same 
conditions.
The modest yields obtained (24-44%) can partly be explained by the difficulty in purification of 
the guanidine products (105,107-108 and 106,110-111). These are almost indistinguishable
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from the amine starting materials (76 and 120). If sufficient material for the required 
pharmacological tests was obtained, the remaining impure product was not purified further. In 
the one instance that further purification was attempted, the yield increased by about 20%.
The role of the mercury salt is not expected to be the same as for the example using the 
protected thiourea derivatives mentioned above, since in this case, the sulfur is alkylated. 
Although a mercury salt is not normally required for guanylations involving S-alkylated 
thiopseudoureas, a previously published article149 has shown similar findings to ours. No 
mechanism has however been proposed. A black solid, presumably mercury sulfide, could be 
isolated from the reaction mixture once the reaction had gone to completion.
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5,-(N'-4-nitrobenzyl)guanidinyl-3,14-dihydroxy- 
indolo^'.S'ie.ZJmorphinan (108) and 17-cyclopropyl-methyl-6,7-didehydro-4,5a-epoxy-5,-(N'-4- 
nitrobenzylJguanidinylethyl-S.M-dihydroxyindoloIZ.S'ie.ZJmorphinan (111) were converted to 
their amino analogues (109 and 112) by Raney nickel catalysed transfer hydrogenation in 50% 
MeOH/cyclohexene yielding 63 and 70%, respectively. The reactions proceeded very cleanly, 
showing the formation of product with only small amounts of starting material remaining. The 
overall mass loss can be explained in terms of the affinity of the catalyst for the compound. 
Although the catalyst was washed thoroughly with solvent, some product remained associated 
with the catalyst and could not be recovered.
Literature precedents for the preparation of trisubstituted guanidines focus mainly on the 
reaction of N,N'-dialkyl-S-alkylisothiourea reagents with amines.150,151 Although it has been 
reported that N,N'-dialkylthioureas do not form guanidines in a HgCI2 promoted reaction with 
amines,146 a report exists in the early literature of the formation of N,N',N"-tributylguanidine from 
the HgO promoted reaction of N,N'-dibutylthiourea and butylamine.152 The HgO guanylation 
reaction would be expected to proceed in a manner analogous to the HgCI2 promoted reaction. 
The synthesis of 5'-N,N'-dibutylguanydinylethylnaltrindole (113) was therefore attempted by 
reacting 5-aminoethylnaltrindole (76) and N,N'-dibutylthiourea under the conditions described 
above for the HgCI2 promoted guanidinylation reactions (scheme 25). It was found, in 
agreement with the later reports, that this reaction was unsuccessful.
Scheme 25
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More recently, a CuSCVsilica gel-promoted procedure has shown good results in the synthesis 
of trisubstituted guanidines from disubstituted thioureas, including both dialkyl- and 
diarylsubstituents.153
It was decided however, to investigate the effects of introducing a BOC group into the N,N'- 
dibutylthiourea reagent, in a reaction similar to that used in the synthesis of compound (104).
N.N'-dibutylthiourea was reacted with 2 equivalents of both BOC anhydride and sodium hydride. 
At this stage we were not concerned whether the mono- or bisBOC-products were obtained, as 
either of these reagents were expected to undergo the guanidinylation. Additionally, it was 
planned to remove this group after forming the guanidine. After stirring at room temperature for 









Subsequent reaction of this guanylating agent with amine (76) was carried out using the HgCI2 
promoted procedures described above. After stirring for only 5 hours, the required trisubstituted 
guanidine (122) could be isolated (scheme 27).
Under similar conditions, reaction of amine (120) with N-BOC-N,N'-dibutylthiourea gave the 
desired product (123) after 48 hours. These longer reaction times can again be explained by 
the lower reactivity of the aromatic amine functionality. As before, removal of the BOC- 
protecting groups with trifluoroacetic acid and subsequent trituration with diethyl ether gave the 







113 n = 2
114 n = 0
Scheme 27
A report in the literature has found that for a successful HgCI2 promoted guanidinylation to 
occur, the thiourea should have at least one proton on each of the nitrogen groups.146 We have, 
however, demonstrated that this is in fact not a strict requirement and hence for these particular 
examples it seems unlikely that the reaction proceeds via a carbodiimide intermediate. Under 
these circumstances, a tetrahedral intermediate seems more likely. Thus it would appear that 
the formation of guanidines by the reaction of amines with thioureas, can proceed via more than 
one mechanism, determined at least in part by the nature of the thiourea itself.
Modification of the substituents on the guanidine functionality, could easily be achieved by 
variation in the substituents on the thiourea guanylating agent. Disubstituted thioureas could 
easily be synthesised by the reaction of amines with either thiophosgene or CS2 in the presence 
of BOP reagent. Since thiophosgene was readily available, this methodology was employed. 
One equivalent of the required amine was reacted with 2 equivalents of thiophosgene to give 
the isothiocyanate, which was isolated and checked for purity by TLC. In all cases the 
isothiocyanate appeared pure by TLC and was subsequently reacted with one equivalent of the 
second amine, to give the desired N.N'-disubstitutedthiourea (scheme 28). In this way, both 
symmetric and asymmetric N.N'-disubstituted GNTI derivatives could be synthesised. BOC 
protection of these guanylating agents, followed by reaction with amine (120) proceeded 
smoothly, affording the required guanidine derivatives in moderate yield (20-40%). The BOC 
group was cleanly removed by stirring in trifluoroacetic acid, giving the guanidine product as the 
bistrifluroacetic acid salt (scheme 28).
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113 n = 2, R1 = R2 = butyt
114 n = 0, R1 = R2 = butyl
115 n = 0, R1 = R2 = propyl
116 n = 0, R1 = propyl, R2 = cyclopropylmethyl
117 n = 0, Rt = benzyl, R2 = cyclopropylmethyl
2.7 NON-COMPETITIVE k - ANTAGONISTS
2.7.1 DESIGN RATIONALE
The interest in K-agonists as potential pharmacotherapies for copaine abuse, yet limited 
information on their relative efficacies prompted us to target non-competitive K-antagonists. As 
described in the introduction, irreversible antagonists can be used to determine the relative 
efficacy of a series of ligands, as well as providing an alternative to the use of knockout mice in 
determining receptor function.
To be of pharmacological use, an irreversible ligand should bind covalently and selectively to 
the target receptor.154 Some ligands such as C-CAM display irreversible characteristics without 
actually forming a covalent bond with the receptor. These ligands are typically known as 
pseudo-irreversible. As mentioned previously, we sought to modify a reversible K-antagonist in 
the hope that this would provide a selective, irreversible ligand devoid of agonist properties. A 
covalent interaction could be achieved through an alkylating agent, such as a nitrogen 
mustard,38 a-haloketone, isothiocyanate56 or Michael acceptor,39 or by means of sulfur
Scheme 28
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crosslinks formed with disulfide compounds.155 The reactivity of the chosen group is important 
as a highly reactive moiety increases the opportunity for nonspecific binding, while a poorly 
reactive group may form only reversible interactions.
The isothiocyanate group is often the alkylating agent of choice in the design of non-competitive 
ligands, since it can be readily introduced into a molecule and the relatively small size usually 
does not affect selectivity to a large degree. Although this group is highly reactive towards 
sulfhydryl and amino functionalities, low reactivity towards water and hydroxyl groups is 
displayed.156
2.7.2 SYNTHESIS
Various methods exist for introducing an isothiocyanate group. Alkyl halides,157 acyl halides158 
or aryl diazonium compounds159 may be reacted with a thiocyanate ion to form the 
corresponding isothiocyanate. In each of these cases, however, S-alkylation is a common 
competing reaction. Isocyanides have also been converted to isothiocyanates by treatment with 
disulfides and thalium(l)acetate or lead(ll)acetate.160 The most common preparation of 
isothiocyanates involves the reaction of a primary amine with a sulfur containing electrophile 
such as carbon disulfide or thiophosgene. The former reaction can take place directly in the 
presence of dicyclohexylcarbodiimide,161 or alternatively, via the formation of a dithiocarbamic 
acid derivative. Subsequent elimination of hydrogen sulfide, yields the desired
isothiocyanate.162 The reaction of a primary amine with thiophosgene163 precedes directly to 
give the isothiocyanate derivative.
The two 4-aminobenzylguanidinium compounds (112) and (109), prepared for evaluation as k -  
selective antagonists in the previous section, are ideal precursors to the potential irreversible 
ligands (124) and (125). Pharmacological tests (see section 4) showed that in the 
benzylguanidinium series, the substituent in the para position on the aromatic ring had little 
influence on the selectivity or affinity of the compounds. The primary amine could be envisaged 
to react with either carbon disulfide or thiophosgene as detailed above. Since alcohols are 
known to react with carbon disulfide to give xanthates, (and compounds 112 and 109 contain 
both a 3-phenolic and 14-hydroxyl moiety) it was decided to use thiophosgene for the 




112 R = NH2 
124 R = NCS
109 R = NH2 
125 R = NCS
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Before removal of the BOC-protecting group, 17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy- 
^-(N'^-aminobenzylJguanidinylethyl-S.M-dihydroxy-indolotZ.S'ie.Zjmorphinan (126) and 17- 
cyclopropylmethyl-6l7-didehydro-4I5a-epoxy-5,-(N'-4-aminobenzyl)guanidinyl-3,14-dihydroxy- 
indolo[2\3':6,7] morphinan (127), were reacted with thiophosgene, to give the bisBOC- 
isothiocyanate derivatives in moderate yields. Subsequent treatment of (126) with 
trifluoroacetic acid removed the BOC protecting groups, affording compound (124). The 
treatment of (127) with trifluoroacetic acid gave a product, the mass spectometric analysis of 
which did not agree with the expected product (125). NMR analysis, however, showed that the 
BOC protecting groups were indeed removed. The poor solubility of both (127) and (125) has 
resulted in NMR spectra that are less than desirable. This reaction should therefore be 
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Numerous structure-activity relationship studies have been conducted on a wide range of opioid 
ligands, including both peptides and non-peptides.1,17,164 Varying degrees of success have 
been achieved via this method, although the studies are normally limited to a defined series of 
compounds. More recently, pharmacophore models have been developed by superimposing 
the structures of various selective ligands.165"168
Most pharmacophore models have been aimed at selective ligands and hence have focussed 
on either the p, k  or 8  receptor. For the kappa receptor more specifically, various groups have 
tried to find a common pharmacophore for benzomorphan and arylacetamide ligands.165,167 
Thus far, no convincing conclusion has been reached, and pharmacophore models are often 
quite dissimilar, despite similar compounds being compared. Site-directed mutagenesis169 and 
chimera studies68 have suggested that different classes of K-selective ligands interact with 
different residues in the receptor. For this reason, the lack of a detailed common 
pharmacophore is not surprising.
Recently, Filizola et a/.168 have attempted to find a 3D pharmacophore common to a wide 
variety of non-selective opioid ligands. By making use of 23, non-specific opioid ligands, a 3D 
model comprising four pharmacophoric centres in a defined spatial arrangement, was 
developed (Fig. 2)
B h y d r o p h o b ic  g ro u p
A-B = 2.51 ±0.07 
A-C = 3.53 ±0.56 
A-D =4.31 ±0.33
B-C = 4.02 ±0.46 
B-D = 3.98 ±0.80
C-D = 3.75 ±0.55
Fig. 2 3D Pharmacophore common to a wide variety of non-selective opioid ligands168
Obviously this method is based on the assumption that ligands can be overlapped about 
common pharmacophoric groups. A more robust approach would be the combination of 
pharmacophore modelling with receptor docking studies.167
C h y d r o p h o b ic  g ro u p
A p r o to n a te d  a m in e
D c e n tr o id  o f  a r o m a tic  g ro u p
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The three opioid receptor types identified to date, belong to the family of guanine nucleotide- 
binding protein (G protein)-coupled receptors (GPCR’s). The amino acid sequence of these 3 
receptor types is highly conserved, with 60 - 70% identity between the different types.165 All G- 
proteins share a conserved heptahelical transmembrane structure. Within the family, both the 
lengths of the 7 transmembrane alpha helices and the 3 extracellular loops are expected to be 
similar.170
Until recently, no high resolution structure for a GPCR had been published. A high quality 3D 
model for bacteriorhodopsin171 (not a member of the GPCR family) which was based on 
cryomicroscopy experiments and published in 1990, however, showed an overall three 
dimensional structure which was remarkably similar to that proposed for GPCR’s, even though 
the sequence homology was extremely low (<10%). It would seem likely that these receptors 
belong to the same functional class although not the same structural class.172 By means of 
homology modelling techniques, various GPCR’s have been modelled using bacteriorhodopsin 
as a template.172,173
A more recently published low resolution (9A) density map of bovine rhodopsin, a member of 
the GPCR family, has however shown distinct differences between bacteriorhodopsin and 
rhodopsin in terms of the arrangement of the seven helices.174 Alternative approaches to 
modelling GPCR’s which do not require the use of a template175 have therefore also been 
developed. The basis of many of these methods is the comparison of the amino acid sequence 
of the protein with that of other GPCRs.176 Firstly, amino acids that conserve polar character 
can be expected at helix-helix interfaces, while residues that conserve apolar character are 
more likely to be in contact with the lipids. Helical domains are most commonly predicted by 
means of a hydrophobicity profile. Further confirmation can be achieved by identifying the 
characteristic a-helix periodicity of 3.6 amino acids/turn. A Pro residue creates a specific 
distortion in an a-helix and hence only conserved Pro residues would be expected to form part 
of an a-helix. Non-conserved Pro residues could therefore indicate the boundary of a helix. 
The sequence divergence technique for the prediction of 3D protein structure also makes use of 
multiple sequence alignments. The variability profile of the aligned sequences is determined 
and used to predict the boundaries of transmembrane regions.
A low resolution structure of frog rhodopsin was published in 1997,177 however in August 2000, 
Palczewski et al. published the X-ray crystallographic structure of bovine rhodopsin (PDB 
1F88), with a resolution of 2.8 A.170 The amino acid sequence of bovine rhodopsin shows about 
20 - 25% identity with that of the 3 opioid receptor types. Since we now have a high resolution 
structure of a receptor belonging to the GPCR family, greater confidence can be placed in 
receptors designed by homology modelling.
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With the receptor model in hand, it is necessary to identify a potential active site for the ligand. 
In this respect it is often useful to look at residues that have been shown to form part of the 
active site in related receptors. Studies to determine the effect of mutations in the amino acid 
sequence have also provided useful insight into which residues influence ligand binding.
The interaction of a basic nitrogen with a conserved Asp residue has been noted for a variety of 
opioid ligands/5,167,169,178'179 and is in fact a common mode of ligand interaction among G 
protein-coupled receptors. Since this residue is found in a region which is highly conserved 
among the three opioid receptor types, it is thought to form a key interaction within the 
“message” locus - allowing non-selective opioid recognition.179 In the case of the kappa opioid 
receptor, this residue is Asp 138, which is located at the top of TM 3. Site-directed 
mutagenesis studies75,178 have shown this residue to play a crucial role in the binding of opioid 
ligands. Further site-directed mutagenesis167,169 and chimera studies68 have shown that apart 
from a common interaction with the acidic Asp 138 residue, the 3 major classes of kappa 
selective ligands, the morphinans, the arylacetamides and the peptides, interact with different 
residues in the receptor.
For the purpose of this study we have concentrated on interactions of the kappa receptor with 
morphinan-type ligands (128). The selectivity of the morphinan antagonists was reported to lie 
in the interaction of a basic “address” moiety with an acidic residue in EL 3 of the kappa 
receptor.68 This residue was identified as Glu 297,69 and further confirmation was obtained by 
site-directed mutagenesis studies.69,75 Portoghese et al. have shown that kappa affinity in the 
morphinan-antagonists depends on the presence of a free 3-OH group.180 This group has been 
reported to interact with the acidic residue His 291.77 Although no site-directed mutagenesis 
studies have been undertaken to confirm the importance of this group in the morphinans, the 
kappa affinity of ketazocine (KCZ, 129) was shown to decrease upon mutation of His 291.181 
Since KCZ displays a certain amount of kappa selectivity and shares a common 
pharmacophore, including a free phenolic OH group, we could expect similar interactions 
between the ligands in this study and the receptor.
HO
128 129
A wide variety of docking packages that show possible interactions of a ligand with a receptor, 
now exist. Large databases of compounds can now be screened within a reasonable amount 
of time in order to find compounds that may exhibit good binding. Currently, the greatest 
limitation to these docking packages is the scoring functions used to estimate the affinity of a
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ligand for the receptor.182 The two most important factors influencing affinity are hydrogen 
bonding and hydrophobic interactions.183 Apart from finding the correct balance between each 
of the above, other contributing factors such as molecular weight and the number of rotational 
bonds should also be included when designing a scoring function. Scoring functions are 
presently unable to rank ligands accurately in order of increasing affinity. The best results are 
obtainable when the ligands involved are highly similar.
3.2 DISCUSSION 
3.2.1 MODELLING THE k-OPIOID RECEPTOR
Specific homology modelling packages now exist which match the amino acid sequence of a 
known receptor with the sequence of the receptor to be modelled. Due to differing lengths 
between conserved regions, this matching can often be improved manually. The structure of 
the conserved regions is then copied from that of the known receptor. In order to propose 
possible 3D structures for the non-conserved regions, the Brookhaven Protein Database is 
searched for sections similar in both amino acid sequence and length, which can then be 
substituted into the receptor model.
The SYBYL homology modelling package, COMPOSER,184 was used to propose a model for 
the kappa opioid receptor (Appendix C). The integrity of this model, in terms of dihedral angle 
and bond planarity, was checked with the program, PROCHECK185 (Appendix D).
3.2.2 PHARMACOPHORIC REQUIREMENTS FOR OPIOID RECEPTOR BINDING
The naltrindole structure is known to bind to all three opioid receptors (although affinity for the 
8-receptor is significantly higher than for the p- or K-receptors). Compliance of this structure to 
the 3D pharmacophore model proposed by Filizola et a/.168, is demonstrated by Fig. 3. Since 
our compounds are all 5'-substituted naltrindole derivatives, it would be expected that binding to 
opioid receptors would occur without exception. A lack of binding could only occur as a result 
of steric interactions (/e. if the synthesised ligand were too large for the opioid binding site).
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A-B = 2.51 A 
A-C = 3.89 A 
A-D = 4.53 A
B-C = 3.96 A 
B-D = 3.66 A
C-D = 3.87 A 
applied to naltrindole
3.2.3 PHARMACOPHORIC REQUIREMENTS FOR SELECTIVE k-OPIOID RECEPTOR 
BINDING
In order for a ligand to show good selectivity for a specific receptor, it is necessary to include 
those features that enhance affinity at that receptor, as well as those features that decrease 
affinity at related receptors. As discussed in section 3.1, for good K-selective morphinan 
antagonist potency and affinity, N(17)H, a second basic nitrogen in the 5'-substituent and the 
phenolic 3-OH group are considered crucial. It has been proposed that these groups interact 
with Asp 138, Glu 297 and His 291, respectively.77 While N(17)H and the phenolic 3-OH group 
form part of the "message" portion of the ligand, possibly contributing towards high affinity, the 
second basic nitrogen forms part of the "address" portion, contributing towards selectivity. In 
this regard, the conferring of selectivity can be explained by means of the unfavourable 
interactions of the basic nitrogen group with the bulky Trp 284 residue and basic Lys 303 
residue, which occupy the analogous positions in the 5- and p-receptors respectively.77
Due to the rigidity of the naltrindole structure, the relative spatial arrangement of N(17)H and 
the 3-OH group is fixed. The 5-side chain, however, may contain a number of rotatable bonds, 
resulting in numerous possible orientations of the second basic nitrogen. It has been 
suggested that the optimum distance between the two basic nitrogen groups is ca. 11 A.71 
This distance approximately matches the distance between Asp 138 and Glu 297. For 
protonated groups such as guanidines, imidazolines and amidines, the positive charge can be 
delocalised across the 2 or 3 nitrogen atoms. Thus, in Table 2 we show the distance from 
N(17)H to each nitrogen group in the side chain of our compounds. Although the amide 
derivatives (130-132,59-63) do not have a basic nitrogen, the amide NH group is able to form a 
hydrogen bond with Glu 297, and are therefore included in this table. NorBNI (40)62 and GNTI 
(47)75 have been included for the sake of comparison.
A protonated amine
OHB hydrophobic group C hydrophobic group
centroid o f  aromatic group
HO
H
Fig. 3 The 3D pharmacophore proposed by Filizola et a/.,168 as
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133 98018 10.64, 11.68
134 98019 10.67, 12.08
135 98020 10.66, 12.07
70 98021 11.22, 13.45
71 99021 10.64, 11.93
72 99029 10.87, 9.86
73 99030 10.83, 9.79
74 99031 11.02, 9.86
82 98029 11.63, 9.79
83 99019 11.57, 9.76
84 99020 11.56, 10.01
85 20003 10.02, 11.46
86 20002 10.21, 11.78
87 99038 10.16, 9.94
76 98017 10.74
98 20032 11.18
104 20031 10.43, 12.05, 12.55
106 20022 9.34, 9.15, 11.07
110 20023 9.15, 9.34, 11.07
111 20024 9.45, 9.33,11.20
112 20025 9.45, 9.33, 11.20
125 20028 9.36, 9.18, 11.08
105 20029 9.57, 10.19, 11.31
107 20030 9.57, 10.19, 11.31
108 01017 9.59, 10.19, 11.32
109 01018 9.59, 10.20, 11.33
124 01019 9.59, 10.69,11.52
GNTI, 47 - 9.58, 10.29, 11.36
NorBNI, 40 - 11.03
aCompounds minimised according to the procedure described in experimental section
Table 2. Distances between N(17)H and the nitrogen groups in our compounds, GNTI and 
norBNI.
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As can be seen from the above table, the distance between the two basic centres in the 
compounds varies from 9.15-13.45 A. It is suggested that a deviation of ± 2 A (as seen in 
these compounds) would not be incompatible with good K-selectivity. There are two main 
reasons for this observation. Firstly, the measurements shown in the table above, and indeed 
for any free ligand with rotatable bonds, are dependent on the orientation of the rotatable 
groups. In order to measure these distances, the structures were first minimised. Although the 
energy of the ligand bound to the receptor should be low, it does not have to be the global 
minimum (usually up to 10kcal/mol above minimum). Therefore these distances could change 
when the ligand interacts with the receptor. Secondly, the distance given has been proposed to 
match the distance between Asp 138 and Glu 297. In order for strong hydrogen bonds to form, 
the two groups need to be 1.8-2.0 A apart (N-H O) and the bond angle should be as close to 
180° as possible.167 As illustrated by Fig. 4, various positions for the second basic group would 
facillitate a strong H-bond. It should also be noted that the position of the Glu 297 side chain 
within the receptor would also be fairly flexible.
H O distance N-H O angle N(17)-Nx distance
(A) (°) (A)
Na 1.74 154.1 9.09
Nb 1.76 173.9 11.23
No 1.73 164.5 9.52
Nd 1.72 158.6 11.08
Ne 1.74 168.1 12.70
Nf 1.78 169.7 13.37
Ng 1.73 163.0 14.10
Nh 1.72 166.3 14.42
Fig. 4 Possible positions of NH groups able to form hydrogen bonds with Glu 297
3.2.4 SPECIFIC PHARMACOPHORE FOR DOCKING STUDIES
Brandt et a/.165 previously reported that in the case of KCZ, the orientation of the hydrogen of 
the protonated nitrogen in the kappa pharmacophore was equatorial, whereas the orientation in 
the X-ray crystal structure was axial. The energy of the compound with the equatorial H group 
was not significantly higher than that of the compound with the axial H group (AAHf = 0.84 
kJ/mol in vacuo), and the inversion could therefore be expected to take place readily. Since 
KCZ and the morphinan-type kappa selective antagonists have been reported to bind similarly 
to the receptor (see section 3.1),165 it was of interest to determine if the model of the kappa 
receptor accommodated the equitorial NH group for the morphinan antagonists. The naltrindole
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pharmacophore, common to all the compounds, is expected to bind in the same orientation in 
each case. The selection of ligand used to determine the docking position and active site is 
therefore arbitrary.
The kappa selective, n-butyl amidine (70), with the proton in the axial position, was placed in a 
putative binding site in the kappa receptor, so that the N(17)H interacted with Asp 138 and the 
side chain amidine group formed two hydrogen bonds and a salt bridge with Glu 297 of the 
receptor. There was an additional interaction formed between Glu 209 and the indolic NH. 
Hydrophobic interactions could be seen with Val 134, lie 135, Trp 139, Met 142, lie 208, Trp 
287, lie 290, Phe 293, lie 294, Leu 309, Phe 314 and Leu 318.
The receptor/ligand complex was then subjected to simulated annealing, molecular dynamics 
and numerous minimisations, however, in each case the Asp 138 residue moved away from the 
N(17)H so that no position could be found where the protonated N(17) could interact with Asp 
138.
The structure with the best interaction energy* was then taken, the nitrogen inverted, and the 
ligand/protein reminimised. The resulting structure showed the retention of the above 
mentioned hydrophobic and ionic interactions, as well as the formation of a salt bridge between 
Asp 138 and the protonated N(17)H. The resultant interaction energy was about 5 kcal/mol 
lower, indicating a better docking position.
3.2.5 COMPOUNDS TO BE DOCKED
In order to gain maximum benefit from the modelling studies, we needed to investigate the 
docking of numerous ligands to the receptor model. It was therefore decided to make use of 
the ligands already described in this thesis (59-63,71-74,76,83-87,98,104-107,110-112,125), as 
well as ligands previously synthesised within our group (70,82,130-135)74 and the prototypical 
opioid K-antagonist, norBNI (40).62 All compounds docked were antagonists with affinities in the 
range of 0.3-22.0 nM at cloned human K-receptors transfected into Chinese Hamster Ovary 
cells {cf. sections 4.4 and 5.5.1).
’ Interaction energy cannot be used as a quantitative measure of the affinity of very different ligands for a receptor since 
changes in entropy and solvation are not taken into account. It is however useful for comparing different binding 
orientations of highly similar ligands in a receptor
59 R  = C H 3. n  = 6
6 0  R  *  C eH s. n  = 1
61 R  -  C 6H s „  n  = 2
62 R  = C6 H5., n  = 4
6 3  R  =  C 6H 40C H 3. n  «  1
130 R  = C H 2C H 3
131 R  = (C H 2)2C H 3
132 R  -  (CH 2)3C H3
72 R = (C H jfe C H j
73  R  = (C H 2)4C H 3
74  R  = (C H 2)eCH3
N -X 1
63 R  = C H C H i
8 4  R  = C (C H 3b
133 R  = C H 3
134 R  « C H 2C H 3
135 R M O b fe C H s
70 R  *  (C H 2h C H 3
71 R  = C H zC H fC H sfe
N - C - N - R
6 5  R  -  C H ^ H s
8 6  R = (C H 2)3C H 3
8 7  R  = (CH2)sC H 3
105 n  *  0 . R  = be nzy l 
107 n  «  0 . R  -  p -ch to rab en zy l
7 6  R  = N H 2 
98  R  = N (C H 3)2
i im  n  •  t,  r \  -  n
106 n » 2 ,  R « be n zy l
110 n  « 2. R  = p -ch to fob en zy t
111 n  *  2. R  *  p -n ttrob en zy l
112 n  •  2. R  = p -a m in o b e n zy l
125 n > 2 ,  R  = p -iso th io cya n a to -b e n zy l
3.2.6 ACTIVE SITE IDENTIFICATION
The above compounds were docked into the K-opioid receptor using the SYBYL package, 
FlexX.183,186 This package is useful in that the conformational flexibility of the ligand is taken 
into account. The receptor is however kept rigid. The active site was defined by selecting 
residues Asp 138, His 291 and Glu 297; and including residues within a radius of 5A. A base 
fragment is automatically selected and placed in the active site using an algorithmic approach 
based on a pattern recognition technique called pose clustering.187 Ideally, a base fragment 
should be large enough to make specific interactions with the receptor, but it should also have 
as few rotatable bonds as possible. In our structures, the rigid naltrindole "core" makes an 
excellent base fragment. The remainder of the ligand is then built up incrementally from other 
fragments. A table was generated for each ligand, showing the 30 best docking positions (as 
scored by the scoring function within the FlexX program).
The various docking positions generated by FlexX showed the naltrindole core of the molecule 
in essentially the same position in each case. For the higher scoring docking positions, the side 
chain was in a position that allowed interaction between the protonated nitrogen and the acidic 
side chain of Glu 297. The aliphatic, terminal portion of the side chain was found to occupy one
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of two hydrophobic pockets - either a pocket formed by residues in extracellular loop (EL) areas 
2 and 3, namely Phe 214, lie 208, Val 205 and Leu 309; or a pocket formed by residues in 
transmembrane (TM) regions 6 and 7, namely Phe 314, lie 290, Phe 293 and Leu 309.
In reality, both the receptor and ligand can display a certain amount of flexibility. In addition, 
FlexX does not take unusual bond angle restrictions into account, ie. the planarity of the amide 
bond was not maintained. The structures could therefore often be improved by inspection, 
manual manipulation and minimisation of the receptor/ligand complex.
Based on the FlexX generated structures, we were able to optimise the docking position for the 
naltrindole portion of the molecule. An ionic interaction could be seen between N(17)H and Asp 
138 (1.90 A , 132.3°), a hydrogen bond between the phenolic hydroxyl group and His 291 (2.49 
A , 147.5°) and a hydrogen bond between the pyrrole NH group and Glu 209 (2.16 A , 150.1°) 
(Fig. 5). Furthermore, hydrophobic interactions could be seen with residues Val 134, lie 135, 
Tyr 139, Met 142, Leu 212, Trp 287, lie 290, lie 294, lie 316 and Leu 318 (Fig. 6).
Fig. 5 Ionic interactions and hydrogen bonds between naltrindole and the K-opioid receptor
Fig. 6 Hydrophobic interactions betw een naltrindole and th e  K-opioid receptor
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3.3. DOCKING AT k-OPIOID RECEPTOR - RESULTS AND DISCUSSION
The naltrindole core of the molecule and most of the receptor residues were then fixed as 
aggregate, leaving only the 5'-side chain and surrounding hydrophobic groups for manipulation. 
In this way, we sought to determine the best position for each side chain. Since docking of the 
naltrindole portion was identical for all these structures, we hoped to find quantitative 
relationships between the Kj at the K-receptor and the interactions of the 5-side chain. Scoring 
the receptor/ligand interactions was accomplished using both the scoring package “SCORES" 
(Kd)188, and by determining the interaction energy (cf. section 3.2.5).
At this stage only at the K-receptor was being studied. Since interactions with the p- and 8- 
receptors were not investigated, the results obtained relate only to the affinity of the ligands for 
the K-receptor but say nothing about the selectivity. Below, descriptions of the interactions 
between the ligands and the receptor are given, as well as possible explanations (as seen from 
ligand/receptor interactions) for the observed pharmacological results. Since the docking of the 
naltrindole portion is constant, the descriptions focus on the interactions of the 5'-substituent. 
The ligands have been grouped together according to their various 5'-side chains, since 
comparison of the interactions is only valid for highly similar ligands (as pointed out previously 
for interaction energy).
3.3.1 ALKYL AMIDES (130-132)
The NH of the amide group, although unable to form ionic interactions, is able to form hydrogen 
bonds, due to hydrogen bond donor capabilities. In the case of these ligands, however, no 
such hydrogen bonds could be seen between Glu 297 and the NH group. Table 3 details the 
lipophilic interactions that could be seen for these compounds.





130 Phe 293, Leu 309, 
Phe 314
Hydrophobic Glu 297
131 lie 293, Phe 293, 
Leu 309, Phe 314
Hydrophobic Glu 297 - -
132 lie 293, Phe 293, 
Leu 309, Phe 314
Hydrophobic Glu 297 * • *












130 -196.4 -283.8 143.2 -55.7 8.93 1.57
131 -198.2 -283.1 143.1 -58.2 9.47 0.85
132 -198.1 -282.9 143.3 -58.5 9.47 0.68
3Total energy of the receptor/ligand complex, Energy of the receptor without the ligand, °Energy of the minimised 
ligand, d(E-Total) -  (E-receptor) -  (E-Ligand), Results from scoring package ‘SCORE’ , 'cf. section 4
TabSe 4 Interaction energy, Kq and K* values for alkyl amides (130-132)
Pharmacological assays (K| values) show that for this series of compounds, affinity for the k -  
receptor increases in the order 130<131<132. This trend would be predicted by both the 
interaction energies and Ko values for these compounds (Table 4). Since the 5-alkylamide 
side chain shows no ionic interactions or hydrogen bonds with the receptor, it is envisaged that 
hydrophobic interactions play an important role in the binding of these ligands. In Fig. 7, the 
increase in hydrophobic interactions, which accompany an increase in the length of the alkyl 
side chain, can clearly be seen.
130 131 132
Fig. 7 Hydrophobic interactions between alkyl amides (130-132) and the K-receptor
3.3.2 AROMATIC AMIDES (59-63)
For the amide series (59-63), the formation of hydrogen bonds was observed between the 
amide NH and both oxygen atoms of Glu 297. Although hydrophobic interactions were 
observed with residues lie 293, Phe 293, Leu 309 and Phe 314 (Table 5), the lipophilic n- 
stacking interactions seen between the aromatic groups of the ligand, Phe 293 and Phe 314 
were the stronger of the interactions. The heptylamide (59) has been included with these 
compounds since the amide functionality occupies the same relative position. Both the 
hydrogen bonds as well as the lipophilic interactions mentioned above for compounds (60-63) 
could be seen. Obviously 7i-stacking was not possible for (59).
66





59 lie 293, Phe 293, Hydrophobic Glu 297 2.19 151.1 H-bond
Leu 309, Phe 314 2.27 126.3 Weak H-bond
60 lie 293, Phe 293, Hydrophobic Glu 297 2.10 150.0 H-bond
Leu 309, Phe 314 2.40 137.5 Weak H-bond
61 lie 293, Phe 293, Hydrophobic Glu 297 2.22 150.9 H-bond
Leu 309, Phe 314 2.27 128.7 Weak H-bond
62 lie 293, Phe 293, Hydrophobic Glu 297 2.19 149.8 H-bond
Leu 309, Phe 314 2.34 130.0 Weak H-bond
63 lie 293, Phe 293, Hydrophobic Glu 297 2.23 146.6 H-bond
Leu 309, Phe 314 2.24 135.1 Weak H-bond











59 -202.9 -284.5 146.0 -64.4 10.4 21.89
60 -204.0 -284.9 146.4 -65.5 9.9 10.33
61 -203.6 -284.7 148.4 -67.3 10.4 2.21
62 -200.6 -284.0 148.7 -65.3 11.0 6.18
63 -204.6 -284.6 147.9 -67.9 9.16 2.11
“Total energy of the receptor/ligand complex, °Energy of the receptor without the ligand, 'Energy of the minimised 
ligand, d(E-Total) -  (E-receptor) -  (E-Ligand), 'results from scoring package “SCORE", 'cf. section 4
Table 6 Interaction energy, KD and Kj values for aromatic amides (59-63)
Kj values show that the affinity of the phenethylamide (61) for the K-opioid receptor is greater 
than that of either the benzyl (60) or phenylbutyl (62) analogues. In Fig. 8, the n-stacking 
interactions between the receptor and ligands (60-63) can be seen from above. The overlap of 
the aromatic rings is clearly best for compound (61). Although the aromatic group in compound 
(63) does not interact optimally with the aromatic residues of the receptor, the p-methoxy group 
is able to enhance the interactions. This is evidenced by a Kj value which approximates that of 
compound (61). Although the heptylamide (59) is able to form hydrophobic interactions, these 
are not as strong as the n-stacking interactions formed with the aromatic analogues. It should 
also be noted however that the end of the alkyl chain protrudes beyond the receptor. At this 
stage it is not clear whether receptors are found individually or as dimers or trimers. It is 
therefore uncertain what the effect of this protrusion would be, and whether the terminal portion 
would come into contact with another receptor or the lipid bilayer. For these amides (59-63), Kj 
values are in good agreement with interaction energies (Table 6). Ko values, however, do not 
seem to correlate well with either the Kj values or interaction energies.
Fig 8 Hydrophobic interactions between aromatic amides (60-63) and the K-receptor (clockwise
from top left 60, 61,63,62)
3.3.3 AMIDINES (133-135,70-71)
The amidines (133-135,70-71) show an ionic bond between the protonated nitrogen group and 
the acidic Glu 297 residue. In addition, weak hydrogen bonds can be seen between the 
amidine NH group and Glu 297, and between the protonated C=NH2+ and Asp 206. Lipophilic 
interactions were observed with residues Val 205, lie 208, Phe 214 and Leu 309 (Table 7).





133 Val 205, lie 208, Hydrophobic Glu 297 1.88 142.0 Salt bridge
Phe 214, Leu 309 2.06 136.9 Weak H-bond
Asp 206 2.71 133.0 Weak H-bond
134 Val 205, lie 208, Hydrophobic Glu 297 1.71 140.9 Salt bridge
Phe 214, Leu 309 1.92 134.2 Weak H-bond
Asp 206 2.58 146.3 Weak H-bond
135 Val 205, lie 208, Hydrophobic Glu 297 1.70 136.9 Salt bridge
Phe 214, Leu 309 1.96 130.0 Weak H-bond
Asp 206 2.60 145.9 Weak H-bond
70 Val 205, lie 208, Hydrophobic Glu 297 1.69 138.8 Salt bridge
Phe 214, Leu 309 1.96 131.7 Weak H-bond
Asp 206 2.63 146.2 Weak H-bond
71 Val 205, lie 208, Hydrophobic Glu 297 1.64 136.3 Salt bridge
Phe 214, Leu 309 1.90 129.0 Weak H-bond
Asp 206 2.63 148.4 Weak H-bond












133 -200.2 -282.5 149.6 -67.3 ND 0.29
134 -203.1 -282.1 149.0 -70.0 ND 0.28
135 -202.3 -281.7 150.1 -70.8 ND 0.25
70 -202.3 -281.9 150.0 -70.4 ND 0.30
71 -193.8 -276.9 150.0 -66.9 ND 1.39
*Total energy of the receptor/ligand complex, ‘’Energy of the receptor without the ligand, °Energy of the minimised 
ligand, d(E-Total) -  (E-receptor) -  (E-Ligand), eresults from scoring package ‘SCORE*, fcf. section 4
Table 8 Interaction energy, Kq and Kj values for amidines (133-135,70-71)
Kj values for this series of amidines (133-135,70-71) show high affinity for the K-opioid receptor. 
In addition, Kj appears to be independent from the length of the alkyl substituent (Table 8). 
This trend is loosely supported by the interaction energies. Kq values were not determined. 
Although compounds (135,70-71), having propyl, butyl and isobutyl groups respectively, show 
slightly better hydrophobic interactions with lie 208, than do the methyl and ethyl analogues 
(133-134), no significant improvement in hydrophobic interactions can be seen as the length of 
the alkyl chain increases. The high affinity seen for these compounds can be attributed to the 
strong ionic interaction and hydrogen bonds formed between the ligand and residues Glu 297 
and Asp 206. These interactions are similar for all compounds in this series (133-135,70-71) 
and are illustrated in Fig 9.
Asp 138
Glu 197
Fig 9 Ionic interactions and H-bonds between ethyl amidine (134) and the K-receptor
3.3.4 REVERSE AMIDINES (72-74)
The reverse amidine compounds (72-74) show an ionic bond between the protonated nitrogen 
group and the acidic Glu 297 residue. Additionally, a weak hydrogen bond can be seen
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between the NH group and Glu 297. Lipophilic interactions were observed with residues lie 
290, Phe 293, Leu 309 and Phe 314 (Table 9).





72 lie 290, Phe 293, Hydrophobic Glu 297 1.88 145.4 Salt bridge
Leu 309, Phe 314 2.28 132.2 Weak H-bond
73 lie 290, Phe 293, Hydrophobic Glu 297 1.83 147.9 Salt bridge
Leu 309, Phe 314 2.38 130.0 Weak H-bond
74 lie 290, Phe 293, Hydrophobic Glu 297 1.91 145.2 Salt bridge
Leu 309, Phe 314 2.25 133.2 Weak H-bond











72 -184.4 -267.4 148.5 -65.6 ND 1.60
73 -190.0 -268.6 148.3 -69.8 ND 1.44
74 -193.7 -268.4 148.7 -74.0 ND 5.61
"Total energy of the receptor/ligand complex, ^Energy of the receptor without the ligand, "Energy of the minimised 
ligand, d(E-Total) -  (E-receptor) -  (E-Ligand), eresults from scoring package ‘SCORE*, *cf. section 4
Table 10 Interaction energy, Kq and Kj values for reverse amidines (72-74)
As expected, amidines (72) and (73), which are able to form both an ionic interaction and a 
hydrogen bond to the K-receptor, show high affinity (low Kj) in binding assays (Fig. 10). Why 
the affinity of amidine (74), which interacts with the receptor in the same way as compounds 
(72) and (73), should be ~A fold lower is not clear at this stage. The long alkyl chain does 
however extend beyond the receptor helix, as was the case for the heptylamide (59), which also 
showed low affinity. For this series (72-74), interaction energies are not reflective of binding 
results (Kj) (Table 10). Kq values were not determined.
Gim
Fig. 10 Io n ic  in t e r a c t io n s  a n d  H - b o n d s  b e t w e e n  p r o p y l  r e v e r s e  a m i d in e  (72) a n d  t h e  K - r e c e p t o r
70
3.3.5 IMIDAZOLINES (82-84)
The imidazoline compounds (82-84) all displayed an ionic interaction between the protonated 
nitrogen and Glu 297 of the K-receptor. The unsubstituted compound (82) was able to form 
hydrophobic interactions with Val 205 and Leu 309 (Table 11).





82 Val 205, Leu 309 Hydrophobic Glu 297 1.68 141.4 Salt bridge
83 - - Glu 297 1.70 156.8 Salt bridge
84 - - Glu 297 1.70 158.0 Salt bridge











82 -202.4 -285.1 149.6 -66.9 ND 0.07
83 -195.1 -284.4 149.8 -60.4 8.67 1.39
84 -186.7 -283.2 149.1 -52.5 9.08 1.97
“Total energy of the receptor/ligand complex, "Energy of the receptor without the ligand, cEnergy of the minimised 
ligand, d(E-Total) -  (E-receptor) -  (E-Ligand), "results from scoring package “SCORE’’, 1cf. section 4
Table 12 Interaction energy, KD and Kj values for imidazolines (82-84)
Once again, the formation of a salt bridge between the K-receptor and the imidazoline ligands 
(82-84), results in low Kj values. The binding of the unsubstituted imidazoline compound (82) is 
further strengthened by the formation of lipophilic interactions between the imidazoline side 
chain, Val 205 and Leu 309 (typically 3.5 - 4.5A). As substitution of the imidazoline ring 
increases however, (83<84), the methyl groups take up a position which is less than the 
optimum distance from Val 205 and Leu 309 (Fig. 11). This results in negative steric 
interactions and lessens the affinity of the ligands for the receptor. The trend that is evident 
from the binding assays (82>83>84), is supported by the interaction energies found for the 
receptor/ligand complexes for these compounds (Table 12). As only two of the three KD values 
were determined, a valid comparison could not be made.
71
82 83 84
Fig. 11 H y d r o p h o b ic  in t e r a c t io n s  b e t w e e n  im id a z o l in e s  (82-84) a n d  t h e  K - r e c e p t o r
3.3.6 UREAS (85-87)
No ionic interactions or hydrogen bonds were seen between the urea derivatives (85-87) and 
the K-receptor. The aliphatic portion of the side chains showed hydrophobic interactions with lie 
290, Phe 293, Phe 314 and Pro 289 (only compound 87) (Table 13).









86 lie 290, Phe 293 
Phe 314
Hydrophobic Glu 297
87 lie 290, Phe 293 
Phe 314, Pro 289
Hydrophobic Glu 297











85 -199.4 -284.4 143.1 -58.0 7.90 12.32
86 -200.1 -284.2 143.3 -59.2 8.44 6.33
87 -201.6 -283.7 144.1 -62.0 8.98 8.13
Total energy of the receptor/ligand complex, Energy of the receptor without the ligand, cEnergy of the minimised 
ligand, d(E-Total) -  (E-receptor) -  (E-Ligand), eresults from scoring package “SCORE*, 'cf. section 4
Table 14 Interaction energy, Kq and Kj values for ureas (85-87)
The affinity of the urea derivatives (85-87) for the K-opioid receptor is not particularly high. 
Since no ionic interactions or hydrogen bonding is seen between the receptor and the ligands, 
the strength of the interaction is most probably dependant on the lipophilic interactions.
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Lipophilic interactions are observed with lie 290, Phe 293, Phe 314 and Pro 289 (for compound 
87). In each case, however, an NH group of the urea points toward the lipophilic residue, Leu 
309 (Fig. 12). This causes unfavourable interactions that would lower the affinity of the ligands 
for the receptor. Both Ko values and interaction energies tend to agree with each other, 
however they do not correctly predict the results of the binding studies (Kj) (Table 14).
85 86 87
Fig. 12 The unfavourable interaction of Leu 309 with the NH group of ureas (85-87)
3.3.7 UNSUBSTITUTED AND SUBSTITUTED AMINES (76,98)
The primary amine (76) showed the formation of a strong ionic interaction between the 
protonated nitrogen and Glu 297. Additionally, hydrophobic interactions could be seen with 
residues Phe 314 and lie 290 (Table 15). Although the substituted amine analogue (98) also 
displayed the formation of an ionic interaction, it was much weaker than that for compound (76) 
due to the less than optimum bond angle. Lipophilic interactions could be seen between the 
ethyl group (preceding the amine functionality) and hydrophobic residues lie 290, Phe 293 and 
Phe 314. (Table 15).





76 lie 290, Phe 314 Hydrophobic Glu 297 1.61 167.0 Salt bridge
98 lie 290, Phe 293, Hydrophobic Glu 297 1.94 129.0 Weak salt
Phe 314 bridge
Table 15 In t e r a c t io n s  b e t w e e n  a m i n e s  (76,98) a n d  t h e  K - r e c e p t o r
73
Compound E-Totala E-Receptor0 E-Ligandc E-lnteractiona Koe - k7
(kcal/moi) (kca l/mol) (kcal/moi) (kca l/mol) (nM)
76 -200.0 -284.7 145.8 -61.1 8.14 1.08
98 -195.1 -283.6 149.5 -61.0 7.80 0.40
ligand, d(E-Total) -  (E-receptor) -  (E-Ligand), ®results from scoring package ‘SCORE’, 'cf. section 4 
Table 16 Interaction energy, Ko and Kj values for amines (76,98)
The affinity of both (76) and (98) for the K-receptor was high, indicating strong ligand/receptor 
interactions (Table 16). The formation of a salt bridge between the protonated 5’-side chain 
and the receptor was therefore expected. Although the ionic interaction formed between the 
primary amine (76) and the receptor is stronger than that formed between tertiary amine (98) 
and the receptor, the latter shows greater affinity (lower Kj). This may be as a result of the 
stronger hydrophobic interactions between (98) and the K-receptor (Fig. 13).
1^p*5P
76 98
Fig. 13 Hydrophobic interactions between amines (76,98) and the K-receptor
3.3.8 GUANIDINYLETHYL DERIVATIVES (104,106,110-112,125)
All the guanidinylethyl derivatives (104,106,110-112,125) bound to the receptor in such a way 
as to allow the formation of a salt bridge between the protonated nitrogen group and Glu 297 
(Table 17). The unsubstituted guanidine (104) was able to form additional hydrogen bonds 
between the basic side chain and both Glu 297 and Asp 206. Lipophilic interactions could be 
seen between the side chain of (104) and Phe 314. The phenyl rings of derivatives (106,1 IQ- 
112,125) were able to interact with the hydrophobic residues lie 290, Phe 293, Leu 309 and 
Phe 314 (Table 17).
D elM
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106 lie 290, Phe 293, 
Leu 309, Phe 314
Hydrophobic Glu 297 1.97 148.2 Salt bridge
110 lie 290, Phe 293, 
Leu 309, Phe 314
Hydrophobic Glu 297 1.94 150.9 Salt bridge
111 lie 290, Phe 293, 
Leu 309, Phe 314
Hydrophobic Glu 297 1.94 150.5 Salt bridge
112 lie 290, Phe 293, 
Leu 309, Phe 314
Hydrophobic Glu 297 1.96 149.0 Salt bridge
125 lie 290, Phe 293, 
Leu 309, Phe 314
Hydrophobic Glu 297 1.95 149.7 Salt bridge












104 -199.4 -282.2 149.2 -66.4 8.81 0.49
106 -200.7 -283.8 154.4 -71.3 9.35 1.42
110 -202.6 -283.6 154.1 -73.1 10.1 2.41
111 -199.9 -283.5 156.8 -73.2 10.0 2.14
112 -200.6 -283.7 154.8 -71.8 9.4 0.95
125 -203.5 -283.6 154.8 -74.7 10.9 awaited
“Total energy of the receptor/ligand complex, “Energy of the receptor without the ligand. cEnergy of the minimised 
ligand, d(E-Total) -  (E-receptor) -  (E-Ligand), “results from scoring package “SCORE", cf. section 4
Table 18 Interaction energy, KD and Kj values for guanidinylethyl derivatives (104,106,110-112,125)
The high affinities of these compounds (104,106,110-112,125) for the K-receptor could be 
expected since a strong ionic interaction is able to form between the protonated 5’-side chain 
and Glu 297 (Fig. 14). The phenyl groups are also able to form strong hydrophobic 
interactions. The unsubstituted guanidine moiety of compound (104) is oriented differently to 
the guanidine moiety of the aromatic analogues. This allows (104) to form additional hydrogen 
bonds (Fig. 15). The aromatic compounds (106,110-112,125) are unable to take up this 
position due to steric hindrance. If the guanidine moiety of compound (104) is positioned as for 
the aromatic guanidines, the resulting ligand/receptor interactions are weaker. For the 
guanidinylethyl series of compounds, (104,106,110-112,125), both Kq values and interaction 
energies would predict a trend in binding affinity opposite to that observed in the 
pharmacological assays (Table 18).
Fig. 14 Ionic interactions and H-bonds between benzyl guanidine (106) and the K-receptor
Asp
Fig. 15 Ionic interactions and H-bonds between the unsubstituted guanidine (104) and the k -
receptor
3.3.9 GUANIDINYL DERIVATIVES (105,107)
The best docking position found for the benzyl and p-chlorobenzyl guanidinyl derivatives 
(105,107) allowed the formation of a weak ionic interaction between the protonated nitrogen 
and the carboxylic group of Glu 297. Hydrophobic interactions were seen with residues Leu 
309, lie 290, Phe 314 and Phe 293 (Table 19).





105 lie 290, Phe 293, Hydrophobic Glu 297 1.77 122.4 Weak salt
Leu 309, Phe 314 bridge
107 lie 290, Phe 293, Hydrophobic Glu 297 1.77 122.4 Weak salt
Leu 309, Phe 314 bridge












105 -195.7 -278.0 155.7 -73.4 ND 0.86
107 -198.2 -278.0 155.3 -75.4 ND 0.66
aTotal energy of the receptor/ligand complex, Energy of the receptor without the ligand, ‘"Energy of the minimised 
ligand, d(E-Total) -  (E-receptor) -  (E-Ligand), eresults from scoring package ‘SCORE*, *cf. section 4
Table 20 Interaction energy, KD and Kj values for guanidinyl derivatives (105,107)
The salt bridge that is able to form between the protonated 5’-side chain and the receptor is 
slightly weaker than the average ionic interaction, since the bond angle is less than ideal (Fig. 
16). Nevertheless, this interaction is sufficient to ensure that guanidinyl derivatives (105,107) 
show good affinity for the K-opioid receptor. The aromatic portion of the side chain lies within a 
hydrophobic pocket formed by residues Phe 293, lie 290, Leu 309 and Phe 314. n-Stacking 
interactions, with the aromatic ring of the ligands lying between Phe 314 and Phe 293 (as seen 
for the aromatic amides), are particularly strong and would therefore enhance ligand affinity. Kj 
values show little change upon substitution of the aromatic ring (Table 20). Once docked into 
the receptor, the aromatic portion of the ligand lies near, but does not extend beyond, the edge 
of the receptor. At the moment it is uncertain if there would be other residues in this vicinity (for 
example from another opioid receptor) with which interactions could take place. The interaction 
energies for the two receptor/ligand complexes are not vastly different, however they would 
predict Kj values less similar than those found during the pharmacological assays.
Asp 138
Glu i n
Fig. 16 Ionic interactions and H-bonds between benzyl guanidine (105) and the K-receptor
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3.3.10 norBNI (40)
The expected salt bridge could be seen between the second protonated N(17)H and Glu 297. 
Lipophilic interactions were seen with residues Val 205, lie 208, Phe 214, Phe 293, Leu 309, 
Tyr 312 and Phe 314 (Table 21).





40 Val 205, lie 208, 
Phe 214, Phe 293, 
Leu 309, Tyr 312, 
Phe 314
Hydrophobic Glu 297 2.16 171.7 Salt bridge
Table 21 Interactions between norBNI (40) and the K-receptor
Compound E-Totala E-Receptor0 E-Ligandc E4nteractiona Koe Kjf
(kcal/moi) (kcal/moi) (kcal/moi) (kca l/mol) (nM)
107 -87.5 -280.0 269.6 -77.1 10.00 0.20
"Total energy of the receptor/ligand complex, bEnergy of the receptor without the ligand, cEnergy of the minimised 
ligand, d(E-Total) -  (E-receptor) -  (E-Ligand), eresults from scoring package “SCORE’, 'cf. section 4
Table 22 Interaction energy, Kq and Kj values for norBNI (40)
In agreement with previous findings, norBNI (40), is able to form ionic interactions between 
N(17)H and N(17’)H and residues Asp 138 and Glu 297^ (Table 22). Interestingly, the second 
pharmacophore was positioned such that hydrophobic interactions occurred with both of the 
hydrophobic pockets identified in section 3.2.7. The second cyclopropylmethyl group was found 
to interact with residues Phe 293, Phe 314 and Leu 309 (TM 6 and TM7), while the phenolic A 
ring and piperidine of the address pharmacophore showed hydrophobic interactions with Val 
205, lie 208, Phe 214 and Tyr 312 (mainly in EL 2) (Fig. 17).
JH
Fig. 17 Hydrophobic interactions between norBNI (40) and the K-receptor
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NorBNI (40), a bivalent K-selective antagonist, was of particular interest to us due to its 
relatively rigid structure. It was once believed that norBNI might bind to two receptors, causing 
dimerisation. This has however been shown to be unlikely, since an isomeric form of norBNI 
meso-norBNI (136),51 in which one of the pharmacophores was substituted with the 
enantiomeric (inactive) pharmacophore, also displays potent kappa-selective antagonist 
activity. We were able to dock meso-norBNI (136) into our receptor model, showing that the 
second pharmacophore would again form hydrophobic contacts with the residues in these two 




3.4 COMPARISON OF DOCKING AT DIFFERENT OPIOID RECEPTORS
After considering the interaction of these compounds with the K-receptor (/e. looking at affinity), 
an investigation was made into selectivity by comparing these interactions with interactions at 
the p- and 5-receptors.
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The n-butyl amidine (70)74 was selected as an example of a compound showing greater affinity 
for the K-opioid receptor than for either the p- or 6-receptors. The hexylurea (87) showed 
slightly greater affinity for the 6-opioid receptor than for the K-receptor, while urea (86), having a 
butyl side chain, showed approximately equal affinity for the p- and K-opioid receptors.
|.nAAA
70 86 87
The results of preliminary docking studies conducted with these ligands are shown below. 
Interaction energies are quoted as a form of comparison, however, these values may be 
misleading due to the differences between the individual receptors. Greater insight can be 
gained by examining the receptor/ligand complexes for ionic interactions, hydrogen bonds and 
hydrophobic interactions.
3.4.1 COMPARISON OF BINDING TO k -  AND 8-RECEPTORS
Amidine (70) was docked into the K-receptor as described in sections 3.2.7 and 3.3.3 (Fig. 19). 
Ionic interactions were seen between N(17)H and Asp 138 and between the protonated 5’-side 
chain and Glu 297. Additional hydrogen bonds were able to form between the pyrrole NH 
group and Glu 209, the phenolic hydroxyl group and His 291 and between the side chain NH 
group and Glu 297. Hydrophobic interactions were made with the lipophilic residues Val 134, 
lie 135, Tyr 139, Met 142, Val 205, lie 208, Leu 212, Phe 214, Trp 287, lie 290, lie 294, Leu 
309, lie 316 and Leu 318 (Table 23). The interaction energy found for amidine (70) with the k -  
opioid receptor is -70.4 kcal/moi.
Compound (70) was then docked into the 6-receptor,189 and manually manipulated and 
minimised until the best docking position was found (Fig. 20). A salt bridge could be seen 
between N(17)H and Asp 128, while C(4)0 formed a hydrogen bond to Trp 274. The 
hydrophobic residues Val 124, Tyr 129, Val 196, Leu 200, Lys 214, Phe 218, Phe 222, lie 277, 
Trp 274, Val 281, lie 282 and Thr 285 were also able to interact with amidine (70). No ionic 
interactions or hydrogen bonds could be seen between the 5’-side chain and the 5-opioid 
receptor (Table 23). The interaction energy found for amidine (70) with the 8-receptor is -46.7  
kcal/moi.
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Val 134, lie 135, Tyr 139, 
Met 142, Val 205, lie 208, 
Leu 212, Phe 214, Trp 287, 
lie 290, lie 294, Leu 309, 
lie 316, Leu 318
70
5-receptor
N(17)H Asp 128 C(4)0 Trp 274 Val 124, Tyr 129, Val 196, 
Leu 200, Lys 214, Phe 
218, Phe 222, lie 277, Trp 
274, Val 281, lie 282, Thr 
285
Table 23 Interactions between amidine (70) and the k -  and 5-receptors
.Val 205 Phe 214
Fig. 19 Ionic interactions and H-bonds between amidine (70) and the K-receptor
As can be seen from the above table, the ionic interactions and hydrogen bonding between 
amidine (70) and the K-receptor are far superior to those that are able to form between (70) and 
the 5-receptor. This would result in greater affinity for the K-opioid receptor. A comparison of 
the interaction energies further confirms this finding.
Lyi 214
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Fig. 20 Ionic interactions and H-bonds between amidine (70) and the 5-receptor
The urea derivative (87) was docked into the K-receptor as described in sections 3.2.7 and 
3.3.6 (Fig. 21). Ionic interactions were seen between N(17)H and Asp 138. Additionally 
hydrogen bonds could be seen between the pyrrole NH group and Glu 209 and between the 
phenolic hydroxyl group and His 291. Lipophilic interactions were made with the hydrophobic 
residues Val 134, lie 135, Tyr 139, Met 142, Leu 212, Trp 287, lie 290, Phe 293, lie 294, Leu 
309, Phe 314, lie 316 and Leu 318 (Table 24). The interaction energy for urea (87) and the k -  
receptor is -62.0 kcal/moi.
The docking position of urea (87) within the 5-receptor,189 was improved by manual 
manipulation and minimisation, until the optimum position was found (Fig. 22). A salt bridge 
could be seen between N(17)H and Asp 128. Hydrogen bonds were formed between C(4)0 
and Trp 274, between the carbonyl of the urea moiety and Lys 214 and between the second NH 
group of the urea and Asp 210. The lipophilic residues Val 124, Tyr 129, Val 196, Leu 200, Lys 
214, Val 217, Leu 200, Phe 222, lie 277, Trp 274, Val 281 and Leu 300 were able to form 
hydrophobic interactions with urea (87) (Table 24). The interaction energy found for urea (87) 
with the 6-receptor is -70.3 kcal/moi.
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Compound Ionic interactions Residue H-bonds Residue Hydrophobic interactions
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K-receptor




Val 134, lie 135, Tyr 139, 
Met 142, Leu 212, Trp 287, 
lie 290, Phe 293, lie 294, 










Val 124, Tyr 129, Val 196, 
Leu 200, Lys 214, Val 217, 
Leu 200, Phe 222, lie 277, 
Trp 274, Val 281,Leu 300
Table 24 Interactions between urea (87) and the k -  and 5-receptors
The interaction energy for urea (87) and the K-opioid receptor is relatively high, although there 
are no ionic interactions between the 5’-side chain and the receptor. This could be attributed to 
strong hydrophobic interactions, which would increase the affinity of the ligand for the receptor. 
However, when urea (87) is docked into the 5-opioid receptor, the 5’-side chain is able to form 
two hydrogen bonds to residues within the 6-receptor active site. Ionic interactions, hydrogen 
bonds and hydrophobic interactions with the naltrindole portion of the molecule further 
contribute to the increased affinity shown by (87) for the 5-receptor. The interaction energy for 
(87) in the 5-receptor is also lower than that for the K-receptor, indicating greater affinity. The 
interaction of the carbonyl group of urea (87) with Lys 214 is particularly interesting since a 
similar interaction has been proposed for 5-selective peptides.190
Asp 138
Fig. 21 Ionic interactions and H-bonds between urea (87) and the K-receptor
Trp 274
Fig. 22 Ionic interactions and H-bonds between urea (87) and the 8-receptor
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3.4.2 COMPARISON OF BINDING TO k -  AND p-RECEPTORS
The docking position of amidine (70) is described in section 3.4.1 (Fig. 19). A summary of the 
interactions described in that section can be found in Table 25. The interaction energy found 
for amidine (70) with the K-opioid receptor is -70.4 kcal/moi.
The butyl amidine (70) was docked into the p-receptor,189 and manually manipulated and 
minimised until the best docking position was found (Fig. 23). An ionic interaction was able to 
form between N(17)H and the acidic Asp 147 residue. In addition, this residue was able to form 
a hydrogen bond with the C(14)OH group. Lipophilic interactions could be seen between the 
ligand and residues Tyr 148, Met 151, Val 236, lie 296, Val 300, lie 301 and Phe 320 (Table 
25). The interaction energy found for amidine (70) in the p-receptor is -33.3 kcal/moi.













Val 134, lie 135, Tyr 139, 
Met 142, Val 205, lie 208, 
Leu 212, Phe 214, Trp 287, 
lie 290, lie 294, Leu 309, 
lie 316, Leu 318
70
p-receptor
N(17)H Asp 147 C(14)OH Asp 147 Tyr 148, Met 151, Val 236, 
lie 296, Val 300, lie 301, 
Phe 320
Table 25 Interactions between amidine (70) and the k -  and p-receptors
Met 151 Asp 147
Val
Fig. 23 Ionic interactions and H-bonds between urea (87) and the p-receptor
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From Table 25, it can clearly be seen that amidine (70) is able to form a greater number of ionic 
interactions, hydrogen bonds and hydrophobic interactions with the K-receptor than with the p- 
receptor. This results in the affinity of amidine (70) for the K-receptor being significantly higher 
than the affinity for the p-receptor. The interaction energies for compound (70) with each of the 
receptors clearly reflect these differences.
The n-butylurea (8 6 ) was docked into the K-receptor as described in sections 3.2.7 and 3.3.6 
(Fig. 24). The docking position allowed the formation of an ionic interaction between N(17)H 
and Asp 138, as well as hydrogen bonds between the pyrrole NH group and Glu 209 and 
between the phenolic hydroxyl group and His 291. Lipophilic interactions were made with the 
hydrophobic residues Val 134, lie 135, Tyr 139, Met 142, Leu 212, Trp 287, lie 290, Phe 293, 
lie 294, Phe 314, lie 316 and Leu 318 (Table 26). The interaction energy for urea (86 ) and the 
K-receptor is -59.2 kcal/moi.
Urea (8 6 ) was placed in such a position within the p-opioid receptor, so as to allow the 
formation of a salt bridge interaction between N(17)H and Asp 147.189 The position was then 
improved by manual manipulation and minimisation, until the optimum position was found (Fig. 
25). Hydrogen bonds could be seen between the C(14)OH group and Asp 147, and between 
the carbonyl group of the urea and His 297. The hydrophobic residues Tyr 148, Val 236, Phe 
237, lie 296, Val 300, lie 301 and Phe 320, were able to form lipophilic interactions with urea 
(8 6 ) (Table 26). The interaction energy found for urea (87) with the p-receptor is -40.2 
kcal/moi.
Compound Ionic interactions Residue H-bonds Residue Hydrophobic interactions
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K-receptor




Val 134, lie 135, Tyr 139, 
Met 142, Leu 212, Trp 287, 
lie 290, Phe 293, lie 294, 








Tyr 148, Val 236, Phe 237, 
lie 296, Val 300, lie 301, 
Phe 320
Table 26 Interactions between urea (8 6 ) and the k -  and p-receptors
The 5'-side chain of urea (8 6 ) is unable to form any ionic interactions or hydrogen bonds with 
the K-opioid receptor. With the p-receptor, however, the carbonyl group of the urea moiety is 
able to interact with the basic His 297 residue. This would strengthen the affinity of the ligand 
for the receptor. The naltrindole portion of urea (8 6 ) is however able to form stronger 
interactions with the K-receptor. In practice, the affinity of urea (8 6 ) for the k -  and p-receptors is
86
approximately equal (cf. 6.33 nM and 4.80 nM respectively). This result could not have been 
predicted by looking at the interaction energies of the two receptor/ligand complexes.
Fig. 24 Ionic interactions and H-bonds between urea (86) and the K-receptor
Val 296
Fig. 25 Ionic interactions and H-bonds between urea (86) and the p-receptor 
3.5 CONCLUSIONS AND FUTURE WORK
Docking of the various ligands to the model of the K-receptor resulted in a complex that utilised 
residues, within the receptor, that had previously been shown to be of importance (mutation and 
chimera studies). It proved impossible to find a quantitative relationship that held for all the 
structures docked. This can, in part, be attributed to the shortcomings of scoring functions as 
discussed in section 3.1. The further development of such a model would therefore be aided by 
the inclusion of factors such as entropy and solvation. The K-affinities of the compounds
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modelled in this study were not vastly dissimilar, making consistent prediction by the model 
more difficult.
It was, however, possible to derive qualitative descriptions of the interactions involved, and in 
this way, to provide a degree of post-hoc rationalisation of the pharmacological data. The hope 
was to identify common trends in series showing both high and low selectivity. Additionally, 
potential structures were sought, which would show good interactions with the modelled 
receptor, in the hope that synthesis and subsequent pharmacological testing of these 
compounds might lead to novel, potent and selective ligands.
For all the compounds docked, the presence of a protonated nitrogen group in the 5-side chain, 
which could be suitably positioned for ionic interaction with the acidic Glu 297 residue, ensured 
good affinity for the K-opioid receptor. This caused a further increase in selectivity by 
decreasing affinity at the p- and 8-receptors. Since the presence of a carbonyl group in the 5’- 
side chain increased affinity for the p- and 5-receptors, this group should be omitted from the 5’- 
side chain of potential K-selective ligands. As the K-selectivity studies were only conducted on 
the above three ligands, further conclusions, such as the influence of steric bulk, cannot be 
discussed at this stage.
By examining the docking of ligands (59-63,70-74,76,82-87,98,104-107,110-112,125,130-135) 
within the K-opioid receptor, further modifications that might increase ligand affinity and/or 
selectivity were identified.
The FlexX generated docking positions highlighted two hydrophobic pockets with which the 
aliphatic portion of the 5-side chain could interact (c f section 3.2.6). Interestingly, norBNI (40), 
a highly potent and selective K-antagonist, was able to interact with both of these hydrophobic 
pockets (cf. section 3.3.10). It was reasoned therefore that the addition of a second aliphatic 
moiety to our basic 5’-side chain, could increase affinity for the K-receptor and, due to increased 
steric bulk, possibly also decrease affinity for the p- and 8-receptors. Compounds (113-117, 
section 2.6) were synthesised in order to test this hypothesis. The pharmacological results are 
however still outstanding.
H H
113 R1 = R2 = (CH2)3CH3 114 R1 = R2 = (CH2)3CH3
115 R1 = R2 = (CH2)2CH3
116 R1 = (CH2)2CH3, R2 = cyclopropylmethyl
117 R1 = CH2C6H5, R2 = cyclopropylmethyl
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The indole NH group is able to form a hydrogen bond with Glu 209. Replacement of the NH by 
an NH2+ group.would allow a stronger ionic interaction to form. A basic Lys 227 residue, which 
would be able to form an ionic interaction with a negatively charged moiety, is also in close 
proximity to the indole. A compound such as (137) would be able to interact with both of these 
residues forming strong ionic interactions (Fig. 26) and enhancing the affinity of the ligand for 
the receptor. Compounds of this nature have yet to be made and tested.
HO





In the early years of opioid research, the pharmacological activity of new opioid ligands could 
only be evaluated by means of in vivo investigations. These techniques involved assessing the 
response of test animals to nociceptive stimuli, before and after treatment with the test ligand. 
The potency of different opioid drugs could be quantitatively compared by measuring the 
response time, or number of responses over a given period of time. The antagonist ability of a 
compound could be measured in terms of its ability to reverse the antinociceptive effects of a 
known opioid agonist, in an animal subjected to nociceptive stimuli.
The potential for misinterpretation of results exists -  of particular significance, the morphine 
antagonist, nalorphine, was originally shown to be inactive as an agonist in animal nociceptive 
tests,191 but later displayed analgesic properties in humans.31 More recently however, 
antinociceptive tests showing greater sensitivity have been developed (eg. abdominal stretch). 
These tests are able to provide information on k- and 5-, as well as p-activity.
Recognizing the presence of opioid receptors in several peripheral tissues, Kosterlitz et a/.192 
developed the guinea-pig ileum (GPI) and mouse vas deferens (MVD) isolated tissue assays 
during the 1960’s. These were assays identifying the agonist or antagonist properties of a test 
compound. Secondary factors, such as drug distribution, metabolism and excretion, which 
complicate in vivo investigations, are less likely to play a role in isolated tissue assays. The 
application of in vitro assays has allowed greater insight into the structure-activity relationships 
found in opioid ligands.
The use of radioligand binding techniques has greatly increased, particularly since the 
identification and subsequent purification of homogenous populations of receptor types. At low 
concentrations, a drug will selectively bind to the site for which it has the highest affinity.193 
Hence, by introducing a radioactive marker into a selective ligand, the amount of ligand bound 
to a specific tissue sample can be measured, and the relative affinity of the test compound for 
each receptor type can be determined.
Following the cloning of opioid receptors in the 1990’s,6 assays have been developed which 
measure the stimulation of individual cloned receptors. Single human opioid receptor types 
have been transfected into Chinese Hamster Ovary cells.194 Binding of an agonist to these 
cloned receptors causes stimulation of [35S] GTPyS binding. The extent of stimulation of [35S] 
GTPyS binding can be measured by radio-emission. Functional assays of the above type are 
now replacing the MVD and GPI assays.
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4.2. IN VITRO ASSAYS 
4.2.1 BINDING ASSAYS
Radioligand binding studies are used to determine ligand binding affinity, and hence selectivity, 
of various ligands for the opioid receptor types. Tritium, and less frequently [125l], have been 
incorporated into the selective agonists DAMGO (11) (p ) ,  DPDPE (13) ( 6 )  and U69593 (16) ( k ), 
and displacement of these radioligands from receptors by a test compound gives a measure of 
ligand affinity.
The ability of unlabeled test compounds to compete for binding sites with receptor selective 
radiolabeled ligands, gives an indication of the affinity of the unlabeled compound for the 
specific receptor type. The concentration of competitor necessary to lower the binding of the 
radioligand by 50% (IC50) can be determined. This figure is used as an indication of the affinity 
of the test compound for the receptor. The IC50 value is related to the dissociation constant for 
the inhibitor (Kj) by equation (1):195
Ki = IC 50/(1+([D ]/K 0)) (1)
where,
K| = dissociation constant of inhibitor
IC50 = concentration of inhibitor lowering binding by 50%
[D] = concentration of radioligand 
Kd = dissociation constant of radioligand
Since the IC50 value is a function of the concentration of radioligand, care must be taken to 
ensure that identical assay conditions are used when comparing data. Kj is however 
independent of [D], and is thus a much more reliable comparison of the affinity of different test 
ligands.
4.2.2 FUNCTIONAL ASSAYS
Until recently, the tissue preparations most commonly used in in vitro assays were the 
myenteric plexus-longitudinal-muscle preparation from the isolated ileum of the guinea pig 
(GPI),196 which contains mainly p- and K-receptors, and the mouse vas deferens (MVD),192 
which contains all three receptor types. The effect of an opioid agonist is to dose-dependently 
inhibit the electrically induced muscle contraction of the sample tissue. Antagonist action can 
be measured by the extent to which contraction is re-established on administration of the test 
drug to a tissue pre-treated with a standard selective agonist.
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In the mid 1990’s Traynor and Nahorski197 showed the binding of the GTP analogue, guanosine- 
5’-0-(3-[35S]thio)triphosphate ([35S] GTPyS), to cell membranes of the human neuroblastoma 
SH-SY5Y cell line, to be a concentration dependent, opioid receptor-mediated process. Assays 
have since been developed, making use of cloned single human opioid receptor types, which 
have been transfected into Chinese Hamster Ovary cells.194 The opioid agonist-mediated 
stimulation of [35S] GTPyS binding in the cell membranes of these cells thus provides a 
functional measure of agonist occupation of opioid receptors and offers a simple method for the 
determination of efficacy and intrinsic activity of opioid agonists. The use of [35S] GTPyS assays 
has now superseded the use of isolated tissue assays. For antagonists, the equilibrium 
dissociation constant, Ke, is calculated.
4.3 IN VIVO ASSAYS
In vivo assays are primarily based upon the response of rodents to various nociceptive stimuli 
such as temperature, (eg. mouse hot plate, rat tail flick and mouse warm water tail withdrawal 
tests), pressure, (rat tail pressure and mouse tail pinch tests), chemical irritants (mouse 
abdominal stretch test) and electric shock.
Thermal assay procedures are widely used, and are useful in assessing the efficacy of p- 
agonists and antagonists by utilizing different water temperatures. At higher temperatures (55 
°C as opposed to 50 °C) the actions of a partial agonist may be ineffective in overcoming the 
nociceptive stimulus, thereby allowing its antagonist actions to become demonstrable. A 
competitive antagonist would shift the dose-response curve of a known agonist to the right. The 
dose-response curve obtained in the presence of a non-competitive (irreversible) antagonist, 
would be flatter as well as shifted to the right. This implies an increase in the dose of the 
agonist required to get the same effect, as well as a decrease in the maximum effect 
attainable.198
Intraperitoneal injection of chemical irritants such as phenylquinone, acetylcholine and acetic 
acid cause an abdominal stretch response in rodents, which can be blocked by various 
analgesic agents. The average number of abdominal stretches (arching of the back, pelvic 
rotation or hind limb rotation) in a group of rodents, pretreated with a test compound, can be 
counted and compared to the average number of stretches in an untreated control group. In a 
study by Tyers and co-workers, in which various in vivo assays were compared, the mouse 
abdominal stretch assay was able to detect the greatest range of agonists with the greatest 
sensitivity.200 Agonists at k -  and 8-receptors have been shown to be consistently active only in 
the anti-stretch assays,201 although K-agonists of high efficacy are active in thermal models. 
Additionally, the selectivity of antagonist actions of a test compound can be determined by use 
of selective prototype agonists.
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At the time of submission, in vivo test results for our compounds were still outstanding.
4.4 RESULTS
In each case the standard K-selective opioid antagonist norBNI (40)62, tested under similar 
conditions to our compounds, has been included in the tables for comparison.
4.4.1 AMIDE SUBSTITUENTS
Compounds 59-63 (Table 27) were prepared as described in section 2.1 and submitted for 
pharmacological evaluation as the hydrochloride salts. These were compared to compounds 
(130-132), prepared by Jales74 and submitted for pharmacological evaluation as the 
hydrochloride salts.







Compound Structure R BU Number
130 A CH2CH3 98022
131* A (CH2)2CH3 98023
132 A (CH2)3CH3 98024
59 B (CH2)6CH3 99028
60 B CH2C6H5 99036
61 B (CH2)2C6H5 99037
62 B (CH2)4C6H5 20001
63 B CH2C6H4OCH3(p ) 20021
from reference 74
Table 27 Amide substituted compounds submitted for pharmacological testing
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The binding affinities of the compounds were measured in cloned human opioid receptors










130 22.97 ± 11.10 3.12 ±0.50 1.57 ±0.80 2 15 2
131* 30.97 ±0.10 3.70 ± 0.34 0.85 ± 0.40 2 36 4
132* 31.59 ±0.59 7.67 ± 0.64 0.68 ± 0.30 2 46 11
59 61.91 ±6.03 70.15 ±33.93 21.89 ±7.11 2 3 3
60 43.95 ± 8.27 11.19 ±2.86 10.33 ±0.66 2 4 1
61 23.53 ± 7.32 3.53 ±1.24 2.21 ± 0.35 2 11 2
62 37.05 ± 9.45 59.45 ± 4.82 6.18 ±0.47 2 6 10
63 4.64 ± 0.58 7.41 ± 0.59 2.11 ± 1.04 2 2 4
40, norBNI 21.0 ±5.0 5.7 ± 0.9 0.20 ± 0.05 2 105 28
from reference 74
Table 28 Binding affinities measured in cloned human opioid receptors
[35S] GTPyS assays were performed in cloned human opioid receptors (Table 29). Data 
provided by NI DA Opiate Treatment Drug Discovery Program (under contract to SRI)
Ke(nM) ± 
SEM
p-CHO 8-CHO k -C H O
Compound membranes membranes membranes n p/K 8/k
DAMGO DPDPE U69,593
130 4.94 ± 1.08 0.38 ± 0.05 0.48 ± 0.27 4 10 1
131* 3.17 ±0.34 0.30 ±0.10 0.35 ± 0.23 4 9 1
132* 3.37 ±1.22 0.23 ± 0.04 0.46 ±0.14 5 7 0.5
59 6.86 ± 0.93 6.95 ± 0.86 0.29 ± 0.08 5 24 24
60 4.40 ± 0.74 2.99 ± 0.22 0.73 ± 0.04 5 6 4
61 2.70 ± 0.31 1.21 ±0.05 0.17 ±0.03 6 16 7
62 2.78 ± 0.21 5.15 ±0.25 0.26 ± 0.02 5 10 20
63 0.94 ±0.12 6.20 ± 0.49 0.28 ± 0.04 8 3 22
40, norBNI 18.9 ±1.8 4.42 ± 0.38 0.04 ± 0.004 484 113
from reference 74
Table 29 [35S] GTPyS assays performed in cloned human opioid receptors
94
Of the more recently synthesised amides, (59) is most closely related to the original amides 
prepared by Jales.74 The heptyl side chain provides a total chain length of 9 atoms, only one 
more than for amide (132). In binding, (59) was of much lower affinity than (130-132), and 
displayed little selectivity for the K-opioid receptor.
The apparent link between K-affinity and lipophilicity was further explored with the synthesis of 
amides (60-63), each having an aryl substituent. In comparison to the alkyl amide (59), the aryl 
amides (60-63) show higher affinity for all three receptor types. A clear trend can be seen 
within this series, with the phenethyl amide (61) having higher affinity at each receptor than 
either its shorter chain benzyl analogue (60) or the longer chain phenylbutyl amide (62). The 
introduction of a p-methoxy group into (60) to give (63) resulted in an increase in affinity at each 
receptor type, but particularly at p  (10 fold) and k  (5 fold).
In keeping with the results of the binding assays, in the GTPyS assays the phenethyl amide (61) 
again showed somewhat higher antagonist potency at either receptor than either (60) or (62). 
(63), the p-methoxy analogue of (60), again displayed higher antagonist potency at p (5 fold) 
and k  (2-3 fold), but reduced potency at 5 (2 fold). The Ke of an antagonist determined in the 
functional assays should approximate to the Kj determined in binding assays. For the amides, 
the Ke was consistently 5-10 fold lower (more potent) than the Kj would have predicted at p- and 
8-receptors and 10-100 fold lower at K-receptors. As a result, the compounds appear somewhat 
more potent and selective in the functional assays than in binding assays. This was particularly 
notable for the heptylamide (59), which displayed a 100 fold increase at k , but only a 10 fold 
increase at p and 5, resulting in reasonable K-antagonist activity and selectivity.
4.4.2 AMIDINE SUBSTITUENTS
Compound (71) was prepared as described in section 3.2 and submitted for pharmacological 
evaluation as the hydrochloride salt. (72-74) Were prepared as described in section 2.2 and 
submitted for pharmacological evaluation as the hydrobromide salts (Table 30). These were 
compared to compounds (133-135,70), prepared by Jales74 and submitted for pharmacological 
evaluation as the hydrochloride salts.
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134 A CH2CH3 98019
135 A (CH2)2CH3 98020
70* A (CH2)3CH3 98021
71 A CH2CH(CH3)2 99021
72 B (CH2)2CH3 99029
73 B (CH2)4CH3 99030
74 B (CH2)6CH3 99031
from reference 74
Table 30 Amidine substituted compounds submitted for pharmacological testing
The binding affinities of the compounds were measured in cloned human opioid receptors 
(Table 31). Data provided by NIDA Opiate Treatment Drug Discovery Program (under contract 
to SRI)









133 22.32 ± 2.27 21.38 ±1.32 0.29 ±0.10 2 77 74
134* 26.35 ± 0.46 21.76 ±1.50 0.28 ±0.10 2 94 78
135* 40.79 ± 6.32 27.56 ±2.11 0.25 ±0.10 2 163 110
70* 219.16 ±84.47 38.22 ± 4.91 0.30 ± 0.20 2 730 127
71 47.40 ± 7.07 20.10 ±4.29 1.39 ±0.14 2 34 14
72 13.48 ±0.54 5.29 ± 0.27 1.60 ±0.28 2 8 3
73 25.29 ± 4.06 17.02 ±7.19 1.44 ±0.04 2 18 12
74 56.62 ± 7.69 7.33 ±1.13 5.61 ± 0.37 2 10 1
40, norBNI 21.0 ±5.0 5.7 ± 0.9 0.20 ± 0.05 2 105 28
from reference 74
Table 31 Binding affinities measured in cloned human opioid receptors
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[35S] GTPyS assays were performed in cloned human opioid receptors (Table 32). Data
provided by NI DA Opiate Treatment Drug Discovery Program (under contract to SRI)
Ke(nM) ± SEM
p-CHO 8-CHO k-CHO
Compound membranes membranes membranes n p/K 8/k
DAMGO DPDPE U69,593
133 3.78 ± 0.68 1.79 ±0.69 0.21 ± 0.04 6 18 9
134* 4.70 ±1.34 1.77 ±0.25 0.24 ± 0.03 4 20 7
135* 4.21 ± 1.61 1.89 ±0.33 0.18 ±0.06 4 23 11
70* 5.33 ± 0.63 3.31 ± 0.54 0.17 ±0.05 5 31 20
71 14.73 ±0.83 5.23 ±0.13 0.32 ± 0.02 5 46 16
72 3.19 ±0.25 4.41 ± 0.79 0.05 ± 0.004 4 64 88
73 5.61 ± 0.28 3.83 ± 0.40 0.21 ± 0.03 5 27 18
74 2.04 ± 0.62 5.83 ± 0.42 0.37 ± 0.06 5 6 16
40, norBNI 18.9 ±1.8 4.42 ± 0.38 0.04 ± 0.004 484 113
from reference 74
Table 32 [35S] GTPyS assays performed in cloned human opioid receptors
Jales74 previously reported on the trend that in the n-alkyl amidine series (133-135,70), an 
increase in K-selectivity accompanied an increase in the length of the alkyl side chain. This was 
due to a decrease in affinity at p- and 8-receptors, rather than an increase in affinity at the k -  
receptor. In a related series of amidines, Portoghese and Olmsted72 showed that introducing a 
branch into the alkyl chain increased K-selectivity (cf. section 2.2.1). The isobutyl amidine (71), 
a branched analogue of the propyl amidine (135), was synthesised to further investigate these 
findings. Comparison of the Kj values for (135) and (71), show that while p- and 8-affinities 
remain unchanged, the affinity of the branched analogue (71) for the K-receptor is greatly 
reduced and hence the compound is less K-selective in binding assays. As seen for the n-alkyl 
amidine series (133-135,70), for the reverse amidine series (72-74), an increase in alkyl chain 
length causes a decrease in p-affinity. No consistent trend can be established for 8-receptor 
affinity. The affinities of the propyl (72) and pentyl (73) reverse amidines for the K-receptor are 
approximately equal, with only the heptyl reverse amidine (74) showing a decrease in affinity. 
This could indicate that the heptyl side chain is beginning to exceed the steric capacity of the k -  
receptor.
In the functional assay, the trends displayed in the binding assay for the n-alkyl amidines (133-
135,70) were again repeated. There was a slight decrease in antagonist potency at both p and 
8 for the isobutyl amidine (71) as compared to the straight chain analogues (133-135,70). 
Antagonist potency at the K-receptor was however essentially unchanged, resulting in greater k -
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selectivity for (71) -  a result which agrees with the previous findings of Portoghese and 
Olmsted.72 For the reverse amidine series (72-74), an increase in the length of the alkyl chain 
appears to have little effect on the antagonist potency of the compounds at jx- and 8-receptors. 
Surprisingly, an increase in chain length appears to result in a slight decrease in antagonist 
potency at the K-receptor. The propyl reverse amidine (72) is therefore the most K-selective and 
potent compound in this series. In the previously discussed series of amidines (133-135,70) 
and amides (130-132), the ligands having the longest side chains showed increased selectivity 
for the K-receptor as compared to their shorter chain homologues. It is entirely possible, that in 
this series of reverse amidines (72-74), the pentyl (73) and in particular the heptyl (74) 
analogues have exceeded the ideal side chain length.
Kj values are once again 5-10 fold higher than Ke values for the p- and 5-receptors. For the k -  
receptor, Kj values are approximately equal to Ke values for the n-alkyl amidine series (133-
135,70). For amidines (71-74) however, Kj values are approximately 5 fold higher than Ke 
values. Shortly after the binding studies were completed on amidines (133-135,70), the K-cell 
line died and had to be replaced. The Kj values for amidines (71-74) were determined with the 
new cell line. It is possible that if the binding assays were performed with the same cell line, the 
affinities for the K-receptor would remain relatively constant as seen in the functional assay.
4.4.3 IMIDAZOLINE SUBSTITUENTS
Compounds (83-84) (Table 33) were prepared as described in section 2.3 and 
pharmacological evaluation as the hydrochloride salts. These were compared




Compound R1 Rz BU Number
82 H H 98027
83 c h 3 H 99019
84 c h 3 c h 3 99020
from reference 74





The binding affinities of the compounds were measured in cloned human opioid receptors










82 2.31 ±0.18 4.72 ±1.26 0.07 ± 0.01 2 33 67
83 19.41 ±4.14 21.09 ±0.33 1.39 ±0.32 2 14 15
84 36.96 ±12.06 45.18 ±7.75 1.97 ±0.20 2 19 23
40, norBNI 21.0 ±5.0 5.7 ± 0.9 0.20 ± 0.05 2 105 28
from reference 74
Table 34 Binding affinities measured in cloned human opioid receptors
[35S] GTPyS assays were performed in cloned human opioid receptors (Table 35). Data 
provided by NIDA Opiate Treatment Drug Discovery Program (under contract to SRI)
Ke(nM) ± 
SEM
p-CHO 8-CHO k -C H O
Compound membranes membranes membranes n p/K 8/k
DAMGO DPDPE U69,593
82 2.85 ± 0.36 3.20 ± 0.78 0.22 ± 0.03 4 13 15
83 14.90 ±2.08 8.87 ± 1.38 0.63 ± 0.03 5 24 14
84 24.17 ±0.97 28.78 ± 3.05 1.14 ±0.10 5 21 25
40, norBNI 18.9 ±1.8 4.42 ± 0.38 0.04 ± 0.004 484 113
from reference 74
Table 35 [35S] GTPyS assays performed in cloned human opioid receptors
The methyl (83) and dimethyl (84) analogues of (82) were synthesised in an attempt to further 
investigate the influence of lipophilicity on K-selectivity and affinity. The general trend that can 
be established from binding assay results is that increased substitution of the imidazoline ring 
decreases affinity at p-, 8- and K-opioid receptors. Each of these compounds shows selectivity 
for the K-receptor. In the binding assay, the unsubstituted imidazoline (82) appears to be the 
most selective compound. The methyl imidazoline (83) can be seen as a constrained analogue 
of the propyl reverse amidine (72). Comparison of the binding data for these two compounds 
show that while affinity for the p- and K-receptors is approximately the same, the affinity of the 
methyl imidazoline (83) for the 8-receptor is significantly lower than that of the equivalent propyl 
reverse amidine (6), resulting in greater k- over 8-selectivity.
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Results for the GTPyS assays were in keeping with the binding assay results. Thus, increased 
substitution of the imidazoline ring caused a decrease in antagonist potency at all three receptor 
types (84 < 83 < 82). The decrease was however less pronounced for the K-receptor, which 
resulted in the methyl (83) and dimethyl (84) analogues showing slightly greater K-selectivity. 
Again, this may indicate greater tolerance for steric bulk within the K-receptor. The Kj values in 
this instance were not significantly different from the Ke values, except for compound (82) at the 
K-receptor. It should be pointed out that this result was obtained with the previous cell line (cf. 
section 4.4.2). When comparing the GTPyS assay data for the constrained methyl imidazoline
(83) and the non-constrained propyl reverse amidine analogue (72), it can be seen that the 
amidine (72) displays higher antagonist potency at all three receptor types, but particularly at 
the K-receptor. In functional assays therefore, the propyl reverse amidine (72) shows greater 
selectivity and antagonist potency at the K-opioid receptor than the methyl imidazoline (83).
4.4.4 UREA SUBSTITUENTS
The urea derivatives (85-87) (Table 36) were prepared as described in section 2.4 and 
submitted for pharmacological evaluation as the hydrochloride salts.
N -C -N -R
HO
H




Table 36 Urea substituted compounds submitted for pharmacological testing
1 0 0
The binding affinities of the compounds were measured in cloned human opioid receptors










85 37.64 ± 14.41 2.43 ± 0.46 12.32 ±1.29 2 3 0.2
86 4.80 ± 0.91 2.60 ± 0.54 6.33 ± 0.40 2 0.8 0.4
87 13.58 ±4.06 2.25 ±0.16 8.13 ±2.67 2 2 0.3
40, norBNI 21.0 ±5.0 5.7 ± 0.9 0.20 ± 0.05 2 105 28
Table 37 Binding affinities measured in cloned human opioid receptors
[35S] GTPyS assays were performed in cloned human opioid receptors (Table 38). Data 
provided by NIDA Opiate Treatment Drug Discovery Program (under contract to SRI)
Ke (nM) ± SEM
p-CHO 5-CHO k-CHO
Compound membranes membranes membranes n p/K 5/k
DAMGO DPDPE 1169,593
85 1.60 ±0.15 0.65 ± 0.02 2.47 ± 0.20 4 0.6 0.3
86 1.63 ±0.12 0.53 ± 0.08 1.52 ±0.16 4 1 0.3
87 1.79 ±0.32 1.04 ±0.18 1.71 ±0.16 4 1 0.6
40, norBNI 18.9 ± 1.8 4.42 ± 0.38 0.04 ± 0.004 484 113
Table 38 [35S] GTPyS assays performed in cloned human opioid receptors
The above urea derivatives were synthesised primarily in order to investigate the degree of 
basicity required for K-selectivity. In binding assays, the three urea compounds (85-87) all had 
affinities of 2-3 nM for the 5-receptor, whereas the affinities for the K-receptor ranged from 6-12 
nM. The affinity of the butyl urea (86) for the K-receptor was slightly greater than the affinity of 
either the ethyl (85) or hexyl (87) analogues. This effect was even more pronounced for the p- 
receptor. The most significant finding is that although these compounds are essentially non- 
selective, a small degree of 5-selectivity was evident. This is surprising since the urea 
substituent is not obviously very different to an amide or amidine substituent. The observed 
change in selectivity has been attributed to an interaction between the carbonyl group and a 
basic Lys residue in the helix bundle of the 6-receptor (see section 3).
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When comparing GTPyS assay results for the urea series (85-87), no significant change in the 
antagonist potency at p-, 8- or K-receptors can be seen. The three urea ligands appear 
equipotent and as found in the binding assays, slightly 5-selective. As shown for many of the 
ligands above, there is approximately a 5 fold difference between Kj and Ke values (although 
slightly greater deviation for p values).
4.4.5 GUANIDINE SUBSTITUENTS
Compounds (104-117) (Table 39) were prepared as described in section 2.6 and submitted for 




Compound n R1 R* BU Number
104 2 H H 20031
106 2 H Benzyl 20022
110 2 H p-Chlorobenzyl 20023
111 2 H p-Nitrobenzyl 20024
112 2 H p-Aminobenzyl 20025
105 0 H Benzyl 20029
107 0 H p-Chlorobenzyl 20030
108 0 H p-Nitrobenzyl 01017
109 0 H p-Aminobenzyl 01018
113 2 Butyl Butyl 01010
114 0 Butyl Butyl 01020
115 0 Propyl Propyl 01021
116 0 Propyl Cyclopropylmethyl 01022
117 0 Benzyl Cyclopropylmethyl 01023
Table 39 Guanidine substituted compounds submitted for pharmacological testing
10 2
The binding affinities of the compounds were measured in cloned human opioid receptors
(Table 40). Data provided by NIDA Opiate Treatment Drug Discovery Program (under contract
to SRI)








104 5.69 ±1.28 4.93 ± 1.28 0.49 ± 0.00 2 12 . 10
106 3.54 ± 0.25 7.24 ± 0.86 1.42 ±0.17 2 2 5
110 7.74 ± 1.98 19.18 ± 0.17 2.41 ± 0.22 2 3 8
111 9.21 ± 3.73 11.70 ±0.28 2.14 ±0.34 2 4 5
112 7.78 ± 2.71 5.05 ± 0.23 0.95 ± 0.04 2 8 5
105 10.47 ± 1.87 26.81 ± 6.47 0.86 ± 0.20 2 12 31
107 29.78 ± 0.50 85.05 ± 5.06 0.66 ± 0.05 2 45 129
108 ROa ROa ROa
109 ROa ROa ROa
113 ROa ROa ROa
114 ROs ROa ROa
115 ROa ROa ROa
116 ROa ROa ROa
117 ROa ROa ROa
40, norBNI 21.0 ±5.0 5.7 ± 0.9 0.20 ± 0.05 2 105 28
aRO = Results Outstanding
Table 40 Binding affinities measured in cloned human opioid receptors
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[35S] GTPyS assays were performed in cloned human opioid receptors (Table 41). Data
provided by NIDA Opiate Treatment Drug Discovery Program (under contract to SRI)
Ke (nM) ± 
SEM
p-CHO 8-CHO k-CHO
Compound membranes membranes membranes n p /K 8/k
DAMGO DPDPE 1169,593
104 1.25 + 0.12 0.88 ±0.15 0.40 ± 0.06 5 3 2
106 2.94 ± 0.31 1.36 ±0.10 0.13 ±0.01 5 23 10
110 2.61 ± 0.41 1.48 ±0.14 0.23 ± 0.02 5 11 6
111 2 .20  ± 0.60 1.34 ±0.24 0.17 ±0.01 5 13 8
112 1.57 ±0.13 0.95 ±0.14 0.25 ± 0.03 5 6 4
105 1.41 ±0.17 4.09 ± 0.63 0.06 ± 0.01 5 24 68
107 5.24 ± 1.13 7.67 ± 1.36 0.14 ±0.01 5 37 55
108 ROa ROa ROa
109 ROa ROa ROa
113 ROa ROa ROa
114 ROa ROa ROa
115 ROa ROa ROa
116 ROa ROa ROa
117 ROa ROa ROa
40, norBNI 18.9 ± 1.8 4.42 ± 0.38 0.04 ± 0.004 484 113
aRO = Results Outstanding
Table 41 [35S] GTPyS assays performed in cloned human opioid receptors
From the guanidine series of compounds, we hoped to gain greater insight into the role of 
lipophilic interactions (hence the aromatic groups) as well as the optimum distance between the 
two basic nitrogen centres. The guanidine series (106,110-112) are benzyl substituted 
analogues of guanidine (104). While benzyl substitution appears to have had little effect on the 
affinity of the compounds for the p-receptor, 8-opioid affinity is slightly reduced. Affinity for the 
K-receptor also seems to have decreased by 3-5 fold. Within this series (106,110-112), the 
introduction of various p-substituents shows no effect on affinity. In the guanidine series 
(105,107-109), the two methylene groups between the guanidine functionality and the 
naltrindole core {cf. ligands 106,110-112) have been removed, effectively bringing the two basic 
nitrogen groups closer together (/e. benzyl analogues of GNTI, 47). Comparison of the data for 
benzylguanidines (106,110-112) and benzylguanidines (105,107-109) shows that although 
decreasing the distance between the naltrindole "message" and the basic benzylguanidinyl 
group has little effect on K-affinity, affinity for both p- and 8-receptors is decreased, in turn 
increasing K-selectivity. This might suggest that an increase in steric bulk near to the
104
indolomorphinan moiety is better tolerated by the K-receptor than by the p- or 8-receptors, or 
that a basic functionality near to the indolomorphinan nucleus is detrimental to p- and 8-affinity. 
This effect is greater for the p-chlorobenzyl substituent than for the benzyl substituent, perhaps 
suggesting that the effect is due to bulk/lipophilicity. It is hoped that the outstanding assay 
results would further confirm these hypotheses.
In GTPyS assays, compounds (104-107,110-112) displayed essentially equal and potent 
antagonist activity at the K-receptor. Comparison of compounds (104,106,110-112) shows that 
the addition of a benzyl substituent to the guanidine group causes very slight decreases in p- 
and 8- antagonist potency, resulting in overall increased K-selectivity. When compared to the 
longer chain benzylguanidine (106), the shorter chain benzylguanidine analogue (105) shows 
slightly increased antagonist potency at the p- and K-receptors, with slightly decreased 
antagonist potency at the 8-receptor. Addition of a p-chloro substituent to the benzyl group (cf. 
105 and 107), causes a decrease in antagonist affinity for both the p- and 8-receptors, resulting 
in increased k -  over p -  and k -  over 8-selectivity.
4.4.6 COMPARISON OF TESTING METHODS
Since the values obtained in binding and functional assays depend on the exact conditions used 
and may be subject to change (as discussed in section 4.4.2), we decided to compare the two 
compounds prepared by both ourselves and the Portoghese group.
Radio Ligand Binding
K, (nM) ± SEM
Compound 8 K p /K 8 /k
104 5.69 ± 1.28a’9 4.93 ± 1.28D,g 0.49 ± 0.00c'9 12 10
104 33.40 ± 4.70d,h 10.70 ±3.00e’h 0.51 ± 0.13f,h 66 21
98 3.59 ± 1.30a’9 8.78 ± 0.37b,g 0.40 ± 0.14Cl9 9 22
98 Not Reported Not Reported Not Reported
a[3H]-DAMGO, b[3H]CI-DPDPE, C[3H]U69,593, yH E K -293 [3H]diprenorphine, e5-HEK-293 [3H]diprenorphine, k-HEK- 
293 [3H]diprenorphine, 9Data provided by NIDA OTDP (under contract to SRI), hData from Stevens, et aI.77
Table 42 Binding affinities
When comparing the results of the SRI binding assay to that of the Portoghese group, we can 
see that for guanidine (104), the affinity at the p-receptor is 6 fold greater, the affinity at the 8- 
receptor is 2 fold greater and the affinity at the K-receptor is unchanged. Compound (104) 
therefore shows lower k -  over p-and k -  over 8-selectivity under SRI assay conditions. A 
comparison could not be made for (98), since no binding affinities were reported.
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Functional Assays
K« (nM) ± SEM
Compound V 8 K p /K 8 /k
104 1.25 ± 0.12a'9 0.88 ± 0.15°’9 0.40 ± 0.06c'9 3 2
104 12d,h 3.4e,h 1.7f,h 7 2
98 3.35 ± 0.80a’9 5.10 ± 1.01b’9 0.31 ± 0.05c’9 11 16
98 ND ND 3.2
a|i-CHO membranes-DAMGO, b5-CHO membranes-DPDPE, °k-CHO membranes-1169593, d(i-GPI-morphine, e8-MVD- 
[D-Ala2,D-Leu5]enkephalin, k-GPI -ethylketazocine, 9Data provided by NIDA OTDP (under contract to SRI), hData from 
Stevens, et al.77
Table 43 Functional assays
In the SRI functional assays, guanidine (104) showed 4 fold greater antagonist potency at both 
the 8- and K-receptors, than in the assays performed by the Portoghese group. This resulted in 
a similar k -  over 8-selectivity ratio for both assay conditions. Compound (104) however, showed 
10 fold lower antagonist potency at the p-receptor under Portoghese's assay conditions, which 
resulted in greater k -  over p-selectivity being reported. A comparison between the two assay 
conditions could not be made for (98), since only data at the K-receptor was reported. (98) is 
reported as being 10 fold less potent than determined under SRI assay conditions.
4.4.7 CONCLUSION
Little variation in K-affinity was observed within, or even between the series of compounds 
synthesised. K-Selectivity differences between series were largely a result of changes in affinity 
at 8 and p. This is in agreement with findings from the Portoghese group,77 and can be 
explained by the negative interactions of the basic side chain with the basic Lys 303 residue (p), 
or the bulky Trp 284 residue (8), as discussed in section 3.2.3. These interactions were not 
specifically examined in the current project, but cursory examination of the models found the 
above mentioned residues to lie within regions which would make interaction with the side chain 
possible.
Results from the functional assays appear to be more consistent than those obtained in binding 
assays. This could be related to the fact that the number of experiments performed, (n), is 
greater for the antagonist functional assays. Deterioration of the radioligand used in binding 
assays could also conceivably influence binding assay results. In lieu of this, it may prove 
preferable to use the results of functional assays in future modelling studies, rather than the 




Column chromatography was performed under gravity, over silica gel 60 (35-70pm) purchased 
from Merck. Preparaiive TLC was performed on plates made with Kieselgel 60 PF254+366 for 
prep. TLC, obtained from Merck. The thickness of the silica layer was approximately 1 mm. 
Analytical TLC was performed using aluminium-backed plates coated with Kieselgel 60 F254, 
from Merck. The chromatograms were visualised using either UV light (UVGL-58, short 
wavelength), ninhydrin (acidic) or potassium permanganate (basic). Melting points were carried 
out using a Reichert-Jung Thermo Galen Kopfler block or a Gallenkamp MFB-595 melting point 
apparatus and are uncorrected. High and low resolution fast atom bombardment (FAB) mass 
spectra were recorded on a Fisons VG AutoSpec Q instrument, with a matrix of m-nitrobenzyl 
alcohol. High and low resolution electron impact (El) mass spectra were recorded using El 
ionisation at 70eV, on a VG AutoSpec instrument, equipped with a Fisons autosampler. 1H 
NMR and 13C NMR spectra were recorded using either JEOL 270 (operating at 270 MHz for 1H 
and 67.8 MHz for 13C); JEOL Lambda 300 (operating at 300 MHz for 1H and 75 MHz for 13C) or 
JEOL EX 400 (operating at 400 MHz for 1H and 100.5 MHz for 13C) spectrometers. Chemical 
shifts (8) are measured in ppm. Spectra were referenced internally using the residual solvent 
resonance. Coupling constants (J) are expressed in Hz and the multiplicities are abbreviated 
as follows: s (singlet), d (doublet), t (triplet), m (multiplet) and br (broad). Only diagnostic peaks 
have been quoted for proton NMR. Microanalysis was performed by the Microanalysis 
Laboratory in the Department of Chemistry, University of Bath. Analytical RP-HPLC was 
performed with a Beckman System Gold 125 solvent module, equipped with a Beckman 
System Gold 166 detector (X = 254nm). The column stationary phase was Beckman 
ultrasphere ODS, 5 pm (15 cm x 4.6 mm). A mobile phase of [MeOH/O.3% NH4CO3 (80:20)] 
was used at a flow rate of 1 ml/min. Infrared spectroscopy was performed on either a Perkin- 
Elmer 782 Instrument, or on a Perkin-Elmer RX 1 FT-IR Instrument. Anhydrous THF, DMF, 
DCM and MeOH were purchased from Aldrich. HPLC solvent grade chloroform and MeOH 
were purchased from Merck. All other solvents used were GPR grade, purchased from Merck
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or Fisher Scientific. Chemicals were purchased from Aldrich, Fluka, Lancaster and Acros 
chemical companies.
5.2 GENERAL PROCEDURES
General Procedure A -  Aromatic Amides
S'-Carboxy-IZ-cydopropylmethyl-O.Z-didehydro-^Sa-epoxy-S.M-dihydroxyindolo^'.S'iO,?]- 
morphinan (64) (1 eq) in anhydrous CH2CI2 at 0  °C was brought into solution by the dropwise 
addition of triethylamine. To this solution was added 1-(3-dimethylaminopropyl)-3- 
ethylcarbodiimide hydrochloride (EDCI) (1.5 eq) and 4-dimethylaminopyridine (DMAP) 
(catalytic). The resultant mixture was allowed to stir for 20 min, after which the aromatic amine 
(1.5 eq) was added. After stirring at RT for 12 h, CH2CI2 (10 ml) was added and the mixture 
further basified with excess aq.NaHC03. The mixture was then washed with brine, dried 
(Na2S04), filtered and concentrated, to give the crude product which was further purified by 
preparative thin layer chromatography [CH3OH/CH2CI2/NH4OH (20:80:1)] with typical yields of 
9-22%.
General Procedure B -  Reverse Amidines
The appropriate amine (1.3 eq) was added portionwise to the thioimidic ester derivative (1 eq) 
(78) in anhydrous CH3OH at RT. After stirring for 12 h, the solution was concentrated in vacuo 
and the residue treated with Et20 . The amidinium salt was filtered and washed with Et20. The 
products were purified by preparative thin layer chromatography [CH3OH/CH2CI2/NH4OH 
(20:80:1)]. The major product was the required reverse amidine. A minor product was the 
disubstituted reverse amidine.
General Procedure C - Imidazolines
p-Toluenesulfonic acid (p-TSA) (1 eq) was stirred in 'PrOH (50 ml) at RT. The required diamine 
was added, after which the solution was stirred for 30 min before being evaporated,
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recrystallised from hot 'PrOH, filtered and washed with CH2CI2 and petroleum ether.74 The p- 
TSA salt of the diamine was added to 5,-cyanomethyl-17-cyclopropylmethyl-6,7-didehydro-4,5a- 
epoxy-S.M-dihydroxyindoloIZ.S'tf^morphinan (75) under N2. The mixture was heated to 160 
°C for 3 h then allowed to cool, after which H20  (2 ml) was added and the mixture basified with 
2N NaOH (pH 10). After extraction with CHCI3, the organic extracts were washed, dried 
(Na2S 04), filtered and concentrated. Further purification by preparative thin layer
chromatography [CH3OH/CH2CI2/NH4OH (20:75:1)] afforded the required imidazoline in yields 
of 5-6%.
General Procedure D - Ureas
S’-AminoethyMT-cyclopropylmethyl-ey-didehydro-^Sa-epoxy-S.H-dihydroxyindoloP'.S'tfJ]- 
morphinan (76) (1 eq) in anhydrous [CH2CI2/CH3OH (10:1)] (20 ml) was added dropwise to an 
ice-bath cooled solution of the appropriate isocyanate (1 eq) in anhydrous CH2CI2 (20 ml). After 
the addition was complete, the solution was allowed to stir at RT for 5 h, after which the solvent 
was removed in vacuo and the crude residue purified by preparative thin layer chromatography 
[CH3OH/CH2CI2/NH4OH (20:80:1)], giving the desired product in a yield of 30-40%. A minor 
product in which the phenolic OH additionally reacted with the isocyanate to form the carbamate 
was also isolated.
General Procedure E - N'-Benzylguanidinylating agents
1,3-Bis-Boc-2-methyl-2-thiopseudourea (1 eq) was dissolved in anhydrous N,N- 
dimethylformamide (20 ml) and cooled in an ice bath. Sodium hydride (1.2 eq) was added in a 
single portion and the solution stirred at this temperature for 1 h. The appropriate benzyl 
bromide (1.1 eq) was added in a single portion and the solution allowed to stir for 12 h at RT. 
The reaction was quenched with water (30 ml) and extracted three times with ethyl acetate. 
The combined organic layers were washed twice with brine, dried (Na2S 04), filtered and 
concentrated to give the crude guanydinylating agent. This crude mixture was subjected to 
column chromatography [hexane/EtOAc (9:2)] providing the desired guanidinylating agent in 
yields of 65 - 80%.
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General Procedure F - Guanidinylation
The required amine (1 eq), guanylating agent (1.3-2.0 eq), triethylamine (1-2 eq) and 
mercury(ll)chloride (1.0-1.5 eq) were all added to anhydrous A/,/V-dimethylformamide (20ml) in 
an ice bath under a nitrogen atmosphere. The solution was then stirred at 50 °C for 12-24 h. 
The solution was subsequently filtered to remove any solid and the reaction quenched by the 
addition of sodium bicarbonate (30 ml). The solution was extracted with ethyl acetate and then 
washed successively with water and brine, dried (Na2S04), filtered and concentrated under 
reduced pressure to give the crude product mixture, which was purified by column 
chromatography - gradient elution (CH2CI2) until unreacted guanidinylating agent has been 
removed then [CH3OH/CH2CI2/NH4OH (10:89:1)], affording the desired products in 25-68% 
yields.
General Procedure G - Removing BOC
The appropriate BOC-protected benzyl guanidinylated amine was dissolved in dichloromethane 
(4ml) and allowed to stir for 10 min at 0 °C. Trifluoroacetic acid (2ml) was added and the 
solution allowed to warm to room temperature. Stirring was continued for 12 h, after which the 
solution was concentrated under reduced pressure. Washing the resultant oil with diethyl ether 
afforded a precipitate that could be isolated by vacuum filtration. Further purification was 
achieved by recrystallization (methanol/diethyl ether).
General Procedure H -  N,N'-disubstituted thioureas
Calcium carbonate (1eq) was dissolved in H20  (2ml) and added to a stirred solution of the 
required amine (1 eq) in CHCI3 (30 ml). Thiophosgene (2 eq) was added and the solution 
stirred at RT for 24 h. The aqueous layer was washed with H20, and concentrated to give the 
required isothiocyanate (purity was checked by TLC and no further purification was needed). 
The isothiocyanate (1eq) was then dissolved in acetone (15 ml) and added dropwise to the 
required amine (1 eq) in acetone (15 ml). The solution was refluxed gently for 3 h, concentrated
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and purified by column chromatography [hexane/EtOAc (1:1)] providing the desired N,N'- 
disubstituted thiourea in yields of 46 - 56%.
General Procedure I -  BOC-protection of N,N'-disubstituted thioureas
To NaH (2 eq) (prewashed with THF) in THF (40 ml) at 0 °C, was added the appropriate N,N'- 
disubstituted thiourea (1eq). The mixture was stirred for 10 min, after which di-terf-butyl- 
dicarbonate (BOC-anhydride) (1.15 eq) in THF (10 ml) was added. The mixture was then 
allowed to warm to RT and stirred for a further 12 h. The reaction mixture was quenched by 
stirring with 10% NaOH for 20 min. The organic layer was then separated and the aqueous 
layer further extracted with EtOAc. The combined organic layers were concentrated and 
subsequently treated with hexane, which caused unreacted starting material to precipitate out. 
The crystals were removed by filtration and the filtrate subsequently purified by column 




P '^ ’iejlmorphinan (64)72
Naltrexone hydrochloride (2.34 g, 6.2 mmol) and 4-hydrazinobenzoic acid (1.09 g, 7.2 mmol) 
were dissolved in glacial acetic acid (100 ml) and stirred under nitrogen at 85 °C for 72 h. The 
mixture was then cooled and filtered, and the crude product washed with glacial acetic acid, 
acetone and then ether. The solid was dissolved in methanol, dried (Na2S04), filtered and 
concentrated in vacuo to give 5'-carboxy-17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-3,14- 
dihydroxyindolop'.^ejjmorphinan (64) (as the hydrochloride salt) 1.90 g, 3.8 mmol, 62%; IR 
vmax/cm (KBr) 1680 (C=0) (Lit.77 1679); 1H NMR (400 MHz, CD3OD) 8 0.38-0.49 [m, 2H, 
NCH2CH(CHHCHH)], 0.63-0.82 [m, 2H, NCH2CH(CHHCHH)], 0.97-1.04 [m, 1H,
NCH2CH(CH2CH2)], 5.65 [s, 1H, C(5)H], 6.79 [d, J=8.4 Hz, 1H, C(1)H], 6.82 [d, J=8.4 Hz, 1H,
I l l
C{2)H\, 7.33 [d, J=8.4 Hz, 1H, C(7’)H], 7.68 [d, J=8.4 Hz, 1H, C(6 ’)H] and 8.09 [s, 1H, C(4’)]; 
13C NMR (67.8 MHz, CD3OD) 8 3.6 [NCH2CH(CH2CH2)], 6 .6  [NCH2CH(CH2CH2)], 7.0 
[NCH2CH(CH2CH2)], 25.2 [C(10)J, 29.9 [C(15)]f 30.2 [C(8 )J, 47.5 [C(16)J, 48.1 [quaternary 
C(13)], 59.0 [C(18)], 63.6 [C(9)], 73.9 [quaternary C(14)], 84.9 [C(5)1, 111.2 [C(7’)], 112.6 
(quaternary Ar), 119.8 [C(2)], 121.5 [C(4')], 122.5 [C(1)], 123.0 [C(6 ')], 123.2 (quaternary Ar),
125.3 (quaternary Ar), 127.6 (quaternary Ar), 130.4 (quaternary Ar), 132.5 (quaternary Ar),
141.6 (quaternary Ar), 142.2 (quaternary Ar), 144.9 (quaternary Ar) and 171.4 (C=0); FAB-MS 




morphinan (64) (0.033 g, 0.067 mmol) in anhydrous CH2CI2 (5 ml) was brought into solution by 
the dropwise addition of triethylamine. (BOP) reagent (30 mg, 0.068 mmol) and heptylamine 
(0.010 g, 0.013 ml, 0.088 mmol) were added, after which the solution was stirred at 25 °C for 24 
h. The reaction mixture was then added to ethyl acetate (30 ml) and washed 3 times with brine 
(pH 10). The organic phase was dried (Na2S04), filtered and concentrated to yield 17- 
cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-(N-heptyl)amido-3,14-dihydroxyindolo[2',3,:6,7]- 
morphinan (59) (31 mg, 0.056 mmol, 83%), which was then converted to the hydrochloride salt, 
mp. 181-183 °C; Rf = 0.66 [CH3OH/CH2CI2/NH4OH (20:80:1)]; HPLC (C18 column) 5.296 
[MeOH/0.3% NH4C 03 (80:20)]; IR vmax/crn (KBr) 3640-2460 (br, bonded OH and amide NH), 
1620 (amide I) and 1540 (amide II); 1H NMR (270 MHz, CD3OD) 8 0.06-0.10 [m, 2H, 
NCH2CH(CHHCHH)], 0.41-0.50 [m, 2H, NCH2CH(CHHCHH)], 0.75-0.79 (m, 3H, CH3), 0.79- 
0.84 [m, 1H, NCH2CH(CH2CH2)], 5.46 [s, 1H, C(5)H\, 6.41-6.49 [m, 2H, C(1 )H and C(2)H\, 7.21 
[d, J=8.7 Hz, 1H, C(T)H], 7.48 [dd, ^=8.7 Hz, J2=1.6 Hz, 1H, C(6 ')H\ and 7.83 [d, J=1.6 Hz, 1H, 
C(4')H]; 13C NMR (67.8 MHz, CD3OD) 8 2.8 [NCH2CH(CH2CH2)], 3.3 [NCH2CH(CH2CH2)]t 8.9 
[NCH2CH(CH2CH2)]( 13.0 (CH3), 22.3 [C(10)]f 22.8, 26.4, 26.8, 28.8, 31.6
(NHCH2CH2CH2CH2CH2CH2CH3), 29.3 [C(15)]f 31.4 [C(8 )], 40.2 (CONHCH2), 43.7 [C(16)]« 47.6 
[quaternary C(13)], 59.1 [C(18)], 62.3 [C(9)], 73.1 [quaternary C(14)], 84.4 [C(5)], 110.7 [C(7')],
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111.2 (quaternary Ar), 117.2 [C(2>], 118.3 [C(4')], 118.6 [C(1)J, 121.2 [C(6 ')], 124.8 (quaternary 
Ar), 125.0 (quaternary Ar), 126.3 (quaternary Ar), 130.7 (quaternary Ar), 131.3 (quaternary Ar),
139.2 (quaternary Ar), 139.8 (quaternary Ar), 143.4 (quaternary Ar) and 170.2 (C=0 ); EI-MS 





morphinan (64) (0.201 g, 0.407 mmol) and benzylamine (0.064 g, 0.066 ml, 0.598 mmol) were 
reacted according to general procedure A, to yield 17-cyclopropylmethyl-6,7-didehydro-4,5a- 
epoxy-S'-fN-benzylJamido-S.H-dihydroxyindoloP'.S'^Jlmorphinan (60) (0.045 g, 0.083 mmol, 
21%). The product was then converted to the hydrochloride salt, mp. 166-169 °C; Rf = 0.45 
[CH3OH/CH2CI2/NH4OH (10:89:1)]; HPLC (Ci8 column) 1.767 [MeOH/O.3% NH4CO3 (80:20)]; 
IR vmax/crn (KBr) 3620-2480 (br, bonded OH and amide NH), 1640 (amide I) and 1560 (amide 
II); 1H NMR (270 MHz, CD3OD) 8 0.49-0.60 [m, 2H, NCH2CH(CHHCHH)], 0.88 [m, 2H, 
NCH2CH(CHHCHH)], 1.28 [m, 1H, NCH2CH(CH2CH2)], 5.71 [s, 1H, C(5)H\, 6 .66 -6.68  [m, 2H, 
C(1)H and C(2)H], 7.18-7.37 [m, 5H, ArH], 7.40 [d, J=8.7 Hz, 1H, C(T)H\, 7.65 [dd, Ji=8.7 Hz, 
J2=1.3 Hz, 1H, C(&)H\ and 8.01 [d, J=1.3 Hz, 1H, C(4’)H\] 13C NMR (67.8 MHz, CD3OD) 8 2.1 
[NCH2CH(CH2CH2)], 4.9 [NCH2CH(CH2CH2)], 5.6 [NCHzCH^HzCHz)], 23.7 [C(10 )], 28.5 
[C(15)], 28.9 [C(8 )], 43.3 (CONHCH2), 46.3 [C(16)]f 46.8 [quaternary C(13)], 57.7 [C(18)]f 62.6 
[C(9)]t 72.4 [quaternary C(14)], 83.6 [C(5)], 109.5 (Ar), 111.0 (Ar), 118.3 (Ar), 118.7 (Ar), 119.3 
(Ar), 121.3 (Ar), 121.5 (Ar), 125.1 (Ar), 126.3 (Ar), 126.7 (Ar), 127.2 (2 x Ar), 128.2 (2 x Ar),
128.9 (Ar), 130.8 (Ar), 139.2 (Ar), 139.5 (Ar), 140.8 (Ar), 143.4 (Ar) and 170.0 (C=0); EI-MS 






morphinan (64) (0.204 g, 0.413 mmol) and phenethylamine (0.073 g, 0.076 ml, 0.607 mmol) 
were reacted according to general procedure A, to yield 17-cyclopropylmethyl-6,7-didehydro- 
4,5a-epoxy-5,-(N-phenethyl)amido-3,14-dihydroxyindolo[2',3':6,7]morphinan (61) (0.021 g,
0.038 mmol, 9%). The product was then converted to the hydrochloride salt, mp. 178 °C; Rf = 
0.55 [CH30 H/CH2CI2/NH4 0 H (10:89:1)]; HPLC (C18 column) 1.850 [MeOH/O.3% NH4C 03 
(80:20)]; IR vmax/crn (KBr) 3660-2820 (br, bonded OH and amide NH), 1640 (amide I) and 1550 
(amide II); 1H NMR (270 MHz, CD3OD) 5 0.24-0.27 [m, 2H, NCH2CH(CHHCHH)], 0.54-0.69 [m, 
2H, NCH2CH(CHHCHH)], 0.88-0.94 [m, 1H, NCH2CH(CH2CH2)], 5.60 [s, 1H, C(5)H\, 6.54-6.60 
[m, 2H, C(1)H and C(2)H\, 7.13 -  7.30 (m, 5H, ArH), 7.34 [d, J=8.7 Hz, 1H, C(7')H], 7.56 [dd, 
Ji=8.7 Hz, J2=1.6 Hz, 1H, C(6 ')H\ and 7.91 [d, J=1.6 Hz, 1H, C(4’)H]; 13C NMR (67.8 MHz, 
CD3OD) 8 2.7 [NCH2CH(CH2CH2)], 3.5 [NCH2CH(CH2CH2)], 8.4 [NCH2CH(CH2CH2)], 23.0 
[C(10)]f 28.5 [C(15)], 31.1 [C(8 )], 35.4 (CONHCH2CH2), 41.4 (CONHCH2), 44.2 [C(16)], 47.5 
[quaternary C(13)], 58.9 [C(18)], 62.4 [C(9)], 73.0 [quaternary C(14)], 84.3 [C(5)], 110.7 [C(7’)],
110.9 (quaternary Ar), 117.3 [C(2)], 118.4 [0(4')], 118.7 [C(1)]« 121.2 [C(6 ’)], 124.4 (Ar), 125.0 
(quaternary Ar), 126.0 (quaternary Ar), 126.3 (quaternary Ar), 128.1 (2 x Ar), 128.5 (2 x Ar),
130.6 (quaternary Ar), 131.2 (quaternary Ar), 139.3 (quaternary Ar), 139.4 (quaternary Ar),
139.9 (Ar), 143.4 (quaternary Ar) and 170.2 (C=0); EI-MS m/z 561 [(M )\ 100%], 520 (20) and 
441 (20); HRMS (El) m/z 561.2626 (M)+, C35H35N30 4 requires 561.2628.
^-Cyclopropylmethyl-ej-didehydrcM.Sa-epoxy-SXN-phenylbutyOamido-S.M-dihydroxy- 
indolo[2',3':6,7]morphinan (62)
S'-Carboxy-^-cyclopropylmethyl-ey-didehydro^.Sa-epoxy-S.M-dihydroxy-indoloP'.S’^ ^ ]-  
morphinan (64) (0.100 g, 0.202 mmol) and phenylbutylamine (0.045 g, 0.048 ml, 0.302 mmol) 
were reacted according to general procedure A, to yield 17-cyclopropylmethyl-6,7-didehydro- 
4,5a-epoxy-5,-(N-phenylbutyl)amido-3,14-dihydroxyindolo[2',3':6,7]morphinan (62) (0.027 g,
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0.045 mmol, 15%). The product was then converted to the hydrochloride salt, mp. >220 °C; Rf 
= 0.51 [CH3OH/CH2CI2/NH4OH (10:89:1)]; HPLC (Ci8 column) 1.672 [MeOH/O.3% NH4CO3 
(80:20)]; IR Vmax/crn (KBr) 3640-2840 (br, bonded OH and amide NH), 1620 (amide I) and 1530 
(amide II); 1H NMR (300 MHz, CD3OD) 8 0.49-0.58 [m, 2H, NCH2CH(CHHCHH)], 0.73-0.80 [m, 
2H, NCH2CH(CHHCHH)], 0.83-0.92 [m, 1H, NCH2CH(CH2CH2)], 5.70 [s, 1H, C(5)H], 6.65-6.71 
[m, 2H, C(1 )H and C(2)H], 7.07 -  7.24 (m, 5H, ArH), 7.39 [d, J=8.6  Hz, 1H, C{7')H], 7.59 [dd, 
J!=8.6  H z , J2=1.6 H z , 1H, C(6 ')H] and 7.95 [d, J=1.6 Hz, 1H, C(4’)H]; 13C NMR (75 MHz, 
CD3OD) 8 3.4 [NCH2CH(CH2CH2)], 6.3 [NCH2CH(CH2CH2)], 6.8  [NCHzCHfCHzC^)], 25.0 
[C(10 )J, 29.8 [C(15)], 30.1 [C(8 )], 30.2, 36.5 and 36.5 (NHCH2CH2CH2CH2), 41.1 (CONHCH2),
47.6 [C(16)], 48.7 [quaternary C(13)], 58.9 [C(18)], 63.7 [C(9)J, 73.7 [quaternary C(14)], 84.8 
[C(5)], 110.8 (quaternary Ar) , 112.3 [C(7')]t 119.5 [C(2)], 120.0 [C(4’)], 120.7 [C(1)], 122.6 
(quaternary Ar), 122.7 [C(6 ')], 126.0 (quaternary Ar), 126.7 (Ar), 127.6 (quaternary Ar), 129.3 (2 
x Ar), 129.4 (2 x Ar), 130.2 (quaternary Ar), 132.2 (quaternary Ar), 140.8 (quaternary Ar), 142.1 
(quaternary Ar), 143.6 (quaternary Ar), 144.9 (quaternary Ar) and 171.7 (C=0); EI-MS m/z 589 





morphinan (64) (0.101 g, 0.204 mmol) and 4-methoxybenzylamine (0.042 g, 0.040 ml, 0.306 
mmol) were reacted according to general procedure A, to yield 17-cyclopropylmethyl-6,7- 
didehydro-4,5a-epoxy-5,-(N-4"-methoxybenzyl)amido-3,14-dihydroxyindolo[2,,3':6,7]morphinan 
(63) (0.031 g, 0.054 mmol, 26%). The product was then converted to the hydrochloride salt, 
mp. >220 °C (dec); Rf = 0.68 [CH3OH/CH2CI2/NH4OH (20:80:1)]; HPLC (C18 column) 2.633 
[MeOH/O.3% NH4CO3 (80:20)]; IR vmax/crn (KBr) 3680-2580 (br, bonded OH and amide NH), 
1660 (amide I) and 1520 (amide II); 1H NMR (270 MHz, CD3OD) 8 0.29-0.45 [m, 2H, 
NCH2CH(CHHCHH)], 0.53-0.77 [m, 2H, NCH2CH(CHHCHH)], 0.86-0.98 [m, 1H,
NCH2CH(CH2CH2)], 5.53 [s, 1H, C(5)H], 6.51-6.63 [m, 2H, C(1)Hand C(2)H\, 6 .6 8  (d, J=5.8 Hz,
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2H, C(3")H and C(5”)H), 7.12 (d, J=8.8  Hz, 2H, C(2")H and C(6")H), 7.23 [d, J=9.2 Hz, 1H, 
C(7’)/-/], 7.48 [d, J=9.2 Hz, 1H, C(6 ’)H] and 7.82 [s, 1H, C(4')H]; 13C NMR (67.8 MHz, CD3OD) 8 
3.8 [NCH2CH(CH2CH2)], 6 .6  [NCH2CH(CH2CH2)], 7.1 [NCH2CH(CH2CH2)], 25.3 [C(10)], 30.1 
[C(15)], 30.5 [C(8 )], 44.4 (CONHCH2), 47.7 [C(16)], 48.4 [quaternary C(13)], 50.3 (OCH3), 56.0 
[0(18)], 63.9 [C(9)], 74.0 [quaternary C(14)], 85.1 [C(5)J, 111.1 (quaternary Ar), 112.7 [C(7')],
115.2 [C(3") and C(5")]f 119.8 [C(2)], 120.4 (Ar), 121.2 (Ar), 123.0 (quaternary Ar), 123.1 [C(6 ')l,
126.5 (quaternary Ar), 127.8 (quaternary Ar), 130.2 [C(2") and C(6")], 130.5 (quaternary Ar),
132.5 (quaternary Ar), 132.7 (quaternary Ar), 141.0 (quaternary Ar), 142.3 (quaternary Ar),
145.1 (quaternary Ar), 160.6 [C(4M)] and 171.5 (C=0); EI-MS m/z 577 [(M)+, 100%], 536 (20) 
and 441 (10).
4-Hydrazinobenzyl cyanide107
A solution of 4-aminobenzylcyanide (1.20 g, 9.09 mmol) in c.HCI (22.5 ml) and H20  (32 ml) was 
cooled in an ice-bath. Sodium nitrite (0.71 g, 10.29 mmol) in H20  (10 ml) was added dropwise 
with stirring. After stirring at 0 °C for 30 min, the diazonium salt was added to SnCI2.H20  (7.91 
g) in H20  (75 ml) at 0 °C and left to stand at 0 °C for 1 h. The precipitate was filtered off and 
washed successively with ether, hexane and petroleum ether. After basification with NH4OH, 
extraction with dichloromethane gave 4-hydrazinobenzyl cyanide (0.89 g, 6.02 mmol, 6 6%) mp. 
73.1-75.2 °C (Lit.107 68-70 °C ); IR vmax/crn (CHCI3) 3370-3003 (br, NH2NH) and 2253 (CN); 1H 
NMR (270 MHz, CDCI3) 5 3.59 (br s, 1H, NH), 3.66 (s, 2H, CH2), 6.82 [d, J=8.6  Hz, 2H, C(3)H 
and C(5)H] and 7.18 [d, J=8.6  Hz, 2H, C(2)H and C(6 )H]; 13C NMR (75 MHz, CDCI3) 8 22.9 
(CH2CN), 112.6 [C(3 and 5)], 120.2 (CN), 121.5 [C(1)], 128.9 [C(2 and 6 )] and 151.0 [C(4)]; EI- 
MS m/z 147 [(M)+, 65%], 131 (90) and 116 (100).
5,-Cyanomethyl-17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-3,14-dihydroxyindolo- 
[2',3':6,7]morphinan (75)
4-Hydrazinobenzyl cyanide (1.30 g, 8.84 mmol) and naltrexone (25) (2.60 g, 7.62 mmol) were 
refluxed under N2 for 3 h in EtOH/2N HCI (5:1). The solution was concentrated, dissolved in
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H20 , basified with NH4OH and extracted with CH2CI2. The combined organic extracts were 
concentrated, dried (Na2S04), filtered and purified by column chromatography
[CH3OH/CH2CI2/NH4OH (5:94.5:0.5)] affording S’-cyanomethyl-^-cyclopropylmethyl-ej-
didehydro-4,5a-epoxy-3l14-dihydroxyindolo[2\3,:6,7]morphinan (75) (2.83 g, 6.25 mmol, 82%) 
mp. 230 °C (dec.); Rf = 0.44 [CH3OH/CH2CI2/NH4OH (2:20:0.1)]; IR vmax/crn (CHCI3) 3466-3005 
(br, OH) and 2250 (CN); 1H NMR (300 MHz, CDCI3) 8 0.18-0.23 [m, 2H, NCH2CH(CHHCHH)], 
0.57-0.65 [m, 2H, NCH2CH(CHHCHH)], 0.89-0.97 [m, 1H, NCH2CH(CH2CH2)], 5.62 [s, 1H, 
C(5)H], 6.54 [d, J=8.2 Hz, 1H, C(1 )H], 6.62 [d, J=8.2 Hz, 1H, C(2)H], 6.97 [d, J=8.6  Hz, 1H, 
C(6 ’)H\, 7.23 [d, J=8 .6  Hz, 1H, C{T)H] and 7.28-7.32 [m, 1H, C(4’)H]; 13C NMR (75 MHz, 
CDCI3) 5 3.8 [NCH2CH(CH2CH2)]f 4.3 [NCH2CH(CH2CH2)], 9.2 [NCH2CH(CH2CH2)], 23.5 
[C(10)], 24.9 (CH2CN), 28.9 [C(15)], 31.4 £C(8 )], 44.1 [C(16)], 49.9 [quaternary C(13)], 59.5 
[C(18)], 62.5 [C(9)], 73.1 [quaternary C(14)], 84.9 [C(5)], 112.2 [C(7’)], 117.4 [C(2)], 118.3 
[C(4’)], 119.1 (CN), 119.3 [C(1)J, 120.2 (quaternary Ar), 122.3 [C(6 ’)l, 124.5 (quaternary Ar),
128.1 (quaternary Ar), 128.2 (quaternary Ar), 130.7 (quaternary Ar), 130.9 (quaternary Ar),
137.0 (quaternary Ar), 139.9 (quaternary Ar) and 143.5 (quaternary Ar); EI-MS m/z 453 [(M)\ 





morphinan (75) (1.02 g, 2.25 mmol) was dissolved in EtOH, and hydrogenated with Raney 
nickel at 25 psi for 72 h. The mixture was filtered through cellite, concentrated, dried (Na2S 04) 
and purified by column chromatography, [CH3OH/CH2CI2/NH4OH (10:89:1)] to give 5’- 
aminoethyl-17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-3,14-dihydroxyindolo[2',3':6,7]- 




morphinan (75) (0.53 g, 1.17 mmol) was dissolved in formic acid. Raney nickel catalyst was 
added and the mixture refluxed gently for 3 h. The mixture was then filtered through cellite and 
concentrated before being dissolved in water, basified with NH4OH and extracted with 
[CHCIij/isopropanol (7:3)]. The combined organic extracts were dried (Na2S04) and 
concentrated under reduced pressure. Further purification was achieved by column 
chromatography, [CH3OH/CH2CI2/NH4OH (10:89:1)] giving S’-aminoethyMZ-cyclopropylmethyl- 
ej-didehydro^.Sa-epoxy-S.H-dihydroxyindolo^'.S'^JJmorphinan (76) (0.48 g, 1.04 mmol, 
89%) mp. >250 °C (dec.); Rf = 0.17 [CH3OH/CH2CI2/NH4OH (10:89:1)]; HPLC (C18 column) 
14.158 [MeOH/O.3% NH4C 0 3 (80:20)]; IR vmax/crn (CHCI3) 3572-3278 (br, NH2 and OH); 1H 
NMR (270 MHz, CD3OD) 5 0.19-0.25 [m, 2H, NCH2CH(CHHCHH)], 0.58-0.62 [m, 2H, 
NCH2CH(CHHCHH)], 0.88-1.0 [m, 1H, NCH2CH(CH2CH2)], 5.62 [s, 1H, C(5)H\, 6.51-6.59 [m, 
2H, C(1)H and C(2)H\, 6.97 [d, J=8.2 Hz, 1H, C(6 ')H], 7.22-7.26 [m, 1H, C(4’)] and 7.31 [d, 
J=8.2 Hz, 1H, C(T)H]', 13C NMR (67.8 MHz, CD3OD) 8 3.2 [NCH2CH(CH2CH2)], 3.5
[NCH2CH(CH2CH2)], 9.0 [NCH2CH(CH2CH2)], 22.7 [C(10)], 28.3 [C(15)]f 31.1 [C(8 )], 38.3 
(CH2CH2NH2), 42.7 (CH2NH2), 43.3 [C(16)], 47.4 [quaternary C(13)], 59.1 [C(18)], 62.0 [0(9)],
72.6 [quaternary C(14)], 84.5 [0(5)], 109.7 (quaternary Ar), 111.0 [C(7’)]f 116.7 [C(2)], 118.1 
[C(4’)], 118.3 [C(1)]t 123.0 [C(6 ’)], 124.2 (quaternary Ar), 126.6 (quaternary Ar), 128.6 
(quaternary Ar), 129.6 (quaternary Ar), 130.4 (quaternary Ar), 135.9 (quaternary Ar), 139.3 
(quaternary Ar) and 143.0 (quaternary Ar); EI-MS m/z 457 [(M )\ 60%] and 428 (100).
17-Cyclopropylmethyl-6,7-didehydro-4l5a-epoxy-5,-[(N-(3-methyl)butylamidino)ethyl]- 
3,14-dihydroxyindolo[2',3':6,7]morphinan (71)
Isovaleronitrile (1.19 g, 14.35 mmol) was dissolved in anhydrous EtOH. Dry HCI was bubbled 
through the solution for 40 min, after which the flask was sealed and left at -20 °C for 7 days.74 
The iminoether was crystallized from the resultant viscous solution, washed with ether and dried 
under a stream of N2 for 2 h (0.71 g, 4.30 mmol, 30%).
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The above iminoether (0.09 g, 0.55 mmol) and 5’-aminoethyl-17-cyclopropylmethyl-6,7- 
didehydro-^a-epoxy-O.M-dihydroxyindoloP'.S'^Jlmorphinan (76) (0.10 g, 0.22 mmol) were 
stirred in anhydrous EtOH (5 ml) under N2 for 72 h. Concentration and subsequent preparative 
thin layer chromatography [CH3OH/CH2CI2/NH4OH (15:84:1)] allowed isolation of branched 
amidine (71) (0.018 g, 0.03 mmol, 15.2%). The compound was converted to its dihydrochloride 
salt, mp. >250 °C (dec.); Rf = 0.21 [CH3OH/CH2CI2/NH4OH (20:80:1)]; HPLC (C18 column) 
1.792 [MeOH/O.3% NH4CO3 (80:20)]; IR Vrnax/cm (KBr) 3675-3008 (br, bonded OH and C=NH) 
and 1654 (C=N); 1H NMR (270 MHz, CD3OD) 6 0.42-0.50 [m, 2H, NCH2CH(CHHCHH)], 0.58- 
0.69 [m, 2H, NCH2CH(CHHCHH)], 0.82-0.88 [m, 1H, NCH2CH(CH2CH2)], 5.62 [s, 1H, C(5)H\, 
6.55-6.61 [m, 2H, C(1 )H and C(2)H], 6.94 [d, J=8.2 Hz, 1H, C(6 ')H\, 7.21-7.24 [m, 1H, C(4’)] 
and 7.25 [d, J=8.2 Hz, 1H, C(7’)H]; 13C NMR (75 MHz, CD3OD) 8 2.2 [NCH2CH(CH2CH2)], 4.9 
[NCH2CH(CH2CH2)], 5.7 [NCH2CH(CH2CH2)], 20.8 [2xCH3], 23.9 [C(10 )], 27.2 [C(15)], 28.5 
[C(8 )]t 29.0 (CH2CH2NH), 33.3 (CH2NH), 40.7 [C(NH)CH2], 41.4 [C(16)], 47.1 [quaternary 
C(13)], 57.8 [0(18)], 62.5 [C(9)], 72.5 [quaternary C(14)], 83.9 [C(5)]f 108.2 (quaternary Ar),
111.7 [C(7’)], 118.1 [C(2 )], 118.4 and 119.3 [C(4’)] and [C(1)]« 121.5 (quaternary Ar), 123.1 
[C(6 ’)], 126.8 (quaternary Ar), 127.1 (quaternary Ar), 129.1 (quaternary Ar), 129.8 (quaternary 
Ar), 136.8 (quaternary Ar), 140.7 (quaternary Ar), and 143.6 (quaternary Ar); FAB-MS m/z 541 
[(M+1)\ 70%] and 458 (50); HRMS (El) m/z 540.3104 (M )\ C33H40N4O3 requires 540.3100.
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5(-(thioethylimidic acid phenyl ester)- 
S.M-dihydroxyindoloP'.S'iBJlmorphinan (78)
A solution of 5’-cyanomethyl-17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-3,14-dihydroxy- 
indoloP'.S'tfJJmorphinan (75) (0.200 g, 0.44 mmol), thiophenol (0.050 g, 0.046 ml, 0.44 mmol) 
and anhydrous MeOH (100 ml) in an ice-salt bath, was purged with dry nitrogen. HBr was 
bubbled through the solution for 45 min. The solution was partially concentrated in vacuo and 
Et20  was added. The Et20  was decanted, removing excess unreacted thiophenol. Et20  was 
again added and the crude thioimidic ester precipitated out. Since the crude compound was not 




Propylamine (0.010 g, 0.014 ml, 0.175 mmol) and thioimidic ether (78) (0.129 g, 0.229 mmol) in 
anhydrous MeOH (25ml) were reacted according to general procedure B, to give major product
(72) (0.024 g, 0.047 mmol, 27%). The dihydrobromide salt of the product was then formed, mp. 
249 °C (dec.); Rf = 0.22 [CH3OH/CH2CI2/NH4OH (20:80:1)]; HPLC (C18 column) 2.696 
[MeOH/O.3% NH4CO3 (80:20)]; IR vmax/crn (KBr) 3680-2700 (br, bonded OH and C=NH) and 
1670 (C=N); 1H NMR (270 MHz, CD3OD) 6 0.35-0.42 [m, 2H, NCH2CH(CHHCHH)], 0.62-0.76 
[m, 2H, NCH2CH(CHHCHH)], 0.87-0.93 [m, 1H, NCH2Ctf(CH2CH2)], 5.65 [s, 1H, C(5)H], 6.61- 
6.63 [m, 2H, C(1 )H and C(2)H\, 7.10 [d, J=8.6  Hz, 1H, C(6 ')H], 7.35 [d, J=8.6  Hz, 1H, C{7')H] 
and 7.44-7.47 [m, 1H, C(4’)]; 13C NMR (75 MHz, CD3OD) 6 3.8 [NCH2CH(CH2CH2)], 5.7 
[NCH2CH(CH2CH2)], 8.3 [NCH2CH(CH2CH2)], 11.5 (CH3), 22.0 [C(10)]f 24.8 (NHCH2CH2), 30.2 
[C(15)], 30.9 [C(8 )], 40.1 (NHCH2) 45.3 [C(16)]f 46.5 (CH2C=NH), 48.7 [quaternary C(13)], 59.5 
[C(18)], 63.6 [C(9)]t 74.0 [quaternary C(14)], 85.4 [C(5)]f 110.4 (quaternary Ar), 113.1 [C(7’)],
119.0 [C(2)], 120.4 [C(1)] and [C(4')], 124.0 [C(6 ’)], 124.6 (quaternary Ar), 128.4 (quaternary 
Ar), 131.0 (quaternary Ar), 131.8 (quaternary Ar), 138.4 (quaternary Ar), 141.6 (quaternary Ar),
144.8 (quaternary Ar) and 168.7 (C=NH); EI-MS m/z 512 [(M)\ 100%], 453 (80) and 412 (25); 
HRMS (El) m/z 512.2788 (M)+, C31H36N4O3 requires 512.2787. Minor product (79) EI-MS m/z 
554 [(M )\ 100%], 453 (40) and 428 (65).
S’^N-pentylJacetamidino-^-cyclopropylmethyl-BJ-didehydro^.Sa-epoxy-S,^- 
dihydroxyindolo-[2\3':6,7]morphinan (73)
Amylamine (0.011 g, 0.015 ml, 0.125 mmol) and thioimidic ether (78) (0.090 g, 0.159 mmol) in 
anhydrous MeOH (25ml) were reacted according to general procedure B, to give major product
(73) (0.016 g, 0.030 mmol, 24%). The dihydrobromide salt of the product was then formed, mp. 
240-243 °C (dec.); Rf = 0.31 [CH3OH/CH2CI2/NH4OH (20:80:1)]; HPLC (C18 column) 3.017 
[MeOH/O.3% NH4CO3 (80:20)]; IR vmax/cm (KBr) 3620-2800 (br, bonded OH and C=NH) and 
1670 (C=N); 1H NMR (270 MHz, CD3OD) 8 0.36-0.49 [m, 2H, NCH2CH(CHHCHH)], 0.67-0.84
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[m, 2H, NCH2CH(CHHCHH)], 0.88-0.98 [m, 1H, NCH2CH(CH2CH2)], 5.67 [br s, 1H, C(5)H\, 
6.54-6.66 [m, 2H, C(1)H and C(2)H], 6.99-7.12 [m, 1H, C(4’)] and 7.25-7.44 [m, 2H, C(6 ')H and 
C(7’)HJ; 13C NMR (67.8 MHz, CD3OD) 5 2.4 [NCH2CH(CH2CH2)], 4.5 [NCH2CH(CH2CH2)], 6.5 
[NCH2CH(CH2CH2)], 12.7 (CH3), 21.9 [C(10)]f 26.9, 27.0, 28.2 (NHCH2CH2CH2CH2CH3), 28.6 
[C(15)], 30.4 [C(8 )], 39.5 (NHCH2) 42.4 [C(16)], 45.6 (CH2C=NH), 48.0 [quaternary C(13)], 58.1 
[C(18)], 62.4 [C(9)], 72.6 [quaternary C(14)], 84.0 [C(5)], 108.9 (quaternary Ar), 111.8  [C(7')],
117.9 (Ar), 119.0 (Ar), 119.1 (Ar), 122.8 (Ar), 123.3 (Ar), 127.1 (Ar), 129.5 (quaternary Ar),
130.5 (quaternary Ar), 137.2 (quaternary Ar), 140.5 (quaternary Ar), 143.5 (quaternary Ar) and
167.4 (C=NH); EI-MS m/z 540 [(M)+, 100%], 453 (50) and 412 (20); HRMS (El) m/z 540.3082 
(M)+, C 33H 4oN 40 3 requires 540.3100. Minor product (80) EI-MS m/z 610 [(M)+, 15%], 471 (5), 
453 (2) and 428 (8 ).
5’-(N-heptyl)acetamidino-17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-3,14- 
dihydroxyindolo-^'^'tfJlmorphinan (74)
Heptylamine (0.014 g, 0.018 ml, 0.122 mmol) and thioimidic ether (78) (0.088 g, 0.156 mmol) in 
anhydrous MeOH (25ml) were reacted according to general procedure B, to give major product
(74) (0.016 g, 0.028 mmol, 23%). The dihydrobromide salt of the product was then formed, mp. 
220 °C (dec.); Rf = 0.47 [CH3OH/CH2CI2/NH4OH (20:80:1)]; HPLC (C18 column) 4.475 
[MeOH/O.3% NH4C 0 3 (80:20)]; IR vmax/crn (KBr) 3640-2840 (br, bonded OH and C=NH) and 
1670 (C=N); 1H NMR (270 MHz, CD3OD) 6 0.28-0.37 [m, 2H, NCH2CH(CHHCHH)], 0.72-0.78 
[m, 2H, NCH2CH(CHHCHH)], 0.79-0.86 [m, 1H, NCH2CH(CH2CH2)], 5.58 [s, 1H, C(5)H], 6.51- 
6.55 [m, 2H, C(1)H and C(2)H\, 6.99 [d, J=8.6  Hz, 1H, C(6 ')H\, 7.27 [d, J=8 .6  Hz, 1H, C(7’)H] 
and 7.32-7.35 [m, 1H, C(4’)]; 13C NMR (67.8 MHz, CD3OD) 8 2.6 [NCH2CH(CH2CH2)], 3.9 
[NCH2CH(CH2CH2)], 7.7 [NCH2CH(CH2CH2)], 13.0 (CH3), 22.1 [C(10)], 23.2, 26.3, 27.3, 28.4 
and 28.7 (NHCH2CH2CH2CH2CH2CH2CH3), 30.4 [C(15)], 31.4 [C(8 )J, 42.3 (NHCH2), 44.6 
[C(16)]« 46.7 (CH2C=NH), 48.1 [quaternary C(13)], 58.7 [C(18)]( 62.4 [C(9)J, 72.9 [quaternary 
C(14)], 84.3 [C(5)], 109.5 (quaternary Ar), 111.8 [C(7')], 117.5 (Ar), 118.7 (Ar), 118.9 (Ar), 122.6 
(Ar), 123.1 (Ar), 127.2 (Ar), 130.2 (quaternary Ar), 130.7 (quaternary Ar), 137.1 (quaternary Ar),
140.1 (quaternary Ar), 143.5 (quaternary Ar) and 167.4 (C=NH); EI-MS m/z 568 [(M)+, 40%],
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453 (100) and 412 (35); HRMS (El) m/z 568.3403 (M)+, C3 5 H4 4 N4 O3 requires 568.3413. Minor 
product (81) EI-MS m/z 666  [(M )\ 45%], 453 (20) and 428 (20).
±17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5,-[4-methyl-(4l5-dihydro-1H-imidazol-
2-yl)methyl]-3,14-dihydroxyindolo[2\3,:6,7]morphinan (83)
1.2-Diaminopropane.p-TSA (2.19 g, 8.91 mmol) and 5’-cyanomethyl-17-cyclopropylmethyl-6,7- 
didehydro-4l5a-epoxy-3,14-dihydroxyindolo[2,,3,:6>7]morphinan (75) (0.41 g, 0.90 mmol) were 
reacted according to general procedure C, giving methyl imidazoline (83) (0.025 g, 0.048 mmol, 
5%). The product was converted to the dihydrochloride salt, mp. 191-193 °C; Rf = 0.37 
[CH3OH/CH2CI2/NH4OH (20:80:1)]; HPLC (C18 column) 2.575 [MeOH/O.3% NH4CO3 (80:20)]; 
IR vmax/cm (KBr) 3660-2700 (br, bonded OH and NH); 1H NMR (270 MHz, CD3OD) 8 0.14-0.26 
[m, 2H, NCH2CH(CHHCHH)], 0.50-0.61 [m, 2H, NCH2CH(CHHCHH)], 0.85-0.98 [m, 1H, 
NCH2CH(CH2CH2)], 5.57 [s, 1H, C(5)H], 6.51-6.55 [m, 2H, C(1)H and C(2)H], 6.97-7.04 [m, 1H, 
ArH\ and 7.26-7.35 [m, 2H, 2x Ar/-/]; 13C NMR (67.8 MHz, CD3OD) 5 2.8 [NCH2CH(CH2CH2)],
3.3 [NCH2CH(CH2CH2)], 8.9 [NCH2CH(CH2CH2)], 19.8 (CH3), 20.1 (CH2), 22.8  (CH2), 28.5 
(CH2), 31.4 (CH2), 43.6 (CH2), 46.7 (CH2), 46.9 (CH2), 47.2 [quaternary C(13)], 52.7 (CH), 59.2 
[C(18)], 62.3 [C(9)J, 73.1 [quaternary C(14)], 84.6 [C(5)]f 110.0 (Ar), 111.6 (Ar), 117.1 (Ar),
118.4 (Ar), 118.8 (Ar), 122.6 (Ar), 124.7 (Ar), 127.2 (Ar), 128.6 (Ar), 130.8 (Ar), 137.0 (Ar),
139.9 (Ar) and 143.4 (Ar); EI-MS m/z 510 [(M)+, 100%] and 455 (20); HRMS (El) m/z 510.2634 
(M )\ C31H34N4O3 requires 510.2631.
^-Cyclopropylmethyl-GJ-didehydro^Sa-epoxy-S'-^^-dimethyl-^S-dihydro-IH- 
imidazol-2-yl)methyl]-3,14-dihydroxyindolo[2’,3':6,7]morphinan (84)
1.2-Diamino-2-methylpropane.p-TSA (2.14 g, 8.22 mmol) and 5’-cyanomethyl-17- 
cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-3,14-dihydroxyindolo[2',3':6,7]morphinan (75) 
(0.38 g, 0.83 mmol) were reacted according to general procedure C, giving dimethyl imidazoline 
(84) (0.028 g, 0.053 mmol, 6%). The product was converted to the dihydrochloride salt, mp. 
>220 °C; Rf= 0.40 [CH3 OH/CH2 CI2/NH4 OH (20:80:1)]; IR vmax/cm (KBr) 3640-2580 (br, bonded
122
OH and NH); 1H NMR (270 MHz, CD3OD) 8 0.12-0.25 [m, 2H, NCH2CH(C//HCHH)], 0.48-0.63 
[m, 2H, NCH2CH(CHHCHH)], 0.86-0.99 [m, 1H, NCH2CH(CH2CH2)], 5.52 [s, 1H, C(5)H], 6.45- 
6.53 [m, 2H, C(1)H and C(2)H\, 7.09-7.16 [m, 1H, ArH] and 7.21-7.30 [m, 2H, 2x Ar/-/]; 13C 
NMR (67.8 MHz, CD3OD) 8 2.8 [NCH2CH(CH2CH2)]f 3.3 [NCH2CH(CH2CH2)], 9.0 
[NCH2CH(CH2CH2)], 19.0 (CH3), 22.4 (CH3), 23.9 (CH2), 27.1 (CH2), 27.5 (CH2), 28.5 (CH2),
29.4 (CH2), 31.5 (CH2), 43.7 (CH2), 47.8 [quaternary C(13)], 59.2 [C(18)J, 62.4 [C(9)], 73.2 
[quaternary C(14)], 84.3 [C(5)], 109.8 (Ar), 111.2 (Ar), 117.7 (Ar), 118.3 (Ar), 118.4 (Ar), 122.6 
(Ar), 127.1 (Ar), 130.5 (Ar), 130.6 (Ar), 136.7 (quaternary Ar) and 143.9 (quaternary Ar); EI-MS 





morphinan (76) (0.100 g, 0.220 mmol) and ethyl isocyanate (0.016 g, 0.017 ml, 0.225 mmol) 
were reacted according to general procedure D, yielding (85) (0.035 g, 0.067 mmol, 30%), 
which was subsequently converted to the dihydrochloride salt, mp. 203-206 °C (dec); Rf = 0.56 
[CH3OH/CH2CI2/NH4OH (10:89:1)]; HPLC (C18 column) 1.892 [MeOH/O.3% NH4C 03 (80:20)]; 
IR vmax/cm (KBr) 3660-2600 (br, bonded OH and CONH) and 1630 (urea); 1H NMR (400 MHz, 
CD3OD) 8 0.49-0.59 [m, 2H, NCH2CH(C//HCHH)], 0.74-0.82 [m, 1H, NCH2CH(CH2CH2)], 0.84- 
0.91 [m, 2H, NCH2CH(CHHCHH)], 5.70 [s, 1H, C(5)H], 6.65 [d, J=8.2, 1H, C(1 )H\, 6.67 [d, 
J=8.2 Hz, 1H, C(2)/-/], 7.00 [d, J=8.2 Hz, 1H, C(6 ')H], 7.25 [s, 1H, C(4')H] and 7.29 [d, J=8.2 Hz, 
1H, C(7')H]; 13C NMR (100 MHz, CD3OD) 8 3.5 [NCH2CH(CH2CH2)], 6.4 [NCH2CH(CH2CH2)],
7.0 [NCH2CH(CH2CH2)], 15.4 (CH3), 25.1 [C(10)J, 29.9 [C(15)], 30.4 [C(8 )], 36.3 (CH2), 36.5 
(CH2), 37.4 (CH2), 43.7 [C(16)], 47.6 [quaternary C(13)], 58.9 [C(18)], 63.7 [C(9)J, 73.6 
[quaternary C(14)], 85.2 [C(5)], 109.1 (Ar), 112.3 (Ar), 119.3 (Ar), 120.3 (Ar), 122.4 (Ar), 124.7 
(Ar), 128.0 (Ar), 130.3 (Ar), 130.5 (Ar), 137.7 (Ar), 141.9 (Ar), 144.7 (Ar) and 161.6 (C=0); 
FAB-MS m/z 529 [(M+1)\ 100%] and 330 (22); HRMS (FAB) m/z 529.2838 (M +1)\ 
C3iH37N40 4 requires 529.2815. The minor product (89) was also isolated (0.010 g, 0.017 mmol,
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8 %) Rf = 0.68 [CH3OH/CH2CI2/NH4OH (10:89:1)]; IR vmax/cm (KBr) 3640-2700 (br, bonded OH 
and CONH) and 1630 (urea); 1H NMR (400 MHz, CD3OD) 8 0.52-0.59 [m, 2H,
NCH2CH(CHHCHH)], 0.75-0.82 [m, 1H, NCH2CH(CH2CH2)], 0.85-0.93 [m, 2H,
NCH2CH(CHHCHH)], 5.77 [s, 1H, C(5)H], 6.80 [d, J=8.4, 1H, C(1 )H\, 6.87 [d, J=8.4 Hz, 1H, 
C(2)H], 7.01 [d, J=8.2 Hz, 1H, C(6 ')H], 7.24 [s, 1H, C(4')H\ and 7.26 [d, J=8.2 Hz, 1H, C(T)H]\ 




morphinan (76) (0.102 g, 0.223 mmol) and butyl isocyanate (0.022 g, 0.025 ml, 0.222 mmol) 
were reacted according to general procedure D, yielding (8 6 ) (0.041 g, 0.073 mmol, 33%). The 
product was then converted to the dihydrochloride salt, mp. 179-181 °C (dec); Rf = 0.42 
[CH3OH/CH2CI2/NH4OH (10:89:1)]; HPLC (C18 column) 1.967 [MeOH/O.3% NH4CO3 (80:20)]; 
IR vmax/cm (KBr) 3660-2500 (br, bonded OH and CONH) and 1630 (urea); 1H NMR (400 MHz, 
CD3OD) 8 0.47-0.59 [m, 2H, NCH2CH(CHHCHH)], 0.71-0.80 [m, 1H, NCH2CH(CH2CH2)], 5.69 
[s, 1H, C(5)H], 6.65-6.71 [m, 2H, C(1)H and C(2)H\, 7.00 [d, J=8.2 Hz, 1H, C(6 ')H\, 7.25 [s, 1H, 
C(4')H] and 7.29 [d, J=8.2 Hz, 1H, C{T)H]\ 13C NMR (100 MHz, CD3OD) 8 3.4
[NCH2CH(CH2CH2)], 6.3 [NCH2CH(CH2CH2)], 6.9 [NCH2CH(CH2CH2)], 14.0 (CH3), 20.8  (CH2),
25.1 [C(10 )]f 29.8 [C(15)], 30.3 [C(8 )J, 32.7 (CH2), 35.3 (CH2), 37.1 (CH2), 41.3 (CH2), 43.8 
[C(16)], 47.5 [quaternary C(13)], 58.8 [C(18)], 64.0 [C(9)], 73.7 [quaternary C(14)], 85.2 [C(5)],
109.3 (Ar), 112.5 (Ar), 119.4 (Ar), 119.5 (Ar), 120.6 (Ar), 122.6 (Ar), 124.8 (Ar), 128.1 (Ar),
130.4 (Ar), 130.7 (Ar), 135.4 (Ar), 137.8 (Ar), 142.0 (Ar) and 144.8 (Ar); FAB-MS m/z 557 






morphinan (76) (0.100 g, 0.219 mmol) and hexyl isocyanate (0.028 g, 0.032 ml, 0.220 mmol) 
were reacted according to general procedure D, yielding (87) (0.052 g, 0.089 mmol, 40%), 
which was then converted to the dihydrochloride salt, mp. 240 °C (dec); Rf = 0.37 
[CH3OH/CH2CI2/NH4OH (10:89:1)]; HPLC (C18 column) 1.800 [MeOH/O.3 % NH4CO3 (80:20)]; 
IR vmax/crn (KBr) 3640-2680 (br, bonded OH and CONH) and 1630 (urea); 1H NMR (270 MHz, 
CD3OD) 8 0.49-0.60 [m, 2H, NCH2CH(CHHCHH)], 0.72-0.81 [m, 1H, NCH2CH(CH2CH2)], 5.70 
[s, 1H, C(5)H], 6.62-6.71 [m, 2H, C(1)Hand C(2)H\, 7.00 [d, J=8.2 Hz, 1H, C(6 ')H\, 7.26 [s, 1H, 
C(4')H\ and 7.29 [d, J=8.2 Hz, 1H, C{T)H\; 13C NMR (67.8 MHz, CD3OD) 8 2.2
[NCH2C H (C H 2CH2)], 5.0 [NCH2C H (C H 2CH2)], 5.6 [NCH2CH(CH2CH2)]f 13.0 (CH3), 22.2 (CH2),
23.9 [C(10)], 26.1 (CH2), 28.6 [C(15)]f 29.1 [C(8 )], 29.2 (CH2), 31.2 (CH 2), 35.8 (CH2), 40.3 
(CH2), 42.6 [C(16)], 46.7 [quaternary C(13)], 57.7 [C(18)], 62.6 [C(9)], 72.5 [quaternary C(14)],
84.0 [C(5)], 108.0 (quaternary Ar), 1112 (Ar), 118.1 (Ar), 118.2 (Ar), 119.2 (Ar), 121.3 
(quaternary Ar), 123.6 (Ar), 126.9 (quaternary Ar), 129.1 (quaternary Ar), 129.5 (quaternary Ar),
136.6 (quaternary Ar), 140.8 (quaternary Ar) and 143.6 (quaternary Ar); FAB-MS m/z 585 




Carbamate (89) (0.010 g, 0.017 mmol) was stirred in [CH30H/H20  (9:1)] with K2C 03 (5 eq) for 
12 h. The CH3OH was removed in vacuo, the aqueous phase extracted with CH2CI2 and 
subsequently purified by preparative thin layer chromatography ['PrOH/CHCI3 (3:7)], yielding 





P'.S'^yjniorphinan (75) (2.22 g, 4.91 mmol), triphenylmethyl chloride (1.53 g, 5.48 mmol), 
triethylamine (0.84 g, 1.15 ml, 8.32 mmol) and a catalytic amount of 4-dimethylaminopyridine 
(DMAP) (0.060g) were added to anhydrous CH2CI2 (50 ml) and stirred at RT, under N2, for 12 h. 
The solution was then basified with NaHC03 and extracted with CH2CI2. The combined organic 
extracts were dried (Na2S04), concentrated, filtered and purified by column chromatography 
[CH3OH/CH2CI2/NH4OH (2:97:1)] affording 5’-cyanomethyl-17-cyclopropylmethyl-6,7-didehydro- 
4,5a-epoxy-14-hydroxy-3-trityloxyindolo[2,,3,:6,7]morphinan (95) (2.22 g, 3.19 mmol, 65%); mp. 
156-157 °C; Rf = 0.50 [CH3OH/CH2CI2/NH4OH (2:97:1)]; 1H NMR (270 MHz, CDCI3) 8 0.35- 
0.46 [m, 2H, NCH2CH(CHHCHH)]f 0.76-0.82 [m, 2H, NCH2CH(CHHCHH)], 1.06-1.18 [m, 1H, 
NCH2CH(CH2CH2)], 5.60 [s, 1H, C(5)H], 6.41-6.58 [m, 2H, C(1)H and C(2)H\, 7.00-7.07 (m, 1H, 
ArH), 7.12-7.18 (m, 1H, ArH) and 7.24-7.60 (m, 16H, ArH); 13C NMR (100 MHz, CDCI3) 5 3.9 
[NCH2CH(CH2CH2)], 4.1 [NCH2CH(CH2CH2)], 9.5 [NCH2CH(CH2CH2)], 23.3 [C(10)], 23.7 
(CH2CN), 28.7 [C(15)], 31.1 [C(8 )], 43.4 [C(16)], 47.6 [quaternary C(13)], 59.4 [C(18)J, 62.0 
[C(9)], 72.2 [quaternary C(14)], 84.0 [C(5)], 92.0 [C(CH3)], 110.9 (Ar), 111.6 (Ar), 117.7 (Ar),
117.9 (Ar), 118.8 (Ar), 120.0 (CN), 121.9 (Ar), 124.9 (Ar), 126.8 (Ar), 127.0 (4 x Ar), 127.6 (Ar),
127.7 (2 x Ar), 127.7 (2 x Ar), 128.4 (Ar), 128.5 (Ar), 129.2 (Ar), 130.1 (Ar), 130.5 (Ar), 136.3 
(Ar), 138.6 (Ar), 143.9 (Ar), 146.7 (Ar) and 149.4 (Ar); FAB-MS m/z 696 [(M+1)\ 100%]; 
HRMS (FAB) m/z 696.3215 (M+1)+, C47H42N30 3 requires 696.3226.
S’-AminoethyMZ-cyclopropylmethyl-ej-didehydro^Sa-epoxy-^-hydroxy-S-trityloxy- 
indolo^'^ 'tfjjm orphinan (94)
5’-Cyanomethyl-17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-14-hydroxy-3-tritylindolo- 
[2',3':6,7]morphinan (95) (2.07 g, 2.98 mmol) was dissolved in CH3OH (50 ml), to which 
cyclohexene (50 ml) and a spatula tip of Raney nickel was added. The mixture was then stirred 
at ca. 50 °C for 6 h, before being dried (Na2S 0 4), concentrated, filtered and purified by column
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chromatography [CH3 OH/CH2 CI2/NH4 OH (10:89:1)] to give 5’-aminoethyl-17-cyclopropylmethyl- 
6,7-didehydro-4,5a-epoxy-14-hydroxy-3-trityloxyindolo[2',3':6,7]morphinan (94) (1.71 g, 2.44 
mmol, 82%); mp. 228 °C; Rf =0.31 [CH3 OH/CH2 CI2/NH4 OH (10:89:1)]; 1H NMR (270 MHz, 
CDCI3 ) 6 0.32-0.41 [m, 2H, NCH2 CH(CHHCHH)], 0.73-0.84 [m, 2H, NCH2 CH(CHHCHH)], 0.89-
1.01 [m, 1H, NCH2CH(CH2CH2)], 5.60 [s, 1H, C(5)H], 6.36 [d, J=8.3Hz, 1H, C(1 )H\, 6.43 [d, 
J=8.3Hz, 1H, C(2)H] and 7.17-7.49 (m, 18H, ArH); 13C NMR (100 MHz, CDC!3) 8 3.7 
[NCH2CH(CH2CH2)], 3.9 [NCH2CH(CH2CH2)], 9.3 [NCH2CH(CH2CH2)], 23.1 [C(10)J, 24.1 (CH2),
25.4 (CH2), 28.6 [C(15)J, 31.0 [C(8 )], 43.4 [C(16)], 47.5 [quaternary C(13)], 59.4 [C(18)], 62.0 
[C(9)]f 72.2 [quaternary C(14)], 84.3 [C(5)J, 91.7 [C(CH3)]( 110.6 (quaternary Ar), 111.2 (Ar),
117.6 (Ar), 118.5 (Ar), 123.6 (Ar), 124.8 (Ar), 126.7 (Ar), 127.0 (Ar), 128.2 (quaternary Ar),
129.1 (Ar), 129.5 (quaternary Ar), 130.0 (quaternary Ar), 130.1 (quaternary Ar), 130.6 
(quaternary Ar), 136.0 (quaternary Ar), 138.7 (quaternary Ar), 144.1 (quaternary Ar) and 149.5 
(quaternary Ar); FAB+MS m/z 700 [(M+1)+, 18%] and 243 (100); HRMS (FAB) m/z 700.3572 
(M+1)+, C47H46N3O3 requires 700.3539.
ToIuene-4-sulfonic acid 3-terf-butoxycarbonylamino propyl ester (96)121
3-Aminopropan-1-ol (3.00g, 40.0 mmol) was dissolved in tetrahydrofuran (THF) (20 ml) and 
stirred at 0 °C. (BOC)20  in THF (40 ml) was added dropwise and the reaction mixture allowed 
to warm to RT and stirred for 12 h. The solvent was then evaporated under reduced pressure 
and the residue purified by column chromatography Rf= 0.57 [CH3OH/CH2CI2/NH4OH (10:89:1)] 
to give 3-(N-BOC-amino)propan-1-ol (4.90 g, 28.0 mmol, 70%).
3-(N-BOC-amino)propan-1-ol (1.83 g, 10.46 mmol), 4-dimethylaminopyridine (1.28 g, 10.46 
mmol) and triethylamine (1.60g, 2.20 ml, 15.70 mmol) were dissolved in anhydrous CH2CI2 (50 
ml) at 0 °C. p-Toluenesulfonyl chloride (4.47 g, 23.55 mmol) was dissolved in anhydrous 
CH2CI2 (50 ml) and added dropwise to the reaction mixture over 1 h. The mixture was then 
stirred for 12 h at RT and subsequently washed with water. The organic layers were dried 
(Na2S04), concentrated and further purified by column chromatography [Hexane/EtOAc 
(50:50)], to give toluene-4-sulfonic acid 3-fe/f-butoxycarbonylamino propyl ester (96) (1.20 g,
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3.65 mmol, 35%) as a volatile, colourless liquid. Rf = 0.45 [Hexane/EtOAc (50:50)]; 1H NMR 
(400 MHz, CDCI3) 6 1.32-1.48 (m, 9H, 3 x CH3), 1.75-1.85 (m, 2H, Ctf2), 2.40 (s, 3H, CH3), 
3.06-3.13 (m, 2H, CH2), 4.00-4.09 (m, 2H, CH2), 4.74 (br s, 1H, NH), 7.30 (d, J=8.6  Hz, 2H, 
ArH) and 7.73 (d, J=8.6  Hz, 2H, ArH). No characterisation reported in reference article.
5,-(Dimethylamino)ethyM7-cyclopropyImethyl-6,7-didehydro-4,5a-epoxy-3f14-dihydroxy- 
indolo^'^'tfJlmorphinan (98)
Formaldehyde (0.017 g, 0.016 ml 37 WT.% solution, 0.21 mmol) was added to a solution of 5’- 
aminoethyl-^-cyclopropylmethyl-ej-didehydrcM.Sa-epoxy-S.M-dihydroxyindoloP'.S'^J]- 
morphinan (76) (0.101 g, 0.22 mmol) in CH3OH (5 ml) and stirred at RT for 30 min (the resulting 
imine precipitated from solution), after which acetic acid (0.024 ml) was added (which made the 
precipitate redissolve), followed by sodium cyanoborohydride (0.021 g, 0.33 mmol). The 
reaction was then stirred at RT, under N2, for 24 h. After this, sodium cyanoborohydride 
(0.021 g, 0.33 mmol) and formaldehyde (0.016 ml, 1M) were added and the reaction stirred for a 
further 1 h, before being concentrated In vacuo and purified by column chromatography 
[CH3OH/CH2CI2/NH4OH (10:89:1)], to give 5'-(dimethylamino)ethyl-17-cyclopropylmethyl-6,7- 
didehydro^.Sa-epoxy-S.M-dihydroxyindolop'.S’^.TJmorphinan (98) (0.071 g, 0.15 mmol, 6 6 %). 
The product was then converted to the dihydrochloride salt, mp. >225 °C; Rf = 0.26 
[CH3OH/CH2CI2/NH4OH (10:89:1)]; 1H NMR (400 MHz, CD3OD) 8 0.47-0.62 [m, 2H, 
NCH2CH(CHHCHH)], 0.72-0.94 [m, 2H, NCH2CH(CHHCHH)], 1.08-1.21 [m, 1H,
NCH2CH(CH2CH2)], 5.69 [s, 1H, C(5)H\, 6.61-6.69 [m, 2H, C(1)Hand C(2)H], 7.00-7.07 (m, 1H, 
ArH) and 7.32-7.39 [m, 2H, ArH]; 13C NMR <100 MHz, CD3OD) 8 3.6 [NCH2CH(CH2CH2)], 6.4 
[NCH2CH(CH2CH2)], 7.0 [NCH2CH(CH2CH2)]r 25.1 [C(10 )], 29.8 [C(15)], 30.4 [C(8 )], 32.0 (CH2),
43.5 (CH2), 43.6 (CH2), 47.5 [quaternary C(13)], 48.0 (2 x CH3) 58.9 [C(18)], 63.6 [C(9)J, 73.7 
[quaternary C(14)], 85.0 [C(5)J, 109.4 (Ar), 112.9 (Ar), 119.2 (Ar), 119.7 (Ar), 120.5 (Ar), 122.5 
(Ar), 124.3 (Ar), 127.4 (Ar), 128.2 (Ar), 130.2 (Ar), 131.0 (Ar), 137.9 (Ar), 141.7 (Ar) and 144.6 
(Ar); FAB+MS m/z 486 [(M+1)\ 100%]; HRMS (FAB) m/z 486.2760 (M +1)\ C30H36N3O3 
requires 486.2757; Anal. (C30H35N3O3.2 HCI.2 H2O) requires C 60.60, H 6.95, N 7.07, found C 





morphinan (64) (0.099 g, 0.200 mmol) and ethylamine hydrochloride (0.025 g, 0.303 mmol) 
were reacted according to general procedure A, to yield 17-cyclopropylmethyl-6,7-didehydro- 
4 I5a-epoxy-5'-(N-ethyl)amido-3,14-dihydroxyindolo[2,,3,:6,7]morphinan (99) (0.019 g, 0.040 
mmol, 20%). The product was then converted to the hydrochloride salt, mp. >220 °C (dec); Rf 
= 0.28 [CH3OH/CH2CI2/NH4OH (10:89:1)]; IR W c m  (KBr) 3640-2860 (br, bonded OH and 
amide NH), 1634 (amide I) and 1540 (amide II); 1H NMR (400 MHz, CD3OD) 8 0.50-0.69 [m, 
2H, NCH2CH(CHHCHH)], 0.74-0.81 [m, 1H, NCH2CH(CH2CH2)], 0.84-0.93 [m, 2H,
NCH2CH(CHHCHH)], 5.71 [s, 1H, C(5)H], 6.67 [d, J=8.2 Hz, 1H, C(1 )H\, 6.70 [d, J=8.2 Hz, 1H, 
C(2)H\, 7.41 [d, J=8.6  Hz, 1H, C(7')H\, 7.60 [dd, ^ = 8.6  Hz, J2=1.5 Hz, 1H, C(6 ')H\ and 7.97 [d, 
J=1.5 Hz, 1H, C(4')H\] 13C NMR (100 MHz, CD3OD) 8 3.5 [NCH2CH(CH2CH2)], 6.4
[NCH2CH(CH2CH2)], 7.0 [NCH2CH(CH2CH2)], 15.0 (CH3), 25.1 [C(1 0 )], 29.8 [C(15)]f 30.3 [C(8 )],
36.3 (CONHCH2), 47.6 [C(16)], 48.1 [quaternary C(13)], 58.9 [C(18)], 63.7 [C(9)], 73.6 
[quaternary C(14)], 84.7 [C(5)], 110.7 [C(7')], 112.2 (quaternary Ar), 119.4 [C(2)], 120.0 (Ar),
120.5 (Ar), 122.5 (Ar), 122.6 (quaternary Ar), 125.4 (quaternary Ar), 127.4 (quaternary Ar),
130.0 (quaternary Ar), 132.1 (quaternary Ar), 140.6 (quaternary Ar), 141.9 (quaternary Ar),
144.6 (quaternary Ar) and 171.4 (C=0); EI-MS m/z 485 [(M)+, 100%], 4 4 4  (2 0 ) and 430 (15).
2(4-Hydrazinophenyl)ethanol
A solution of 4-aminophenethyl alcohol (1.23 g, 8.98 mmol) in c.HCI (22.5 ml) and H20  (32 ml) 
was cooled in an ice-bath. Sodium nitrite (0.71 g, 10.29 mmol) in H20  (10 ml) was added 
dropwise with stirring. After stirring at 0 °C for 30 min, the diazonium salt was added to 
SnCI2.H20  (7.91 g) in H20  (75 ml) at 0 °C and left to stand at 0 °C for 1 h. After basification with 
NH4OH, the mixture was centrifuged and the supernatant liquid concentrated in vacuo. 
[CH3CI/'PrOH (7:3)] (50 ml) was added and the inorganic salts which precipitated out, were 
removed by filtration. The solution was partially concentrated and cooled, allowing
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crystallisation of the desired product, 4-hydrazinophenethyl alcohol (0.76 g, 4.98 mmol, 55%); 
mp. 137-138 °C; Rf = 0.47 [CH3OH/CH2CI2/NH4OH (10:89:1)]; IR vmax/cm (CHCI3) 3660-2500 
(br, OH and NH2NH); 1H NMR (270 MHz, CDCI3) 8 2.68 (t, J=7.0 Hz, 2H, ArCH2), 3.21 (br s, 
1H, NH), 3.62 (t, J=7.0 Hz, 2H, CH2OH), 6.85 [d, J=8.4 Hz, 2H, C(3)Hand C(5)H\ and 7.12 [d, 
J=8.4 Hz, 2H, C(2)H and C(6)H\; 13C NMR (67.8 MHz, CDCI3) 5 39.7 (ArCH2), 64.5 (CH2OH),
116.9 [C(3 and 5)], 131.3 [C(2 and 6 )], 135.7 [C(1)] and 144.7 [C(4)]; EI-MS m/z 152 [(M)+, 
25%], 121 (70) and 106 (80).
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-hydroxyethyl-3,14-dihydroxyindolo- 
[2\3':6,7]morphinan (101)
4-Hydrazinophenethyl alcohol (0.75 g, 4.93 mmol) and naltrexone (1.45 g, 4.25 mmol) were 
refluxed under N2 for 3 h in EtOH/2N HCI (5:1). The solution was concentrated, dissolved in 
H20 , basified with NH4OH and extracted with [CH3CI/'PrOH (7:3)]. The residue was converted 
to the hydrochloride salt and purified by recrystallisation (MeOH/CH2CI2) to give 17- 
cyclopropylmethyl-ej-didehydro-^a-epbxy-S'-hydroxyethyl-S.M-dihydroxyindoloIZ.S'tf^]- 
morphinan (101) (0.16 g, 0.34 mmol, 8 %) mp. 186-192 °C; Rf = 0.24 [CH3OH/CH2CI2/NH4OH 
(10:89:1)]; HPLC (Ci8 column) 2.467 [MeOH/O.3% NH4C 03 (80:20)]; IR vmax/cm (CHCI3) 3660- 
2560 (br, NH and OH); 1H NMR (400 MHz, CD3OD) 8 0.14-0.24 [m, 2H, NCH2CH(CHHCHH)], 
0.50-0.62 [m, 2H, NCH2CH(CHHCHH)], 0.87-0.98 [m, 1H, NCH2CH(CH2CH2)], 5.57 [s, 1H, 
C(5)H], 6.52 [d, J=8.2 Hz, 2H, C(1 )H\, 6.55 [d, J=8.2 Hz, 2H, C(2)H], 6.96 [d, J=8.2 Hz, 1H, 
C(6 ')H\, 7.21 [s, 1H, C(4’)] and 7.22 [d, J=8.2 Hz, 1H, C(7’)H]; 13C NMR (67.8 MHz, CD3OD) 8
4.2 [NCH2CH(CH2CH2)], 4.8 [NCH2CH(CH2CH2)], 10.2  [NCH2CH(CH2CH2)], 24.2 [C(10)], 29.9 
[C(15)], 32.6 [C(8 )], 40.5 (CH2CH2OH), 45.0 [C(16)], 49.1 [quaternary C(13)], 60.4 [C(18)], 63.6 
[C(9)], 65.0 (CH2OH), 74.4 [quaternary C(14)], 86.1 [C(5)], 110.8 (Ar), 111.9 (Ar), 118.2 (Ar),
119.3 (Ar), 119.6 (Ar), 124.5 (Ar), 125.8 (Ar), 128.1 (Ar), 130.0 (Ar), 130.9 (Ar), 132.0 (Ar),




Thiourea (1.60 g, 21.1 mmol) was added to NaH (1.75 g, 60% in oil, 43.8 mmol) (prewashed 
with THF) in THF (80 ml) at 0 °C and the mixture stirred for 10 min. (BOC)20  (9.40 g, 43.1 
mmol) in THF (10 ml) was then added over 30 min. The mixture was allowed to warm to RT 
and stirred for a further 3 h. The reaction mixture was quenched by stirring with 10% NaOH for 
20 min. The organic layer was then separated and the aqueous layer further extracted with 
EtOAc. The combined organic layers were concentrated and subsequently treated with 
hexane, which caused the crude product to precipitate out. The crystals were further purified by 
column chromotography [CH3OH/CH2CI2/NH4OH (1:98:1)], to give 1,3-bis-BOC-thiourea (2.27 
g, 8.2 mmol, 39% )75 and 1-mono-BOC-thiourea (1.35 g, 7.7 mmol, 36%). 1,3-Bis-BOC-thiourea 
1H NMR (270 MHz, CDCI3) 8 1.52 [s, 18H, 2 x C(CH3)]; 13C NMR (100 MHz, CDCI3) 8 28.1
[C(CH3)3], 84.1 [C(CH3)3], 150.1 (2  x C=0) and 177.4 (C=S); EI-MS m/z 276 [(M)+, 1%] and 57 
(100). 1 -Mono-BOC-thiourea 1H NMR (270 MHz, CDCI3) 8 1.49 [s, 9H, C(CH3)], 6.94 (br s, 1H, 
NH), 8.06 (br s, 1H, NH) and 9.21 (br s, 1H, NH); 13C NMR (100 MHz, CDCI3) 8 27.7 [C(CH3)3],
83.8 [C(CH3)3], 151.3 (C=0) and 181.9 (C=S); EI-MS m/z 176 [(M)\ 30%] and 57 (100).
1,3-Bis-BOC-thiourea (0.08 g, 0.30 mmol), 5’-aminoethyl-17-cyclopropylmethyl-6,7-didehydro- 
4,5a-epoxy-3,14-dihydroxyindolo[2',3,:6,7]morphinan (76) (0.126 g, 0.28 mmol), HgCI2 (0.084 g, 
0.30 mmol) and triethylamine (0.028 g, 0.039 ml, 0.28 mmol) were reacted according to general 
procedure F and stirred at RT for 12 h, to give 17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy- 
S'-bis-BOC-guanidinylethyl-S.H-dihydroxyindolo^'.S'^JJmorphinan (119) (0.13 g, 0.19 mmol, 
67%); Rf = 0.58 [CH3OH/CH2CI2/NH4OH (89:10:1)]; 1H NMR (270 MHz, CDCI3) 8 0.04-0.17 [m, 
2H, NCH2CH(CHHCHH)], 0.42-0.57 [m, 2H, NCH2CH(CHHCHH)], 0.75-0.92 [m, 1H, 
NCH2CH(CH2CH2)], 1.36 [s, 9H, C(CH3)], 1.43 [s, 9H, C(CH3)], 5.60 [s, 1H, C(5)H], 6.37 [d, 
J=8.1 Hz, 1H, C(1 )H], 6.48 [d, J=8.1 Hz, 1H, C(2)H], 6.84 [d, J=8.4 Hz, 1H, C{7')H], 7. 06 [d, 
J=8.4 Hz, 1H, C(6 ')H], 7.15 [s, 1H, C(4')H], 7.88 (br s, 1H, NH), 8.33 (br s, 1H, NH) and 8.74 (br 
s, 1H, NH); 13C NMR (67.8 MHz, CDCI3) 8 3.6 [NCH2CH(CH2CH2)], 3.9 [NCHzCHfCHzCHz)],
9.3 [NCH2CH(CH2CH2)], 22.9 [C(10 )]f 27.8 [C(CH3)3], 27.9 [C(CH3)3], 28.1 (CH2CH2NH2), 28.7
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(CH2NH2), 31.3 [C(15)], 36.4 [C(8 )], 42.8 [C(16)]f 47.9 [quaternary C(13)], 59.3 [C(18)], 62.2 
[C(9)J, 72.6 [quaternary C(14)], 79.0 [C(CH3)3], 82.7 [C(CH3)3], 85.2 [0(5)], 110.9 (Ar), 111.3 
(Ar), 117.2 (Ar), 118.4 (Ar), 118.6 (Ar), 123.4 (Ar), 124.7 (quaternary Ar), 126.8 (Ar), 128.8 
(quaternary Ar), 129.4 (quaternary Ar), 130.6 (quaternary Ar), 136.1 (quaternary Ar), 139.2 
(quaternary Ar), 142.9 (quaternary Ar), 152.9 (C=0), 155.9 (C=0) and 163.4 (C=N).
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-bis-Boc-guanidinylethyl-3,14-dihydroxy- 
indolo[2’,3':6,7]morphinan (119) (0.13 g, 0.19 mmol) was treated as described in general 
procedure G, to give 17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-guanidinylethyl-3,14- 
dihydroxyindolo[2',3':6,7]morphinan (104) as the bistrifluoroacetic acid salt (0.09 g, 0.19 mmol, 
95%); mp. 203-206 °C; Rf = 0.09 [CH3OH/CH2CI2/NH4OH (10:89:1)]; IR vmax/cm (KBr) 3650- 
2500 (br, bonded OH and NH) and 1675 (br, C=N, NH and NH2); 1H NMR (400 MHz, CD3OD) 5 
0.46-0.57 [m, 2H, NCH2CH(CHHCHH)], 0.71-0.90 [m, 2H, NCH2CH(CHHCHH)], 1.07-1.14 [m, 
1H, NCH2CH(CH2CH2)], 5.68 [s, 1H, C(5)H], 6.65-6.70 [m, 2H, C(1)Hand C(2)H\, 7.01-7.06 (m, 
1H, ArH) and 7.25-7.33 [m, 2H, ArH]; 13C NMR (100 MHz, CD3OD) 8 3.5 [NCH2CH(CH2CH2)],
6.3 [NCH2CH(CH2CH2)], 6.9 [NCH2CH(CH2CH2)], 25.0 [C(10)]f 29.8 (CH2CH2NH2), 30.3 
(CH2NH2), 36.1 [C(15)]> 44.3 [C(8 )], 47.5 [C(16)]f 48.0 [quaternary C(13)], 58.9 [C(18)], 63.7 
[C(9)], 73.6 [quaternary C(14)], 85.1 [C(5)]f 109.2 (Ar), 112.5 (Ar), 119.2 (Ar), 119.4 (Ar), 120.4 
(Ar), 122.4 (Ar), 124.5 (Ar), 128.0 (Ar), 129.4 (Ar), 130.2 (Ar), 130.7 (Ar), 137.7 (Ar), 141.8 (Ar),
144.6 (Ar) and 158.4 (C=NH); FAB+MS m/z 500 [(M+1)\ 100%]; HRMS (FAB) m/z 500.2670 
(M+1)\ CzgH^NgOa requires 500.2662; Anal. (C29H33N50 3.2TFA.3H20 )  requires C 50.70, H 
5.29, N 8.96, found C 50.60, H 4.98, N 8.63.
17-Cyclopropylmethyl-6,7-didehydro-4>5a-epoxy-5’-nitro-3,14-dihydroxyindolo[2,,3,:6,7]- 
morphinan (1 2 1 )
Naltrexone (4.98 g, 14.60 mmol) and 4-nitrophenylhydrazine (2.68 g, 17.52 mmol) were 
refluxed under N2, in [EtOH/cHCI (50:50)] (150 ml) for 18 h. After this the solution was 
concentrated, dissolved in H20 , basified and extracted with CH2CI2. Further purification was 
achieved by column chromatography (CH2CI2), to give 17-cyclopropylmethyl-6,7-didehydro-
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4,5a-epoxy-5'-nitro-3,14-dihydroxyindolo[2,,3,:6,7]morphinan (121) (2.00 g, 4.35 mmol, 30%); 
Rf = 0.54 [CH3OH/CH2CI2/NH4OH (10:89:1)]; 1H NMR (400 MHz, CDCI3) 8 0.12-0.25 [m, 2H, 
NCH2CH(CHHCHH)], 0.48-0.63 [m, 2H, NCH2CH(CHHCHH)], 0.86-0.99 [m, 1H,
NCH2CH(CH2CH2)], 5.52 [s, 1H, C(5)H], 6.45-6.53 [m, 2H, C(1 )Hand C(2)H], 7.09-7.16 [m, 1H, 
ArH] and 7.21-7.30 [m, 2H, 2x ArH]; 13C NMR (100 MHz, CDCI3) 5 4.1 [NCH2CH(CH2CH2)] and 
[NCH2CH(CH2CH2)], 9.4 [NCH2CH(CH2CH2)], 23.2 [C(10)], 28.0 [C(15)], 31.4 [C(8 )], 43.5 
[C(16)], 48.0 [quaternary C(13)], 59.4 [C(18)]t 62.1 [0(9)]. 72.8 [quaternary C(14)], 84.4 [C(5)],
110.0 (Ar), 113.5 (Ar), 114.9 (Ar), 117.0 (Ar), 117.7 (Ar), 119.6 (Ar), 124.7 (Ar), 125.6 (Ar),
130.5 (Ar), 131.6 (Ar), 138.6 (Ar), 139.6 (Ar), 139.7 (Ar) and 142.6 (Ar); FAB-MS m/z 460 [(M)\ 




morphinan (121) (1.97 g, 4.29 mmol), in tCH3OH/cyclohexene (50:50)] (140 ml), was added a 
catalytic amount of Raney nickel. The mixture was stirred at ca. 50 °C for 7 h. The mixture was 
then filtered through a celite pad, concentrated and purified by column chromatography 
[CH3OH/CH2CI2/NH4OH (10:89:1)], yielding 5'-amino-17-cyclopropylmethyl-6,7-didehydro-4,5a- 
epoxy-S.M-dihydroxyindoloP'.S'tfJJmorphinan (120) (0.81 g, 1.90 mmol, 44%); Rf = 0.41 
[CH3OH/CH2CI2/NH4OH (10:89:1)]; 1H NMR (400 MHz, CD3OD) 8 0.25-0.31 [m, 2H, 
NCH2CH(CHHCHH)], 0.63-0.70 [m, 2H, NCH2CH(CHHCHH)], 0.87-0.96 [m, 1H,
NCH2CH(CH2CH2)], 5.70 [s, 1H, C(5)H\, 6.61 [d, J=8.2 Hz, 1H, C(1 )H], 6.69 [d, J=8.2 Hz, 1H, 
C(2)H], 7.45 [d, J=9.0 Hz, 1H, C(7')H], 8 . 08 [dd, ^=9.0 Hz, J2=2.1 Hz, 1H, C(6 ')H] and 8.45 [d, 
J=2.1 Hz, 1H, C(4')HJ; 13C NMR (100 MHz, CD3OD) 8 3.3 [NCH2CH(CH2CH2)], 3.8
[NCH2CH(CH2CH2)], 8.7 [NCH2CH(CH2CH2)], 22.9 [C(10)J, 28.4 [C(15)], 30.8 [C(8 )J, 43.6 
[C(16)J, 47.4 [quaternary C(13)], 58.8 [C(18)]« 61.9 [C(9)]f 72.5 [quaternary C(14)], 84.5 [C(5)J,
104.3 (Ar), 108.8 (Ar), 111.3 (Ar), 113.5 (Ar), 116.6 (Ar), 118.2 (Ar), 123.7 (Ar), 126.8 (Ar),
129.4 (Ar), 130.1 (Ar), 132.2 (Ar), 137.1 (Ar), 139.1 (Ar) and 142.7 (Ar); FAB-MS m/z 430 [(M)+, 
60%]; HRMS (FAB) m/z 430.2119 (M)+, C26H28N3O3 requires 430.2131.
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1.3-Bis-ferf-butoxycarbonyM -benzyl-2-methyl-2-thiopseudourea
1.3-Bis-BOC-2-methyl-2-thiopseudourea (2g, 6.90 mmol), sodium hydride (60% in oil, 0.334 g,
8.36 mmol) and benzyl bromide (1.30 g, 0.90 ml, 7.60 mmol) were reacted according to general 
procedure E to give 1,3-bis-BOC-1-benzyl-2-methyl-2-thiopseudourea (1.72 g, 4.53 mmol, 
6 6 %); Rf = 0.44 [hexane/EtOAc (9:2)]; 1H NMR (400 MHz, CDCI3) 8 1.36 [s, 9H, C(CH3)3], 1.49 
[s, 9H, C(CH3)3], 2.24 (s, 3H, SCH3), 4.74 (s, 2H, CH2) and 7.21-7.31 (m, 5H, ArH); 13C NMR 
(100 MHz, CDCI3) 8 15.4 (SCH3), 27.8 [C(CH3)3], 27.9 [C(CH3)3], 52.2 (CH2), 81.3 [C(CH3)3],
82.3 [C(CH3)3], 127.1 (p-Ar), 127.3 [C(2) and C(6 ) Ar], 128.0 [C(3) and C(5) Ar], 136.9 
(quaternary Ar), 151.5 (C=0), 157.4 (C O ) and 162.6 (C=N); FAB'MS m/z 381 [(M+1)+, 75%] 
and 225 (100); HRMS (FAB) m/z 381.1852 (M+1)+, C19H29N20 4S requires 381.1848.
1.3-Bis- ferf-butoxycarbonyl -1 -(4'-chlorobenzyl)-2-methyl-2-thlopseudourea148
1.3-Bis-BOC-2-methyl-2-thiopseudourea (2g, 6.90 mmol), sodium hydride (60% in oil, 0.334 g,
8.36 mmol) and 4-chlorobenzylbromide (1.56 g, 7 60 mmol) were reacted according to general 
procedure E, yielding 1,3-bis-BOC-1-(4'-chlorobenzyl)-2-methyl-2-thiopseudourea (2.21 g, 5.33 
mmol, 77%) Rf = 0.42 [hexane/EtOAc (9:2)]; 1H NMR (400 MHz, CDCI3) (data in agreement 
with reference) 8 1.36 [s, 9H, C(CH3)3], 1.47 [s, 9H, C(CH3)3], 2.24 (s, 3H, SCH3), 4.68 (s, 2H, 
CH2) and 7.24 (s, 4H, ArH); 13C NMR (100 MHz, CDCI3) 8 16.0 (SCH3), 28.3 [C(CH3)3], 28.4 
[C(CH3)3], 52.0 (CH2), 82.0 [C(CH3)3], 83.1 [C(CH3)3], 128.7 [C(3) and C(5) Ar], 129.4 [C(2) and 
C(6 ) Ar], 133.4 (quaternary Ar), 136.0 (quaternary Ar), 151.9 (C=0), 157.9 (C=0) and 162.7 
(C=N); FAB+MS m/z 415 [(M+1)\ 30%] and 259 (65); HRMS (FAB) m/z 415.1439 (M+1)+, 
Ci9H28N20 4SCI requires 415.1458.
1.3-Bis- fe/t-butoxycarbonyl -1 -(4'-nitrobenzyl)-2-methyl-2-thiopseudourea
1.3-Bis-BOC-2-methyl-2-thiopseudourea (2g, 6.90 mmol), sodium hydride (60% in oil, 0.334 g,
8.36 mmol) and 4-nitrobenzylbromide (1.64 g, 7.60 mmol) were reacted according to general 
procedure E, giving 1,3-bis-BOC-1-(4'-nitrobenzyl)-2-methyl-2-thiopseudourea (2.20 g, 5.18
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mmol, 75%) Rf = 0.36 [hexane/EtOAc (9:2)]; 1H NMR (400 MHz, CDCI3) 5 1.38 [s, 9H, 
C(CH3)3], 1.50 [s, 9H, C(CH3)3], 2.33 (s, 3H, SCH3), 4.84 (s, 2H, CH2), 7.50 [d, J 8 .6 , 2H, C(2)H 
and C(6 )H] and 8.17 [d, J 8 .6 , 2H, C(3)H and C(5)H]; 13C NMR (100 MHz, CDCI3) 8 15.7 
(SCH3), 28.0 [C(CH3)3], 28.1 [C(CH3)3], 51.7 (CH2), 82.0 [C(CH3)3], 83.4 [C(CH3)3], 123.5 [C(3) 
and C(5) Ar], 128.2 [C(2) and C(6 ) Ar], 144.7 [C(1) quaternary Ar], 147.1 [C(4) quaternary Ar],
151.5 (C=0), 157.4 (C=0) and 161.9 (C=N); FAB'MS m/z 426 [(M+1)\ 55%] and 270 (100); 
HRMS (FAB) m/z 426.1699 (M+1)\ C19H28N30 6S requires 426.1699.
^-Cyclopropylmethyl-ej-didehydro^.Sa-epoxy-S'-lN'-benzylJguanidinylethyl-S,^- 
dihydroxyindolo^'^ejjm orphinan (106)
1,3-Bis-BOC-1-benzyl-2-methyl-2-thiopseudourea (0.208 g, 0.53 mmol), 5’-aminoethyl-17- 
cyclopropylmethyl-ej-didehydro^.Sa-epoxy-S.M-dihydroxyindoloIZ.S'tf^Jmorphinan (76) 
(0.123 g, 0.27 mmol), HgCI2 (0.081 g, 0.30 mmol) and triethylamine (0.055 g, 0.075 ml, 0.54 
mmol) were reacted according to general procedure F and stirred at 50 °C for 12 h, to give 17- 
cyclopropylmethyl-ej-didehydro^.Sa-epoxy-S'-bis-BOC^N'-benzylJguanidinylethyl-S.H- 
dihydroxyindolo[2',3':6,7]morphinan (0.050 g, 0.06 mmol, 24%); Rf = 0.63
[CH3OH/CH2CI2/NH4OH (89:10:1)]; 1H NMR (400 MHz, CDCI3) 8 0.26-0.34 [m, 2H, 
NCH2CH(CHHCHH)], 0.64-0.73 [m, 2H, NCH2CH(CHHCHH)], 0.96-1.05 [m, 1H,
NCH2CH(CH2CH2)], 1.29 [s, 9H, C(CH3)3], 1.33 [s, 9H, C(CH3)3], 5.75 [s, 1H, C(5)H\, 6.58 [d, 
J=8.2 Hz, 1H, C(1)H], 6.68  [d, J=8.2 Hz, 1H, C(2)H\, 6.82-6.91 [m, 1H, ArH] and 7.15-7.47 [m, 
7H, ArH]; 13C NMR (100 MHz, CDCI3) 8 3.9 [NCH2CH(CH2CH2)], 4.2 [NCH2CH(CH2CH2)], 9.5 
[NCH2CH(CH2CH2)], 23.3 [C(10)], 28.2 [C(CH3)3], 28.3 [C(CH3)3], 28.9 (CH2CH2NH2), 31.4 
(CH2NH2), 31.5 [C(15)], 36.5 [C(8 )], 43.8 [C(16)J, 46.1 (benzylic CH2), 48.1 [quaternary C(13)],
59.5 [C(18)], 62.3 [C(9)], 72.6 [quaternary C(14)], 79.2 [C(CH3)3], 82.4 [C(CH3)3], 85.2 [C(5)],
111.0 (Ar), 111.3 (Ar), 117.1 (Ar), 118.6 (Ar), 118.7 (Ar), 123.3 (Ar), 124.7 (Ar), 126.8 (Ar),
127.3 (Ar), 128.3 (Ar), 129.3 (Ar), 130.5 (Ar), 136.0 (Ar), 137.5 (Ar), 139.1 (Ar), 142.8 (Ar) and
162.4 (C=N); FAB+MS m/z 790 [(M+1)+, 70%] and 590 (100).
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1 7-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5,-bis-Boc-(N'-benzyl)guanidinylethyl-3, 14- 
dihydroxyindolo[2\3':6,7]morphinan (0.042 g, 0.05 mmol) was treated as described in general 
procedure G, to give 17-cyclopropylmethyl-6,7-didehydro-4I5a-epoxy-5,-(N'-benzyl)guanidinyl- 
ethyl-3,14-dihydroxyindolo[2\3':6,7]morphinan (106) as the bistrifluoroacetic acid salt (0.037 g, 
0.045 mmol, 85%); mp. 169 °C; Rf= 0.21 [CH3OH/CH2CI2/NH4OH (89:10:1)]; IR vmax/crn (KBr) 
3680-2460 (br, bonded OH and NH) and 1660 (br, C=N, NH and NH2); 1H NMR (400 MHz, 
CD3OD) S 0.46-0.61 [m, 2H, NCH2CH(CHHCHH)], 0.70-0.92 [m, 2H, NCH2CH(CHHCHH)],
1.07-1.21 [m, 1H, NCH2CH(CH2CH2)], 5.70 [s, 1H, C(5)H], 6.65 [s, 2H, C(1 )H and C(2)H\ and 
6.98-7.32 [m, 8 H, ArH]; 13C NMR (100 MHz, CD3OD) 6 3.4 [NCH2CH(CH2CH2)], 6.2 
[NCH2CH(CH2CH2)], 6.9 [NCH2CH(CH2CH2)], 25.0 [C(10 )], 29.8 (CH2CH2NH2), 30.4 (CH2NH2), 
36.2 [C(15)], 44.4 [C(8 )], 45.8 [C(16)]f 47.6 [quaternary C(13)], 48.1 (benzylic CH2), 58.9 
[C(18)], 63.7 [C(9)], 73.7 [quaternary C(14)], 85.2 [C(5)]t 109.3 (Ar), 112.7 (Ar), 119.4 (Ar),
119.5 (Ar), 120.4 (Ar), 122.5 (Ar), 124.6 (Ar), 127.9 (2 x Ar), 128.2 (Ar), 128.8 (Ar), 129.5 (Ar),
129.7 (2 x Ar), 130.3 (Ar), 130.8 (Ar), 137.4 (Ar), 137.9 (Ar), 142.0 (Ar), 144.8 (Ar) and 157.4 
(C=NH); FAB+MS m/z 590 [(M+1)+, 100%]; HRMS (FAB) m/z 590.3163 (M+1)+, C36H4oN50 3 
requires 590.3131; Anal. (C36H39N50 3.2TFA.3 .75H20 ) requires C 54.27, H 5.52, N 7.91, found 
C 53.90, H 4.93, N 7.65.
17-Cyclopropylmethyl-6l7-didehydro-4>5a-epoxy-5,-(N,~4-chlorobenzyl)guanidinylethy|..
3,14-dihydroxyindolo[2',3':6,7]morphinan (110)
1,3-Bis-BOC-1-(4'-chlorobenzyl)-2-methyl-2-thiopseudourea (0.318 g, 0.77 mmol), 5’- 
aminoethyl-^-cyclopropylmethyl-ej-didehydro^.Sa-epoxy-S.H-dihydroxyindolo^'.S'^J]- 
morphinan (76) (0.177 g, 0.39 mmol), HgCI2 (0.106 g, 0.39 mmol) and triethylamine (0.078 g, 
0.110 ml, 0.77 mmol) were reacted according to general procedure F and stirred at 50 °C for 12 
h, to give 17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5,-bis-BOC-(N'-4-chlorobenzyl)- 
guanidinylethyl-3,14-dihydroxyindolo[2',3':6,7]morphinan (0.088 g, 0.11 mmol, 28%); Rf = 0.36 
[CH3OH/CH2CI2/NH4OH (89:10:1)]; 1H NMR (400 MHz, CDCI3) 8 0.32-0.39 [m, 2H, 
NCH2CH(CHHCHH)], 0.72-0.80 [m, 2H, NCH2CH(CHHCHH)], 1.04-1.12 [m, 1H,
NCH2CH(CH2CH2)], 1.50 [s, 9H, C(CH3)3], 1.63 [s, 9H, C(CH3)3], 5.84 [s, 1H, C(5)HJ, 6.64 [d,
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J=8.2 Hz, 1H, C(1)H], 6.73 [d, J=8.2 Hz, 1H, C(2)H], 6.40-6.52 [m, 1H, ArH] and 7.24-7.49 [m, 
6 H, ArH]; 13C NMR (100 MHz, CDCI3) 5 4.2 [NCH2CH(CH2CH2)], 4.6 [NCH2CH(CH2CH2)], 9.8 
[NCH2CH(CH2CH2)], 23.6 [C(10)], 28.5 [C(CH3)3], 28.6 [C(CH3)3], 29.2 (CH2CH2NH2), 31.8 
(CH2NH2), 31.9 [C(15)], 36.9 [C(8 )], 44.1 [C(16)], 46.5 (benzylic CH2), 48.4 [quaternary C(13)], 
59.8 [C(18)], 62.6 [C(9)], 73.0 [quaternary C(14)], 79.7 [C(CH3)3], 83.2 [C(CH3)3], 85.6 [C(5)],
111.3 (Ar), 111.8 (Ar), 117.5 (Ar), 118.9 (Ar), 119.1 (Ar), 123.5 (Ar), 125.1 (Ar), 127.2 (Ar),
128.4 (Ar), 128.8 (Ar), 129.7 (Ar), 130.0 (Ar), 130.9 (Ar), 133.4 (Ar), 136.4 (Ar), 139.4 (Ar),
143.1 (Ar) and 162.8 (C=NH); FAB+MS m/z 824 [(M+1)+, 95%] and 624 (100).
^-Cyclopropylmethyl-ej-didehydrcM.Sa-epoxy-S'-bis-BOC-fN'^-chlorobenzylJguanidinylethyl- 
S.M-dihydroxyindoloP'.S'^Jlmorphinan (0.088 g, 0.11 mmol) was treated as described in 
general procedure G, to give ^-cyclopropylmethyl-e^-didehydro^.Sa-epoxy-SXN'^- 
chlorobenzylJguanidinyl-ethyl-S.M-dihydroxyindolo^'.S'tf^morphinan (110 ) as the 
bistrifluoroacetic acid salt (0.089 g, 0.10 mmol, 98%); mp. 204-205 °C; Rf = 0.26 
[CH3OH/CH2CI2/NH4OH (89:10:1)]; IR Vmax/cm (KBr) 3680-2500 (br, bonded OH and NH) and 
1660 (br, C=N, NH and NH2); 'H NMR (400 MHz, CD3OD) 6 0.47-0.59 [m, 2H,
NCH2CH(CHHCHH)], 0.71-0.93 [m, 2H, NCH2CH(CHHCHH)], 1.05-1.21 [m, 1H,
NCH2CH(CH2CH2)], 5.70 [s, 1H, C(5)H], 6.67 [s, 2H, C(1)H and C(2)H], 7.00 [d, J=8.2 Hz, 1H, 
C(6 ’)H], 7.12 [d, J=8.2 Hz, 1H, C(7’)H], 7.13 (s, 1H, C(4')H\ and 7.24-7.36 [m, 4H, ArH]; 13C 
NMR (100 MHz, CD3OD) 6 3.5 [NCH2CH(CH2CH2)], 6.3 [NCH2CH(CH2CH2)]t 6.9 
[NCH2CH(CH2CH2)], 25.0 [C(10)], 29.8 (CH2CH2NH2), 30.3 (CH2NH2), 36.2 [C(15)]t 44.5 [C(8 )]f
45.1 [C(16)], 47.5 [quaternary C(13)], 48.0 (benzylic CH2), 58.8 [C(18)]« 63.6 [C(9)], 73.6 
[quaternary C(14)], 85.1 [C(5)], 109.2 (Ar), 112.6 (Ar), 119.2 (Ar), 119.5 (Ar), 120.4 (Ar), 122.4 
(Ar), 124.5 (Ar), 128.0 (Ar), 129.4 (Ar), 129.5 (2 x Ar), 129.6 (2 x Ar), 130.2 (Ar), 130.7 (Ar),
134.4 (Ar), 136.3 (Ar), 137.7 (Ar), 141.8 (Ar), 144.6 (Ar) and 157.3 (C=NH); FAB+MS m/z 624 
[(M+1)+, 100%]; HRMS (FAB) m/z 624.2721 (M +1)\ C36H39N50 3CI requires 624.2741; Anal. 




1,3-Bis-BOC-1-(4’-nitrobenzyl)-2-methyl-2-thiopseudourea (0.381 g, 0.90 mmol), 5’-aminoethyl- 
^-cyclopropylmethyl-ej-didehydrcM.Sa-epoxy-S.M-dihydroxyindolop'.S’^Jlmorphinan (76) 
(0.206 g, 0.45 mmol), HgCI2 (0.122 g, 0.45 mmol) and triethylamine (0.091 g, 0.125 ml, 0.90 
mmol) were reacted according to general procedure F and stirred at 50 °C for 12 h, to give 17- 
cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5’-bis-BOC-(N'-4-nitrobenzyl)guanidinylethyl-3,14- 
dihydroxyindolo[2',3':6,7]morphinan (0.167 g, 0.20 mmol, 44%); Rf = 0.57
[CH3OH/CH2CI2/NH4OH (89:10:1)]; 1H NMR (400 MHz, CDCI3) 6 0.16-0.23 [m, 2H, 
NCH2CH(C/7HCHH)], 0.54-0.63 [m, 2H, NCH2CH(CHHCHAV)], 0.87-0.96 [m, 1H,
NCH2CH(CH2CH2)], 1.33 [s, 9H, C(CH3)3], 1.49 [s, 9H, C(CH3)3J, 5.70 [s, 1H, C(5)H], 6.50 [d, 
J=8.0 Hz, 1H, C(1 )HJ, 6.58 [d, J=8.0 Hz, 1H, C(2)H], 6.75-6.87 [m, 1H, C(4')H], 7.07-7.28 [m, 
2H, C(6 ')H and C(7')H\ and 7.95-8.07 [m, 4H, ArH\\ 13C NMR (100 MHz, CDCI3) 8 4.2 
[NCH2CH(CH2CH2)], 4.6 [NCH2CH(CH2CH2)], 9.9 [NCH2CH(CH2CH2)], 23.5 [C(10 )J, 28.4 
[C(CH3)3], 28.6 [C(CH3)3]. 29.1 (CH2CH2NH2), 31.9 (CH2NH2) and [C(15)], 36.9 [C(8 )] and 
(benzylic CH2), 44.1 [C(16)], 48.4 [quaternary C(13)], 59.8 [C(18)], 62.5 [C(9)]t 73.0 [quaternary 
C(14)], 79.8 [C(CH3)3], 83.6 [C(CH3)31, 85.5 [C(5)], 111.2  (Ar), 111.7 (Ar), 117.4 (Ar), 118.8 (Ar),
119.0 (Ar), 123.4 (Ar), 123.7 (Ar), 125.0 (Ar), 127.1 (Ar), 128.2 (Ar), 128.8 (Ar), 130.0 (Ar),
131.0 (Ar), 136.4 (Ar), 139.5 (Ar), 143.2 (Ar), 147.1 (Ar) and 162.8 (C=NH); FAB+MS m/z 835 
[(M+1)\ 100%] and 635 (95); HRMS (FAB) m/z 835.4022 (M +1)\ C46H54N60 9 requires 
835.4030.
^-Cyclopropylmethyl-e.Z-didehydro^.Sa-epoxy-S'-bis-BOC^NM-nitrobenzyOguanidinylethyl-
3,14-dihydroxyindolo[2',3':6,7]morphinan (0.075 g, 0.09 mmol) was treated as described in 
general procedure G, to give 17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-(N’-4- 
nitrobenzyl)guanidinyl ethyl-3,14-dihydroxyindolo[2’,3’:6,7]morphinan (111) as the 
bistrifluoroacetic acid salt (0.078 g, 0.09 mmol, 99%); mp. 187-190 °C; Rf = 0.21 
[CH3OH/CH2CI2/NH4OH (89:10:1)]; IR vmax/crn (KBr) 3660-2540 (br, bonded OH and NH) and 
1665 (br, C=N, NH and NH2); 1H NMR (400 MHz, CD3OD) 8 0.46-0.62 [m, 2H,
138
NCH2CH(CHHCHH)], 0.72-0.93 [m, 2H, NCH2CH(CHHCHH)], 1.06-1.21 [m, 1H,
NCH2CH(CH2CH2)], 5.76 [s, 1H, C(5)H], 6.61-6.74 [m, 2H, C(1)Hand C(2)H\, 7.03 [d, J=8.2 Hz, 
1H, C(6 ')H], 7.22 [d, J=8.2 Hz, 1H, C(7')H\, 7.25-7.36 [m, 3H, C(4')H and ArH\ and 8.00-8.13 
(m, 2H, ArH); 13C NMR (100 MHz, CD3OD) 6 3.5 [NCH2CH(CH2CH2)], 6.3 [NCH2CH(CH2CH2)],
6.9 [NCH2CH(CH2CH2)], 25.1 [C(10)]> 29.8 (CH2CH2NH2), 30.3 (CH2NH2), 36.3 [C(15)J, 44.5 
[C(8 )], 45.0 [C(16)], 47.6 [quaternary C(13)], 48.0 (benzylic CH2), 58.9 [C(18)], 63.7 [C(9)], 73.7 
[quaternary C(14)], 85.1 [C(5)J, 109.2 (Ar), 112.6 (Ar), 119.2 (Ar), 119.6 (Ar), 120.3 (Ar), 122.4 
(Ar), 124.5 (Ar), 124.6 (Ar), 128.0 (Ar), 128.5 (2 x Ar), 129.5 (Ar), 130.2 (Ar), 130.8 (Ar), 137.8 
(Ar), 141.8 (Ar), 144.7 (Ar), 145.2 (Ar) and 157.4 (C=NH); FAB+MS m/z 635 [(M+1)+, 100%]; 
HRMS (FAB) m/z 635.2990 (M+1)+, C36H39N60 5 requires 635.2982; Anal.




3,14-dihydroxyindolo[2',3':6,7]morphinan (0.082 g, 0.10 mmol) was dissolved in CH3OH (30 ml) 
and cyclohexene (30 ml). To this was added a few drops of triethylamine and a catalytic 
amount of Raney Nickel catalyst. The biphasic solution was stirred at ca. 30 °C for 3 h, filtered 
through a cellite pad, and concentrated to yield the crude product, which was then purified by 
column chromatography [CH3OH/CH2CI2/NH4OH (89:10:1)] to afford 17-cyclopropylmethyl-6,7- 
didehydro-4,5a-epoxy-5,-bis-BOC-(N'-4-aminobenzyl)guanidinylethyl-3,14-dihydroxyindolo- 
[2\3':6,7]morphinan (127) (0.055 g, 0.07 mmol, 70%); Rf = 0.42 [CH3OH/CH2CI2/NH4OH 
(89:10:1)]; 1H NMR (400 MHz, CDCI3) 6 0.13-0.21 [m, 2H, NCH2CH(CHHCHH)], 0.52-0.62 [m, 
2H, NCH2CH(CHHCHH)], 0.84-0.93 [m, 1H, NCH2CH(CH2CH2)], 1.46 [s, 9H, C(CH3)3], 1.48 [s, 
9H, C(CH3)3], 5.65 [s, 1H, C(5)HJ, 6.25-6.38 (m, 1H, ArH), 6.50 [d, J=8.2 Hz, 1H, C(1)H], 6.58 
[d, J=8.2 Hz, 1H, C(2)H] and 6.74-7.24 (m, 6 H, ArH); 13C NMR (100 MHz, CDCI3) 5 3.9 
[NCH2CH(CH2CH2)], 4.2 [NCH2CH(CH2CH2)], 9.4 [NCH2CH(CH2CH2)], 23.3 [C(10)J, 28.2 
[C(CH3)3], 28.3 [C(CH3)3], 28.9 (CH2CH2NH2), 29.8 (CH2NH2), 31.4 [C(15)], 37.2 [C(8 )]> 43.8 
[C(16)]f 46.0 (benzylic CH2), 48.0 [quaternary C(13)], 59.4 [C(18)]f 62.3 [C(9)], 72.8 [quaternary
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C(14)], 79.2 [C(CH3)3], 82.2 [C(CH3)3], 85.2 [C(5)], 110.9 (Ar), 111.3 (Ar), 115.1 (2 x Ar), 115.3 
(Ar), 117.5 (Ar), 118.5 (Ar), 118.9 (Ar), 119.8 (Ar), 123.4 (Ar), 124.5 (Ar), 126.8 (Ar), 128.4 (Ar),
129.3 (2 x Ar), 130.4 (Ar), 136.1 (Ar), 139.2 (Ar), 142.7 (Ar), 145.3 (Ar) and 156.1 (C=NH); 
FAB+MS m/z 805 [(M+1)+, 30%], 700 (75) and 500 (100); HRMS (FAB) m/z 805.4273 (M+1)+, 
C46H57N6O7 requires 805.4289.
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-bis-BOC-(N'-4-aminobenzyl)guanidinyl- 
ethyl-S.M-dihydroxyindoloP'.S'ie^Jmorphinan (126) (0.055 g, 0.07 mmol) was treated as 
described in general procedure G, to give 17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'- 
(NM-aminobenzylJguanidinylethyl-S.M-dihydroxyindoloP'.S'tfJJmorphinan (112) as the 
tristrifiuoroacetic acid salt (0.051 g, 0.05 mmol, 79%); mp. 184-188 °C; Rf = 0.18 
[CH3OH/CH2CI2/NH4OH (89:10:1)]; IR vmax/crn (KBr) 3680-2400 (br, bonded OH and NH) and 
1670 (br, C=N, NH and NH2); 1H NMR (400 MHz, CD3OD) 5 0.48-0.61 [m, 2H,
NCH2CH(CHHCHH)], 0.72-0.93 [m, 2H, NCH2CH(CHHCHH)], 1.09-1.22 [m, 1H,
NCH2CH(CH2CH2)], 5.73 [s, 1H, C(5)HJ, 6.65 [d, J=8.2 Hz, 1H, C(1 )H], 6.67 [d, J=8.2 Hz, 1H, 
C(2)H\, 6.99-7.06 (m, 1H, ArH) and 7.21-7.35 (m, 6 H, ArH); 13C NMR (100 MHz, CD3OD) 8 3.5 
[NCH2CH(CH2CH2)], 6.3 [NCH2CH(CH2CH2)], 6.9 [NCH2CH(CH2CH2)], 25.1 [C(10)J, 29.9 
(CH2CH2NH2), 30.4 (CH2NH2), 36.3 [C(15)], 44.6 [C(8 )], 45.1 [C(16)], 47.6 [quaternary C(13)],
48.1 (benzylic CH2), 58.9 [C(18)], 63.7 [C(9)], 73.7 [quaternary C(14)], 85.2 [C(5)], 109.3 (Ar),
112.6 (Ar), 119.2 (Ar), 119.5 (Ar), 120.4 (Ar), 120.9 (Ar), 122.5 (Ar), 123.1 (2Ar), 124.6 (Ar),
128.1 (Ar), 129.0 (Ar), 129.4 (Ar), 129.5 (2Ar), 130.2 (Ar), 130.7 (Ar), 137.8 (Ar), 141.7 (Ar),
144.6 (Ar) and 157.3 (C=NH); FAB+MS m/z 605 [(M+1)\ 80%] and 500 (80); HRMS (FAB) m/z 
605.3232 (M +1)\ C36H4iN60 3 requires 605.3240; Anal. (C36H40N6O3.3TFA.1H2O) requires C 
52.28, H 4.70, N 8.71, found C 52.50, H 4.90, N 8.47.
^-Cyclopropylmethyl-ej-didehydro-^Sa-epoxy-S'-fN'-benzyOguanidinyl-S,14-dihydroxy- 
indolo[2’,3’:6,7]morphinan (105)
1,3-Bis-BOC-1-benzyl-2-methyl-2-thiopseudourea (0.180 g, 0.46 mmol), 5’-amino-17- 
cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-3,14-dihydroxy-indolo[2',3':6,7]morphinan (120)
140
(0.099 g, 0.23 mmol), HgCI2 (0.063 g, 0.23 mmol) and triethylamine (0.047 g, 0.065 ml, 0.46 
mmol) were reacted according to general procedure F and stirred at 50 °C for 24 h, to give 17- 
cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5,-bis-BOC-(N,-benzyl)guanidinyl-3,14-dihydroxy- 
indoloP'^ejlmorphinan (0.053 g, 0.07 mmol, 30%); Rf = 0.50 [CH3OH/CH2CI2/NH4OH 
(89:10:1)]; 1H NMR (270 MHz, CDCI3) 5 0.08-0.21 [m, 2H, NCH2CH(CHHCHH)], 0.48-0.63 [m, 
2H, NCH2CH(CHHCHH)], 0.80-0.92 [m, 1H, HCH2CH(CH2CH2)], 1.35 [s, 9H, C(CH3)3], 1.42 [s, 
9H, C(CH3)3], 5.56 [s, 1H, C(5)H\, 6.46 [d, J=7.8 Hz, 1H, C(1 )H], 6.54 [d, J=7.8 Hz, 1H, C(2)H\, 
6.56-6.65 [m, 1H, ArH], 6.70-6.79 [s, 1H, ArH], 6.92-7.02 [m, 1H, ArH] and 7.10-7.49 [m, 5H, 
ArH]; 13C NMR (100  MHz, CDCI3) 5 3.9 [NCH2CH(CH2CH2)], 4.1 [NCH2CH(CH2CH2)], 9.5 
[NCH2CH(CH2CH2)], 23.3 [C(10 )], 27.7 [C(CH3)3], 28.0 [C(15)], 28.2 [C(CH3)3], 28.9 [C(8 )], 43.7 
[0(16)], 48.0 (CH2Ph), 51.0 [quaternary C(13)], 59.4 [C(18)]t 62.3 [C(9)], 72.3 [quaternary 
C(14)], 81.6 [C(CH3)3], 82.5 [C(CH3)3], 84.9 [C(5)], 111.3 (Ar), 111.5 (Ar), 112.5 (Ar), 117.2 (Ar),
118.7 (Ar), 124.5 (Ar), 126.6 (Ar), 126.9 (Ar), 127.3 (Ar), 127.9 (Ar), 128.2 (2 x Ar), 128.7 (Ar),
128.9 (2 x Ar), 130.1 (Ar), 130.5 (Ar), 135.1 (Ar), 137.5 (Ar), 139.3 (Ar), 142.7 (C=0), 152.6 
(C=0) and 153.4 (C=N); FAB+MS m/z 762 [(M+1)+, 100%], 662 (10) and 562 (20); HRMS 
(FAB) m/z 762.3859 (M+1f, C44H52N5O7 requires 762.3867.
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-bis-BOC-(N'-benzyl)guanidinyl-3,14- 
dihydroxyindolop'.S'tf^morphinan (0.053 g, 0.07 mmol) was treated as described in general 
procedure G, to give ^-cyclopropylmethyl-e^-didehydro^.Sa-epoxy-SXN'-benzyOguanidinyl-
3,14-dihydroxyindolo [2',3':6,7]morphinan (105) as the bistrifluoroacetic acid salt (0.046 g, 0.07 
mmol, 84%); mp. 180-182 °C; Rf = 0.17 [CH3OH/CH2CI2/NH4OH (89:10:1)]; IR v^/cm  (KBr) 
3710-2450 (br, bonded OH and NH) and 1678 (br, C=N, NH and NH2); 1H NMR (400 MHz, 
CD3OD) 5 0.49-0.59 [m, 2H, NCH2CH(CHHCHH)], 0.72-0.92 [m, 2H, NCH2CH(CHHCHH)], 
1.09-1.23 [m, 1H, NCH2CH(CH2CH2)], 5.72 [s, 1H, C(5)H], 6.64 [d, J=8.2 Hz, 1H, C(1 )HJ, 6.67 
[d, J=8.2 Hz, 1H, C(2)H\, 6.99-7.03 (m, 1H, ArH) and 7.28-7.46 [m, 7H, ArH]; 13C NMR (100 
MHz, CD3OD) 5 3.5 [NCH2CH(CH2CH2)], 6.3 [NCH2CH(CH2CH2)], 6.9 [NCH2CH(CH2CH2)], 25.1 
[C(10)], 29.8 [C(15)], 30.3 [C(8 )], 46.0 [C(16)], 47.6 [quaternary C(13)], 48.1 (CH2Ph), 58.9 
[C(18)], 63.6 [C(9)], 73.5 [quaternary C(14)], 84.8 [C(5)J, 109.9 (Ar), 113.7 (Ar), 118.1 (Ar),
119.2 (Ar), 120.4 (Ar), 122.2 (Ar), 122.4 (Ar), 126.7 (Ar), 128.0 (2 x Ar), 128.4 (Ar), 128.8 (Ar),
141
129.7 (2 x Ar), 130.1 (Ar), 132.3 (Ar), 137.5 (Ar), 138.0 (Ar), 141.9 (Ar), 144.6 (Ar) and 157.5 




1,3-Bis-BOC-1-(4'-chlorobenzyl-2-methyl-2-thiopseudourea (0.243 g, 0.59 mmol), 5’-amino-17- 
cyclopropylmethyl-6>7-didehydro-4,5a-epoxy-3114-dihydroxyindolo[2\3':6l7]morphinan (120)
(0.126 g, 0.29 mmol), HgCI2 (0.079 g, 0.29 mmol) and triethylamine (0.059 g, 0.082 ml, 0.59 
mmol) were reacted according to general procedure F and stirred at 50 °C for 24 h, to give 17- 
cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-bis-BOC-(N'-4-chlorobenzyl)guanidinyl-3,14- 
dihydroxyindoloIZ.S'^yjmorphinan (0.103 g, 0.13 mmol, 44%); Rf = 0.47
[CH3OH/CH2CI2/NH4OH (89:10:1)]; 1H NMR (400 MHz, CDCI3) 5 0.16-0.27 [m, 2H,
NCH2CH(CHHCHH)], 0.56-0.68 [m, 2H, NCH2CH(CHHCHH)], 0.88-1.00 [m, 1H,
NCH2CH(CH2CH2)], 1.37 [s, 9H, C(CH3h], 1.43 [s, 9H, C(CH3)3], 5.60 [s, 1H, C(5)Hj, 6.55 [d, 
J=8.2 Hz, 1H, C(1)H], 6.59 [d, J=8.2 Hz, 1H, C(2)H], 6.70 (s, 1H, C(4')H\, 6.78 [d, J=8.6  Hz, 1H, 
C(6 ')H], 7.21 [d, J=8.6  Hz, 1H, C(7*)H] and 7.25-7.48 [m, 4H, Ar/-/]; 13C NMR (100 MHz, CDCI3) 
8 3.4 [NCH2CH(CH2CH2)], 3.9 [NCH2CH(CH2CH2)], 9.2 [NCH2CH(CH2CH2)], 22.9 [C(10)]f 27.2 
[C(CH3)3], 27.6 [C(15)], 27.7 [C(CH3)3], 28.4 [C(8 )]f 43.5 [C(16)], 47.6 (CH2Ph), 47.9 [quaternary 
C(13)], 59.1 [C(18)], 61.8 [C(9)], 72.3 [quaternary C(14)], 79.7 [C(CH3)3], 82.6 [C(CH3)3], 84.3 
[C(5)], 110.2 (Ar), 111.2 (Ar), 112.0 (Ar), 116.6 (Ar), 118.1 (Ar), 118.4 (Ar), 124.2 (Ar), 126.3 
(Ar), 127.8 (Ar), 128.2 (2 x Ar), 129.9 (Ar), 130.1 (2 x Ar), 130.2 (Ar), 130.4 (Ar), 132.8 (Ar),
135.1 (Ar), 135.3 (Ar), 139.0 (Ar), 142.6 (C=0) and 162.7 (C=N); FAB+MS m/z 796 [(M+1)+, 
100%], 696 (20) and 596 (30); HRMS (FAB) m/z 796.3463 (M +1)\ C44H51N5O7CI requires 
796.3477.
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-bis-BOC-(N,-4-chlorobenzyl)guanidinyl- 
S.M-dihydroxyindoloP'.S'^JJmorphinan (0.100 g, 0.13 mmol) was treated as described in 
general procedure G, to give 17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5,-(N'-4-
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chlorobenzylJ-guanidinyl-S.M-dihydroxyindolo^'.S'^yjmorphinan (107) as the bistrifluoroacetic 
acid salt (0.077 g, 0.09 mmol, 74%); mp. 186-189 °C; Rf = 0.13 [CH3OH/CH2CI2/NH4OH 
(89:10:1)]; IR vmax/crn (KBr) 3630-2475 (br, bonded OH and NH) and 1678 (br, C=N, NH and 
NH2); 1H NMR (400 MHz, CDCI3) 8 0.48-0.59 [m, 2H, NCH2CH(CHHCHH)], 0.73-0.91 [m, 2H, 
NCH2CH(CHHCHH)], 1.09-1.22 [m, 1H, NCH2CH(CH2CH2)], 5.71 [s, 1H, C(5)H], 6.64 [d, J=8.2 
Hz, 1H, C(1)/-/], 6 .68  [d, J=8.2 Hz, 1H, C{2)H], 6.98-7.02 (m, 1H, ArH) and 7.28-7.46 [m, 6 H, 
Ar/-/]; 13C NMR (100 MHz, CDCI3) 8 3.5 [NCH2CH(CH2CH2)], 6.3 [NCH2CH(CH2CH2)], 6.9 
[NCH2CH(CH2CH2)], 25.1 [C(i0)]f 29.7 [C(15)], 30.2 [C(8 )], 45.3 [C(16)]f 47.5 [quaternary 
C(13)], 48.0 (CH2Ph), 58.9 [C(18)], 63.6 [C(9)], 73.5 [quaternary C(14)], 84.8 [C(5)J, 109.9 (Ar),
113.7 (Ar), 118.0 (Ar), 119.2 (Ar), 120.5 (Ar), 122.2 (Ar), 122.4 (Ar), 126.6 (Ar), 128.3 (Ar),
129.6 (2 x Ar), 129.7 (2 x Ar), 130.1 (Ar), 132.3 (Ar), 134.4 (Ar), 136.4 (Ar), 138.0 (Ar), 141.8 
(Ar), 144.5 (Ar) and 157.5 (C=NH); FAB+MS m/z 596 [(M+1)+, 100%]; HRMS (FAB) m/z 
596.2416 (M +1)\ C34H35N5O3CI requires 596.2428; Anal. (C34H34N5O3CI.2TFA.3 H2O) requires 
C 51.97, H 4.82, N 7.97, found C 51.80, H 4.43, N 7.81.
17-Cyclopropylmethyl-6,7-didehydro-4l5a-epoxy-5,-(N,-4-nitrobenzyl)guanidinyl-3,14- 
dihydroxyindolo^'^'tfJlmorphinan (108)
1,3-Bis-BOC-1-(4'-nitrobenzyl-2-methyl-2-thiopseudourea (1.046 g, 2.47 mmol), 5’-amino-17- 
cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-3,14-di-hydroxyindolo[2',3,:6,7]morphinan (120)
(0.530 g, 1.24 mmol), HgCI2 (0.336 g, 1.24 mmol) and triethylamine (0.254 g, 0.35 ml, 2.51 
mmol) were reacted according to general procedure F and stirred at 50 °C for 24 h, to give 17- 
cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-bis-BOC-(N,-4-nitrobenzyl)guanidinyl-3I14- 
dihydroxyindolo[2\3':6,7]morphinan (0.426 g, 0.53 mmol, 43%); Rf = 0.52
[CH3OH/CH2CI2/NH4OH (89:10:1)]; 1H NMR (400 MHz, CDCI3) 8 0.09-0.21 [m, 2H, 
NCH2CH(CHHCHH)], 0.49-0.61 [m, 2H, NCH2CH(CHHCHH)], 0.80-0.94 [m, 1H,
NCH2CH(CH2CH2)], 1.36 [s, 9H, C(CH3)3], 1.44 [s, 9H, C(CH3)3], 5.60 [s, 1H, C(5)H\, 6.39-6.53 
[m, 2H, C(1 )H and C(2)H\, 6.69-7.40 (m, 4H, ArH), 7.59-7.66 (m, 1H, ArH), 7.88-7.98 (m, 1H, 
ArH) and 8.03-8.12 [m, 1H, ArH]; 13C NMR (67.8 MHz, CDCI3) 8 3.7 [NCH2CH(CH2CH2)], 4.0 
[NCH2CH(CH2CH2)], 9.3 [NCH2CH(CH2CH2)], 23.0 [C(10 )], 27.5 [C(CH3)3], 27.9 [C(CH3)3], 28.6
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[C(15)], 31.4 [C(8 )], 36.4 [C(16)]f 43.5 (CH2Ph), 47.9 [quaternary C(13)], 59.3 [C(18)], 62.1 
[C(9)], 72.8 [quaternary C(14)], 83.2 [C(CH3)3], 84.9 [C(5>], 110.7 (Ar), 117.2 (Ar), 118.7 (Ar),
123.3 (2 x Ar), 124.9 (Ar), 127.4 (Ar), 128.8 (2 x Ar), 130.6 (Ar), 139.2 (Ar), 143.0 (Ar), 146.6 
(Ar), 154.6 (Ar) and 162.7 (C=N); FAB+MS m/z 807 [(M+1)\ 100%], 707 (20) and 607 (10); 
HRMS (FAB) m/z 807.3731 (M+1)\ C44H51N6O9 requires 807.3718.
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-bis-BOC-(N'-4-nitrobenzyl)guanidinyl-3,14- 
dihydroxyindoloP'.S'^^morphinan (0.058 g, 0.07 mmol) was treated as described in general 
procedure G, to give ^-cyclopropylmethyl-ey-didehydro^.Sa-epoxy-S'-tN'^-nitrobenzyl)- 
guanidinyl-3,14-dihydroxyindolo[2',3':6,7]morphinan (108) as the bistrifluoroacetic acid salt 
(0.059 g, 0.07 mmol, 98%); mp. 206-208 °C; Rf = 0.13 [CH3OH/CH2Cl2/NH4OH (89:10:1)]; IR 
Vmax/cm (KBr) 3700-2400 (br, bonded OH and NH) and 1677 (br, C=N, NH and NH2); 1H NMR 
(400 MHz, CD3OD) 8 0.50-0.59 [m, 2H, NCH2CH(CHHCAVH)], 0.74-0.92 [m, 2H, 
NCH2CH(CHHCHH)], 1.11-1.21 [m, 1H, NCH2CH(CH2CH2)], 5.72 [s, 1H, C(5)H], 6.63 [d, J=8.2 
Hz, 1H, C(1 )H], 6.67 [d, J=8.2 Hz, 1H, C(2)H], 7.04 [dd, J1=2.0 Hz, J2=8.6  Hz, 1H, C(6 ')H], 7.33 
[d, J=2.0 Hz, 1H, C(4')H\, 7.45 [d, J=8.6  Hz, 1H, C(7*)/-/], 7.55 [d, J=8.7 Hz, 2H, ArH] and 8.24 
[d, J=8.7 Hz, 2H, ArH]; 13C NMR (100 MHz, CD3OD) 5 4.3 [NCH2CH(CH2CH2)], 7.1 
[NCH2CH(CH2CH2)], 7.7 [NCH2CH(CH2CH2)], 25.9 [C(10)], 30.6 [C(15)]t 31.1 [C(8 )], 46.1 
[C(16)], 48.4 [quaternary C(13)], 48.9 (CH2Ph), 59.8 [C(18)], 67.6 [C(9)], 74.4 [quaternary 
C(14)], 85.6 [C(5)], 110.8 (Ar), 114.6 (Ar), 118.9 (Ar), 120.1 (Ar), 121.3 (Ar), 123.0 (Ar), 123.0 
(Ar), 125.5 (2 x Ar), 127.4 (Ar), 129.2 (Ar), 129.7 (2 x Ar), 130.9 (Ar), 133.2 (Ar), 138.9 (Ar),
142.7 (Ar), 145.4 (Ar), 146.2 (Ar), 149.5 (Ar) and 158.6 (C=NH); FAB+MS m/z 607 [(M+1)+, 
100%]; HRMS (FAB) m/z 607.2677 (M+1)+, C^HasNeOg requires 607.2669; Anal. 




dihydroxyindoloP'.S'tfJJmorphinan (0.113 g, 0.14 mmol) was dissolved in CH3OH (30 ml) and
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cyclohexene (30 ml). To this was added 3 drops of triethylamine and a catalytic amount of 
Raney Nickel catalyst. The biphasic solution was stirred at RT for 5 h, filtered through a cellite 
pad, and concentrated to yield the crude product, which was then purified by column 
chromatography [CH3OH/CH2CI2/NH4OH (89:10:1)] to afford 17-cyclopropylmethyl-6,7- 
didehydro-4,5a-epoxy-5'-bis-BOC-(N,-4-aminobenzyl)guanidinyl-3,14-dihydroxyindolo[2',3,:6,7]- 
morphinan (126) (0.068 g, 0.09 mmol, 63%); Rf = 0.47 [CH3OH/CH2CI2/NH4OH (89:10:1)]; 1H 
NMR (CDCI3) 8 0.25-1.67 [m; 23H; NCH2CH(CHHCHH), NCH2CH(CHHCHH),
NCH2CH(CH2CH2), C(CH3)3, C(CH3)3], 5.72 [s, 1H, C(5)H\ and 6.68-7.43 [m, 9H, ArH); 13C 
NMR (67.8 MHz, CD3OD) 8 4.6 [NCH2CH(CH2CH2)], 4.9 [NCH2CH(CH2CH2)], 10.5 
[NCH2CH(CH2CH2)], 24.4 [C(10 )], 28.5 [C(15)], 28.7 [C(CH3)3], 30.1 [C(8 )], 32.8 [C(16)J, 45.0 
(benzylic CH2), 48.3 [quaternary C(13)], 60.5 [C(18)]t 63.7 [C(9)J, 74.4 [quaternary C(14)], 81.3 
[C(CH3)3], 83.7 [C(5)], 111.9 (Ar), 112.9 (Ar), 113.5 (Ar), 116.5 (2 x Ar), 118.5 (Ar), 119.5 (Ar),
120.2 (Ar), 126.3 (Ar), 127.3 (Ar), 128.3 (Ar), 131.5 (2 x Ar), 132.4 (2 x Ar), 137.0 (Ar), 141.3 
(Ar), 144.8 (Ar), 148.7 (Ar) and 154.6 (C=N); FAB+MS m/z 777 [(M+1)\ 100%], 677 (55) and 
576 (55); HRMS (FAB) m/z 777.3992 (M+1)+, C44H53N6O7 requires 777.3976.
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-bis-BOC-(N,-4-aminobenzyl)guanidinyl- 
S.M-dihydroxyindoloP'.S'tfJlmorphinan (127) (0.036 g, 0.05 mmol) was treated as described 
in general procedure G, to give 17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5,-(N'-4- 
aminobenzylJ-guanidinyl-S.M-dihydroxyindoloP'.S'^JJmorphinan (109) as the tristrifluoroacetic 
acid salt (0.033 g, 0.04 mmol, 78%); mp. >250 °C; Rf = 0.10 [CH3OH/CH2CI2/NH4OH 
(89:10:1)]; IR vmax/crn (KBr) 3680-2420 (br, bonded OH and NH) and 1677 (br, C=N, NH and 
NH2); 1H NMR (400 MHz, CD3OD) 8 0.49-0.60 [m, 2H, NCH2CH(CHHCHH)], 0.74-0.92 [m, 2H, 
NCH2CH(CHHCHH)], 1.12-1.20 [m, 1H, NCH2CH(CH2CH2)], 5.72 [s, 1H, C(5)H], 6.64 [d, J=8.2 
Hz, 1H, C(1 )H\, 6.67 [d, J=8.2 Hz, 1H, C(2)H], 7.01 [dd, ^=1.8 Hz, J2=8.4 Hz, 1H, C(6')H], 7.14 
[d, J=8.2 Hz, 2H, ArH\, 7.32 [d, J=8.2 Hz, 2H, ArH], 7.34 [d, J=1.8 Hz, 1H, C(4')H\ and 7.44 [d, 
J=8.4 Hz, 1H, C{T)H\] 13C NMR (67.8 MHz, CD3OD) 8 3.7 [NCH2CH(CH2CH2)], 6.5
[NCH2CH(CH2CH2)], 7.1 [NCH2CH(CH2CH2)], 25.3 [C(10)J, 30.0 [C(15)]f 30.5 [C(8 )], 45.9 
[C(16)], 47.9 [quaternary C(13)], 48.3 (benzylic CH2), 59.2 [C(18)], 63.9 [C(9)]p 73.9 [quaternary 
C(14)], 85.2 [C(5)]« 110.4 (Ar), 114.2 (Ar), 118.6 (Ar), 119.7 (Ar), 120.9 (Ar), 121.4 (Ar), 122.7
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(Ar), 122.9 (Ar), 127.2 (Ar), 128.9 (Ar), 130.1 (Ar), 130.6 (Ar), 132.8 (Ar), 138.6 (Ar), 142.4 (Ar),
145.1 (Ar) and 158.0 (C=NH); FAB+MS m/z 577 [(M+1)+, 65%] and 472 (100); HRMS (FAB) 
m/z 577.2922 (M+1)+, C34H37N603  requires 577.2927; Anal. (C34H36N6O3.3TFA.IH2O) requires 
C 51.29, H 4.41, N 8.97, found C 51.40, H 4.55, N 8.78.
N- ferf-butoxycarbonyl -N,N'-dibutylthiourea
N,N'-Dibutylthiourea (4.05 g, 21.56 mmol), NaH (1.75 g, 60% in oil, 43.75 mmol) and (BOC)20  
(5.41 g, 24.80 mmol) were reacted according to general procedure I, to give N-tert- 
butoxycarbonyl-N,N'-dibutylthiourea (3.52 g, 12.22 mmol, 57%); Rf = 0.59 [EtOAc/hexane 
(1:3)]; 1H NMR (400 MHz, CDCI3) 5 0.78-0.84 (m, 6 H, 2 x CH3), 1.17-1.31 [m, 4H, 2 x CH2CH3], 
1.40 [s, 9H, C(CH3)3], 1.47-1.55 [m, 4H, 2 x CH2CH2CH3], 3.44-3.51 (m, 2H, NHCH2), 4.10-4.18 
(m, 2H, CONCH2) and 10.70 (br s, 1H, NH); 13C NMR (100 MHz, CDCI3) 8 13.5 (CH3), 13.6 
(CH3), 19.7 (CH2CH3), 2 0 .0  (CH2CH3), 27.7 [C(CH3)3], 30.0 (CH2CH2CH3), 30.4 (CH2CH2CH3)
46.4 (HNCH2), 48.7 (CONCH2), 83.3 [C(CH3)3], 154.7 (C=0) and 182.5 (C=S); FAB+MS m/z 
289 [(M+1)+, 45%] and 233 (100).
17-Cyclopropylmethyl-6,7-didehydro-4>5a-epoxy-5,-(N\N,,-dibutyl)guanidinylethyl-3,14- 
dihydroxyindolo[2\3':6,7]morphinan (113)
N-BOC-N,N'-dibutylthiourea (0.09 g, 0.32 mmol), 5’-aminoethyl-17-cyclopropylmethyl-6,7- 
didehydro^.Sa-epoxy-S.^-dihydroxyindoloP'.S'tf^morphinan (76) (0.112 g, 0.25 mmol), 
HgCI2 (0.087 g, 0.32 mmol) and triethylamine (0.025 g, 0.035 ml, 0.25 mmol) were reacted 
according to general procedure F and stirred at 50 °C for 5 h, to give 17-cyclopropylmethyl-6,7- 
didehydro-4,5a-epoxy-5'-BOC-(N,,N,,-dibutyl)guanidinylethyl-3,14-dihydroxyindolo[2,,3,:6,7]- 
morphinan (0.033 g, 0.05 mmol, 19%); Rf = 0.33 [CH3OH/CH2CI2/NH4OH (89:10:1)]; 1H NMR 
(400 MHz, CDCI3) 8 0.10-0.19 [m, 2H, NCH2CH(CHHCHH)], 0.50-0.61 [m, 2H,
NCH2CH(CHHCHH)], 0.85-0.92 [m, 1H, NCH2CH(CH2CH2)], 1.42 [s, 9H, C(CH3)3], 5.60 [s, 1H, 
C(5)H], 6.45 [d, J=7.8 Hz, 1H, C(1 )H\, 6.61 [d, J=7.8 Hz, 1H, C(2)H], 6.74-6.88 [m, 1H, ArH\ and 
6.97-7.16 [m, 2H, ArH]; 13C NMR (100 MHz, CDCI3) 8 3.9 [NCH2CH(CH2CH2)], 4.2
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[NCH2CH(CH2CH2)], 9.5 [NCH2CH(CH2CH2)], 13.6 (2 x CH3), 13.7 (2 x CH2), 19.9 (2 x CH2),
21.2 (2  x CH2), 23.2 [C(10)], 28.1 [C(CH3)3], 28.9 (CH2), 30.4 (CH2), 30.6 (CH2), 31.4 (CH2),
43.7 [C(16)J, 48.0 [quaternary C(13)], 59.5 [C(18)], 62.4 [C(9)], 72.6 [quaternary C(14)], 84.9 
[C(5)J, 110.6 (Ar), 111.2 (Ar), 117.4 (Ar), 118.4 (Ar), 118.6 (Ar), 123.4 (Ar), 124.4 (Ar), 126.8 
(Ar), 129.7 (Ar), 130.6 (Ar), 136.0 (Ar), 139.5 (Ar) and 143.1 (Ar); FAB+MS m/z 712 [(M+1)+, 
45%] and 612 (100).
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-BOC-(N\N,,-dibutyl)guanidinylethyl-3,14- 
dihydroxyindolo^'.S'iOJjmorphinan (0.033 g, 0.05 mmol) was treated as described in general 
procedure G, to give 17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-(N',N"-dibutyl)- 
guanidinylethyl-3,14-dihydroxyindolo[2',3':6,7]morphinan (113) as the bistrifluoroacetic acid salt 
(0.033 g, 0.04 mmol, 85%); mp. 160-162 °C; Rf = 0.17 [CH3OH/CH2CI2/NH4OH (89:10:1)]; IR 
vmax/cm (KBr) 3670-2470 (br, bonded OH and NH) and 1678 (br, C=N, NH and NH2); 1H NMR 
(270 MHz, CD3OD) 8 0.39-0.49 [m, 2H, NCH2CH(CHHCHH)], 5.60 [s, 1H, C(5)H\, 6.52-6.61 [m, 
2H, C(1)H and C(2)H], 6.88-6.95 [m, 1H, C(6 ’)H], 7.16 [s, 1H, C(4')H] and 7.18-7.24 [m, 1H, 
C(7’)H]; 13C NMR (67.8 MHz, CD3OD) 8 3.3 [NCH2CH(CH2CH2)], 6.2 [NCH2CH(CH2CH2)], 6.8  
[NCH2CH(CH2CH2)], 13.8 (CH3), 20.7 (CH2), 25.0 [C(10)], 29.8 (CH2), 30.3 (CH2), 31.8 (CH2),
36.2 (CH2), 42.1 (CH2), 44.4 [C(16)J, 47.5 [quaternary C(13)], 58.8 [C(18)], 63.6 [C(9)], 73.7 
[quaternary C(14)], 85.1 [C(5)]f 109.2 (Ar), 112.7 (Ar), 119.3 (Ar), 119.6 (Ar), 120.4 (Ar), 122.4 
(Ar), 124.7 (Ar), 128.3 (Ar), 129.8 (Ar), 130.3 (Ar), 131.0 (Ar), 138.0 (Ar), 142.1 (Ar), 144.8 (Ar) 
and 155.8 (C=N); FAB+MS m/z 612 [(M+1)+, 100%]; HRMS (FAB) m/z 612.3901 (M+1)\ 
C37H5oN50 3 requires 612.3914; Anal. (C37H49N5O3.2TFA.IH2O) requires C 57.40, H 6.23, N 
8.16, found C 57.60, H 5.99, N 7.91.
17-Cyclopropylmethyl-6>7-didehydro-4>5a-epoxy-5'-(N\N,,-dibutyl)guanidinyl-3>14-di- 
hydroxyindolo^'^'iejjmorphinan (114)
N-BOC-N,N'-dibutylthiourea (0.095 g, 0.33 mmol), 5’-amino-17-cyclopropylmethyl-6,7- 
didehydro-4,5a-epoxy-3,14-dihydroxyindolo[2',3':6,7]-morphinan (120) (0.087 g, 0.20 mmol), 
HgCI2 (0.090 g, 0.33 mmol) and triethylamine (0.026 g, 0.036 ml, 0.26 mmol) were reacted
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according to general procedure F and stirred at 50 °C for 48 h, to give 17-cyclopropylmethyl-
6,7-didehydro-4,5a-epoxy-5'-BOC-(N,,N"-dibutyl)guanidinyl-3,14-dihydroxyindolo[2',3,:6,7]- 
morphinan (0.027 g, 0.04 mmol, 20%); Rf = 0.52 [CH3OH/CH2CI2/NH4OH (89:10:1)]; 1H NMR 
(400 MHz, CDCI3) 5 0.15-0.21 [m, 2H, NCH2CH(CF/HCHH)], 0.55-0.62 [m, 2H, 
NCH2CH(CHHCHH)], 1.49 [s, 9H, C(CH3)3], 5.62 [s, 1H, C(5)H\, 6.43-7.10 (m, 5H, ArH); 13C 
NMR (100 MHz, CDCI3) 8 4.0 [NCH2CH(CH2CH2)], 4.1 [NCH2CH(CH2CH2)], 9.6 
[NCH2CH(CH2CH2)], 13.9 (CH3), 2 0 .2  (CH2), 23.3 [C(10 )], 28.5 [C(CH3)3], 28.6 (CH2), 29.0 
(CH2), 30.8 (CH2), 31.6 (CH2), 43.8 [C(16)], 48.1 [quaternary C(13)], 59.6 [C(18)], 63.1 [C(9)],
72.7 [quaternary C(14)], 81.0 [quaternary C(CH3)3], 85.2 [C(5)], 110.9 (Ar), 111.5 (Ar), 117.4 
(Ar), 118.0 (Ar), 118.6 (Ar), 124.6 (Ar), 127.3 (Ar), 127.4 (Ar), 130.6 (Ar), 134.1 (Ar), 139.3 (Ar) 
and 143.2 (Ar); FAB+MS m/z 684 [(M+1)\ 100%] and 584 (40); HRMS (FAB) m/z 684.4128 
(M+1)+, C40H54N5O5 requires 684.4125.
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-BOC-(N',N"-dibutyl)guanidinyl-3,14-di- 
hydroxyindolo[2',3':6,7]morphinan (0.020 g, 0.03 mmol) was treated as described in general 
procedure G, to give 17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5,-(N,,N"-dibutyl)- 
guanidinyl-3,14-dihydroxyindolo P'.S'^.TJmorphinan (114) as the bistrifluoroacetic acid salt 
(0.020 g, 0.03 mmol, 8 6%); mp. 196-199 °C; Rf = 0.09 [CH3OH/CH2CI2/NH4OH (89:10:1)]; IR 
vmax/cm (KBr) 3650-2680 (br, bonded OH and NH) and 1678 (br, C=N, NH and NH2); 1H NMR 
(400 MHz, CD3OD) 5 0.52-0.59 [m, 2H, NCH2CH(CHHCHH)], 5.74 [s, 1H, C(5)H], 6.64 [d, J=8.2 
Hz, 1H, C(1)/-/], 6.67 [d, J=8.2 Hz, 1H, C(2)H], 7.00 [dd, ^ = 8.6  Hz, J2=2.1 Hz, 1H, C(6 ')H], 7.31 
[d, J=2.1 Hz, 1H, C(4’)H\ and 7.46 [d, J=8.6  Hz, 1H, C(7')H]; 13C NMR (67.8 MHz, CD3OD) 8
3.7 [NCH2CH(CH2CH2)], 6.5 [NCH2CH(CH2CH2)], 7.1 [NCH2CH(CH2CH2)], 14.3 (CH3), 15.7 
(CH2), 21.2  (CH2), 25.3 [C(10)], 30.0 (CH2), 30.6 (CH2), 32.4 (CH2), 42.8 [C(16)J, 47.9 
[quaternary C(13)], 59.2 [C(18)], 63.9 [C(9)], 73.9 [quaternary C(14)], 85.2 [C(5)], 110.3 (Ar),
114.2 (Ar), 118.7 (Ar), 119.7 (Ar), 120.9 (Ar), 122.9 (Ar), 127.4 (Ar), 129.0 (Ar), 130.6 (Ar),
132.9 (Ar), 138.5 (Ar), 142.5 (Ar), 145.1 (Ar), 147.0 (Ar) and 156.6 (C=N); FAB+MS m/z 584 
[(M+1)\ 100%]; HRMS (FAB) m/z 584.3603 (M+1)+, C35H46N5O3 requires 584.3601.
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NtN'-Dipropylthiourea
Propylamine (1.16 g, 19.67 mmol), calcium carbonate (1.97 g, 19.67 mmol) and thiophosgene 
(4.52 g, 3 ml, 39.34 mmol) were reacted according to general procedure H, to give 
propylisothiocyanate; Rf= 0.72 [EtOAc/hexane (1:1)]. Propylisothiocyanate (0.48 g, 4.75 mmol) 
and propylamine (0.28 g, 4.75 mmol) were then reacted to give N.N’-dipropylthiourea (0.35 g, 
2.19 mmol, 46%); Rf = 0.37 [EtOAc/hexane (1:1)]; 1H NMR (270 MHz, CDCI3) 8 0.92 (t, J=7.3 
Hz, 6 H, 2 x CH3), 1.58 [q, J=7.3 Hz, 4H, 2 x CH2CH3), 3.36 [br s, 4H, 2 x NCH2] and 6.09 [br s, 
2H, 2 x NH]; 13C NMR (67.8 MHz, CDCI3) 8 11.3 (CH3), 22.2 (CH2CH3), 46.0 (NCH2) and 181.3 
(C=S); FAB+MS m/z 161 [(M+1)+, 100%]; HRMS (FAB) m/z 161.1111 (M+1)+, C7H17N2S 
requires 161.1112.
N-fe/t-butoxycarbonyl-N.N'-dipropylthiourea
N.N'-Dipropylthiourea (0.26 g, 1.64 mmol), NaH (0.08 g, 60% in oil, 3.28 mmol) and (BOC)20  
(0.41 g, 1.88 mmol) were reacted according to general procedure I, to give N-terf- 
butoxycarbonyl-N.N'-dipropylthiourea (0.18 g, 0.71 mmol, 43%); Rf = 0.70 [EtOAc/hexane 
(1:3)]; 1H NMR (270 MHz, CDCI3) 8 0.79-0.95 (m, 6 H, 2 x CH3), 1.34-1.48 [m, 9H, C(CH3)3], 
1.49-1.69 [m, 4H, 2 x CH2CH3], 3.45-3.61 (m, 2H, NHCH2), 4.07-4.29 (m, 2H, CONCH2) and 
10.80 (br s, 1H, NH); 13C NMR (67.8 MHz, CDCI3) 8 11.0 (CH3), 11.6 (CH3), 21.4 (CH2CH3),
21.9 (CH2CH3), 30.2 [C(CH3)3], 48.7 (HNCH2), 50.7 (CONCH2), 83.7 [C(CH3)3], 155.2 (C=0) 
and 183.2 (C=S); FAB+MS m/z 261 [(M+1)\ 40%]; HRMS (FAB) m/z 261.1628 (M+1)\ 
Ci2H25N20 2S requires 261.1637.
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5,-(N\N,,-dipropyl)guanidinyl-3>14-di- 
hydroxyindolo[2’,3':6,7]morphinan (115)
N-BOC-N.N’-dipropylthiourea (0.100 g, 0.39 mmol), 5’-amino-17-cyclopropylmethyl-6,7- 
didehydro^.Sa-epoxy-S.M-dihydroxyindoloP'.S'tf^-morphinan (120) (0.113 g, 0.26 mmol), 
HgCI2 (0.105 g, 0.39 mmol) and triethylamine (0.030 g, 0.042 ml, 0.30 mmol) were reacted
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according to general procedure F and stirred at 50 °C for 48 h, to give 17-cyclopropylmethyl-
6,7-didehydro-4,5a-epoxy-5'-BOC-(N',N"-dipropyl)guanidinyl-3,14-dihydroxyindolo[2',3':6,7]- 
morphinan (0.068 g, 0.10 mmol, 39%); Rf = 0.50 [CH3OH/CH2CI2/NH4OH (89:10:1)]; 1H NMR 
(270 MHz, CDCI3) 6 0.12-0.20 [m, 2H, NCH2CH(CHHCHH)], 0.52-0.61 [m, 2H, 
NCH2CH(CHHCHH)], 1.48 [s, 9H, C(CH3)3], 5.61 [s, 1H, C(5)H], 6.41-7.09 (m, 5H, ArH); 13C 
NMR (67.8 MHz, CDCI3) 5 3.8 [NCH2CH(CH2CH2)], 3.9 [NCH2CH(CH2CH2)], 9.4 
[NCH2CH(CH2CH2)], 11.4 (CH3), 21.8  (CH2), 23.1 [C(10)], 28.3 [C(CH3)3], 28.8 (CH2), 31.4 
(CH2), 43.6 (CH2), 44.7 [C(16)]t 47.9 [quaternary C(13)], 59.5 [C(18)J, 62.4 [C(9)J, 72.7 
[quaternary C(14)], 81.1 [quaternary C(CH3)3], 85.1 [C(5)J, 110.8 (Ar), 117.6 (Ar), 118.6 (Ar),
124.6 (Ar), 127.3 (Ar), 129.6 (Ar), 130.6 (Ar), 134.2 (Ar), 139.5 (Ar), 143.3 (Ar) and 154.1 (C=N); 
FAB+MS m/z 656 [(M+1)\ 100%] and 556 (50); HRMS (FAB) m/z 656.3817 (M+1)+, 
C38H50N5O5 requires 656.3812.
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5,-BOC-(N',N”-dipropyl)guanidinyl-3,14-di- 
hydroxyindolo[2',3':6,7]morphinan (0.025 g, 0.04 mmol) was treated as described in general 
procedure G, to give 17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-(N',N"-dipropyl)- 
guanidinyl-3,14-dihydroxyindolo[2',3':6,7]morphinan (115) as the bistrifluoroacetic acid salt 
(0.023 g, 0.03 mmol, 78%); mp. 174-175 °C; Rf = 0.09 [CH3OH/CH2CI2/NH4OH (89:10:1)]; IR 
vmax/crn (KBr) 3700-2730 (br, bonded OH and NH) and 1678 (br, C=N, NH and NH2); 1H NMR 
(270 MHz, CD3OD) 6 0.41-0.52 [m, 2H, NCH2CH(CHHCHH)], 5.64 [s, 1H, C(5)H\, 6.53-6.62 [m, 
2H, C(1)H and C(2)H], 6.91 [dd, ^ = 8.6  Hz, J2=2.2 Hz, 1H, C(6')H], 7.23 [d, J=2.2 Hz, 1H, 
C(4')H\ and 7.37 [d, J=8.6  Hz, 1H, C(7')H]\ 13C NMR (67.8 MHz, CD3OD) 5 3.7
[NCH2CH(CH2CH2)], 6.5 [NCH2CH(CH2CH2)], 7.1 [NCH2CH(CH2CH2)], 11.6 (CH3), 23.6 [C(10)],
25.3 (CH2), 30.0 (CH2), 30.6 (CH2), 44.6 [C(16)], 47.9 [quaternary C(13)], 59.2 [C(18)], 63.9 
[C(9)]f 73.9 [quaternary C(14)], 85.2 [C(5)], 110.3 (Ar), 114.2 (Ar), 118.8 (Ar), 119.7 (Ar), 120.9 
(Ar), 122.9 (Ar), 123.0 (Ar), 127.3 (Ar), 129.0 (Ar), 130.6 (Ar), 132.9 (Ar), 138.5 (Ar), 142.5 (Ar),
145.1 (Ar), and 156.6 (C=N); FAB+MS m/z 556 [(M+1)+, 100%]; HRMS (FAB) m/z 556.3287 
(M +1)\ C33H42N5O3 requires 556.3288.
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N-Propyl-N'-cyclopropylmethylthiourea
Propylamine (1.16 g, 19.67 mmol), calcium carbonate (1.97 g, 19.67 mmol) and thiophosgene 
(4.52 g, 3 ml, 39.34 mmol) were reacted according to general procedure H, to give 
propylisothiocyanate; Rf= 0.72 [EtOAc/hexane (1:1)]. Propylisothiocyanate (0.44 g, 4.38 mmol) 
and aminomethylcyclopropane (0.31 g, 4.38 mmol) were then reacted to give N-propyl-N'- 
cyclopropylmethylthiourea (0.42 g, 2.44 mmol, 56%); Rf= 0.38 [EtOAc/hexane (1:1)]; 1H NMR 
(270 MHz, CDCI3) 5 0.21-0.30 [m, 2H, NCH2CH(CHHCHH)], 0.52-0.62 [m, 2H, 
NCH2CH(CHHCHH)], 0.97 (t, J=7.3 Hz, 3H, CH3), 1.02-1.13 [m, 1H, NCH2CH(CH2CH2)], 1.64 
[q, J=7.3 Hz, 2H, CH2CH3), 3.30-3.41 [m, 4H, 2 x NCH2] and 6.24 [br s, 2H, 2 x NH]; 13C NMR 
(67.8 MHz, CDCI3) 8 3.5 [NCH2CH(CH2CH2)] and [NCH2CH(CH2CH2)], 10.0
[NCH2CH(CH2CH2)], 11.3 (CH3), 22.1 (CH2CH3), 45.9 (NCH2), 49.4 (NCH2CH) and 181.0 
(C=S); FAB+MS m/z 173 [(M+1)\ 100%]; HRMS (FAB) m/z 173.1116 (M+1)+, C8Hi7N2S 
requires 173.1112.
N-terf-butoxycarbonyl-N-propyl-N'-cyclopropylmethylthiourea
N-Propyl-N'-cyclopropylmethylthiourea (0.41 g, 2.38 mmol), NaH (0.19 g, 60% in oil, 4.75 mmol) 
and (BOC)20  (0.60 g, 2.73 mmol) were reacted according to general procedure I, to give N-tert- 
butoxycarbonyl-N-propyl.N'-cyclopropylmethylthiourea (0.30 g, 1.09 mmol, 46%); Rf = 0.66 
[EtOAc/hexane (1:3)]; 1H NMR (400 MHz, CDCI3) 8 0.22-0.49 [m, 4H, NCH2CH(CHHCHH) and 
NCH2CH(CHHCHH)], 0.51-0.57 [m, 1H, NCH2CH(CH2CH2)], 0.88 (t, J=7.4 Hz, 3H, CH3), 1.51 
[s, 9H, C(CH3)3], 1.65 [q, J=7.4 Hz, 2H, CH2CH3], 3.39-3.60 (m, 2H, NHCH2), 4.16-4.30 (m, 2H, 
CONCH2) and 10.86 (br s, 1H, NH); 13C NMR (100 MHz, CDCI3) 8 4.0 [NCH2CH(CH2CH2)], 4.1 
[NCH2CH(CH2CH2)], 11.0 [NCH2CH(CH2CH2)], 11.7 (CH3), 22.3 (CH2CH3), 28.4 [C(CH3)3], 51.1 
(HNCH2), 57.2 (CONCH2), 83.3 [C(CH3)3], 151.7 (C=0) and 183.0 (C=S); FAB+MS m/z 273 





N-BOC-N-propyl.N’-cyclopropylmethylthiourea (0.152 g, 0.56 mmol), 5’-amino-17- 
cyclopropylmethyl-6)7-didehydro-4,5a-epoxy-3,14-dihydroxyindolo[2,f3,:6I7]-morphinan (120) 
(0.120  g, 0.28 mmol), HgCI2 (0.152 g, 0.56 mmol) and triethylamine (0.028 g, 0.040 ml, 0.28 
mmol) were reacted according to general procedure F and stirred at 50 °C for 48 h, to give 17- 
cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-BOC-(N,-propyl,N"-cyclopropylmethyl)- 
guanidinyl-S.^-dihydroxyindolotZ.S'ieJlmorphinan (0.062 g, 0.09 mmol, 33%); Rf = 0.61 
[CH3OH/CH2CI2/NH4OH (89:10:1)]; 1H NMR (270 MHz, CDCI3) 8 0.05-0.10 [m, 2H, 
NCH2CH(CHHCHH)], 0.11-0.20 [m, 2H, NCH2CH(CHHCHH)], 0.35-0.44 [m, 2H,
NCH2CH(CHHCHH)], 0.46-0.58 [m, 2H, NCH2CH(CHHCHH)], 0.73-0.83 [m, 1H,
NCH2CH(CH2CH2)], 0.84-0.98 [m, 1H, NCH2CH(CH2CH2)], 1.47 [s, 9H, C(CH3)3], 5.60 [s, 1H, 
C(5)H\, 6.38-7.10 (m, 5H, ArH); 13C NMR (67.8 MHz, CDCI3) 8 3.3 [NCH2CH(CH2CH2)l, 3.4 
[NCH2CH(CH2CH2)], 3.8 [NCH2CH(CH2CH2)], 3.9 [NCH2CH(CH2CH2)], 9.4 [NCH2CH(CH2CH2)],
10.5 [NCH2CH(CH2CH2)], 11.4 (CH3), 21.8 (CH2), 23.1 [C(10)]« 28.3 [C(CH3)3], 28.8 (CH2), 31.4 
(CH2), 43.6 (CH2), 47.9 [quaternary C(13)], 59.5 [C(18)], 62.4 [C(9)], 72.7 [quaternary C(14)],
81.0 [quaternary C(CH3)3], 85.0 [C(5)J, 110.7 (Ar), 111.7 (Ar), 117.5 (Ar), 117.9 (Ar), 118.5 (Ar),
124.5 (Ar), 127.3 (Ar), 129.6 (Ar), 130.6 (Ar), 134.2 (Ar), 139.6 (Ar), 143.4 (Ar), 153.9 (Ar) and
154.1 (C=N); FAB+MS m/z 668  [(M+1)\ 100%] and 568 (30); HRMS (FAB) m/z 668.3819 
(M+1)+, C39H50N5O5 requires 668.3812.
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5,-BOC-(N'-propyl,N"-cyclopropylmethyl)- 
guanidinyl-3,14-dihydroxyindolo[2',3':6,7]morphinan (0.046 g, 0.07 mmol) was treated as 
described in general procedure G, to give IZ-cyclopropylmethyl-ej-didehydro^.Sa-epoxy-S'- 
(N'-propyl,N,,-cyclopropylmethyl)guanidinyl-3,14-dihydroxyindolo[2,,3,:6,7]morphinan (116) as 
the bistrifluoroacetic acid salt (0.039 g, 0.07 mmol, 99%); mp. 177-178 °C; Rf = 0.24 
[CH3OH/CH2CI2/NH4OH (89:10:1)]; IR vmax/crn (KBr) 3700-2620 (br, bonded OH and NH) and 
1678 (br, C=N, NH and NH2); 1H NMR (400 MHz, CD3OD) 8 0.12-0.21 [m, 2H, 
NCH2CH(CHHCHH)], 5.65 [s, 1H, C(5)H\, 6.56 [d, J=8.2 Hz, 1H, C(1 )H], 6.59 [d, J=8.2 Hz, 1H,
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C(2)H\, 6.93 [dd, ^ = 8.6  Hz, J2=1.9 Hz, 1H, C(6 ')H\, 7.25 [d, J=1.9 Hz, 1H, C(4’)H] and 7.38 [d, 
J=8.6  Hz, 1H, C(7’)HJ; 13C NMR (67.8 MHz, CD3OD) 8 3.7 [NCH2CH(CH2CH2)], 4.2
[NCH2CH(CH2CH2)], 6.5 [NCH2CH(CH2CH2)], 7.1 [NCH2CH(CH2CH2)], 11.5 
[NCH2CH(CH2CH2)], 11.7 (CH3), 23.6 [C(10)], 25.3 (CH2), 30.0 (CH2), 30.5 (CH2), 44.6 [C(16)],
47.6 (CH2), 47.9 [quaternary C(13)], 59.2 [C(18)]t 63.9 [C(9)], 73.9 [quaternary C(14)], 85.2 
[C(5)], 110.3 (Ar), 114.2 (Ar), 118.6 (Ar), 119.7 (Ar), 120.9 (Ar), 122.8 (Ar), 122.9 (Ar), 127.4 
(Ar), 129.0 (Ar), 130.6 (Ar), 132.9 (Ar), 138.5 (Ar), 142.4 (Ar), 145.1 (Ar) and 156.6 (C=N); 
FAB+MS m/z 568 [(M+1)+, 100%]; HRMS (FAB) m/z 568.3275 (M +1)\ C ^ N s O a  requires 
568.3288; Anal. (C34H41N5O3.2TFA.2 H2O) requires C 54.87, H 5.70, N 8.42, found C 54.90, H 
5.44, N 8.12.
N-Benzyl-N'-cyclopropylmethylthiourea
Benzylamine (2.11 g, 2.15 ml, 19.67 mmol), calcium carbonate (1.97 g, 19.67 mmol) and 
thiophosgene (4.52 g, 3 ml, 39.34 mmol) were reacted according to general procedure H, to 
give benzylisothiocyanate. Benzylisothiocyanate (0.90 g, 6.02 mmol) and 
aminomethylcyclopropane (0.43 g, 5.99 mmol) were then reacted to give N-benzyl-N- 
cyclopropylmethylthiourea (0.62 g, 2.82 mmol, 47%); Rf = 0.39 [EtOAc/hexane (1:1)]; 1H NMR 
(270 MHz, CDCI3) 5 0.00-0.14 [m, 2H, NCH2CH(CHHCHH)], 0.26-0.46 [m, 2H, 
NCH2CH(CHHCHH)], 0.75-0.90 [m, 1H, NCH2CH(CH2CH2)], 3.11 (br s, 2H, CH2), 4.50 (br s, 
2H, CH2Ph), 6.33 (br s, 1H, NH), 6.56 (br s, 1H, NH) and 7.11-7.26 (m, 5H, ArH); 13C NMR 
(67.8 MHz, CDCI3) 8 3.3 [NCH2CH(CH2CH2)] and [NCH2CH(CH2CH2)]f 9.8 [NCH2CH(CH2CH2)],
48.1 (CH2), 49.3 (CH2), 127.3 [C(2) and C(6 )], 127.5 [C(4)], 128.5 [C(3) and C(5)], 137.0 
[quaternary C(1)] and 181.2 (C=S); FAB+MS m/z 221 [(M+1)+, 100%].
N-fe/t-butoxycarbonyl-N-benzyl-N'-cyclopropylmethylthiourea
N-Benzyl-N'-cyclopropylmethylthiourea (0.30 g, 1.36 mmol), NaH (0.11 g, 60% in oil, 2.73 
mmol) and (BOC)20  (0.34 g, 1.57 mmol) were reacted according to general procedure I, to give 
N-terf-butoxycarbonyl-N-benzyl-N'-cyclopropylmethylthiourea (0.26 g, 0.63 mmol, 46%); Rf =
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0.60 [EtOAc/hexane (1:4)]; 1H NMR (400 MHz, CDCI3) 5 0.00-0.04 [m, 2H, 
NCH2CH(CHHCHH)]t 0.13-0.19 [m, 2H, NCH2CH(CHHCHH)], 0.26-0.32 [m, 1H,
NCH2CH(CH2CH2)], 1.21 [s, 9H, C(CH3)3], 3.20-3.26 (m, 2H, NCH2), 3.99-4.08 (m, 1H, NCHH), 
4.54-4.57 (m, 1H, NCHH) and 6.88-7.08 (m, 5H, ArH); 13C NMR (100 MHz, CDCI3) § 4.1 
[NCH2CH(CH2CH2)], 4.2 [NCH2CH(CH2CH2)], 10.0 [NCH2CH(CH2CH2)], 28.2 [C(CH3)3], 52.6 
(NCH2), 53.0 (NCH2), 84.7 [C(CH3)3], 126.7 [C(2) and C(6 )], 126.9 [C(4)J, 128.4 [C(3) and C(5)],
138.9 [quaternary C(1)]f 155.2 (C=0), 155.5 (C=0) and 183.6 (C=S); FAB+MS m/z 321 




N-BOC-N-benzyl.N'-cyclopropylmethylthiourea (0.135 g, 0.32 mmol), 5’-amino-17- 
cyclopropylmethyl-ej-didehydro^.Sa-epoxy-S.M-dihydroxyindoloP'.S'ieyj-morphinan (120 ) 
(0.100 g, 0.23 mmol), HgCI2 (0.09 g, 0.32 mmol) and triethylamine (0.024 g, 0.033 ml, 0.23 
mmol) were reacted according to general procedure F and stirred at 50 °C for 48 h, to give 17- 
cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-BOC-(N'-benzyl,N"-cyclopropylmethyl)- 
guanidinyl-S.M-dihydroxyindoloP'.S'iejJrnorphinan (0.058 g, 0.08 mmol, 35%); Rf = 0.47 
[CH3OH/CH2CI2/NH4OH (89:10:1)]; 1H NMR (270 MHz, CDCI3) 5 0.06-0.21 [m, 2 x 2H, 
NCH2CH(CHHCHH)], 0.33-0.47 [m, 2H, NCH2CH(CHHCHH)], 0.49-0.60 [m, 2H,
NCH2CH(CHHCHH)], 0.86-0.98 [m, 2 x 1H, NCH2Ctf(CH2CH2)], 1.49 [s, 9H, C(CH3)3], 5.54 [s, 
1H, C(5)H], 6.47-6.56 [m, 2H, C(1)H and C(2)H], 6.68-6.76 (m, 1H, ArH), 6.80-6.93 (m, 1H, 
ArH) and 7.01-7.48 (m, 6 H, ArH); 13C NMR (67.8 MHz, CD3OD) 5 4.2 [NCH2CH(CH2CH2)], 4.5 
[NCH2CH(CH2CH2)], 4.9 [NCH2CH(CH2CH2)], 10.6 [NCH2CH(CH2CH2)], 11.4 
[NCH2CH(CH2CH2)], 24.4 [C(10)]f 28.9 [C(CH3)3], 29.0 (2 x CH2), 29.1 (CH2), 30.4 (CH2), 33.0 
(CH2), 45.2 [quaternary C(13)], 60.8 [C(18)], 64.0 [C(9)], 74.7 [quaternary C(14)], 83.0 
[quaternary C(CH3)3], 86.2 [C(5)], 111.2 (Ar), 112.3 (Ar), 119.1 (Ar), 120.0 (Ar), 125.4 (Ar),
128.3 (Ar), 128.9 (Ar), 129.0 (Ar), 129.5 (2 x Ar), 129.6 (2 x Ar), 130.0 (Ar), 132.0 (Ar), 132.3 
(Ar), 136.1 (Ar), 138.6 (Ar), 142.8 (Ar), 145.4 (Ar), 155.2 (Ar) and 155.9 (C=N); FAB+MS m/z
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716 [(M+1)+, 100%] and 616 (25); HRMS (FAB) m/z 716.3802 (M+1)\ C43H50N5O5 requires 
716.3812.
17-Cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5,-BOC-(N,-benzyl,N"-cyclopropylmethyl)- 
guanidinyl-3,14-dihydroxyindolo[2',3':6)7]morphinan (0.058 g, 0.08 mmol) was treated as 
described in general procedure G, to give 17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'- 
(N'-benzyl,N"-cyclopropylmethyl)guanidinyl-3,14-dihydroxyindolo[2',3':6,7]morphinan (117) as 
the bistrifluoroacetic acid salt (0.048 g, 0.08 mmol, 96%); mp. 157-158 °C; Rf = 0.08 
[CH3OH/CH2CI2/NH4OH (89:10:1)]; IR vmax/crn (KBr) 3800-2450 (br, bonded OH and NH) and
1679 (br, C=N, NH and NH2); 1H NMR (400 MHz, CD3OD) 6 0.00-0.08 [m, 2H,
NCH2CH(CHHCHH)], 0.31-0.37 [m, 2H, NCH2CH(CHHCHH)], 0.38-0.46 [m, 2H,
NCH2CH(CHHCHH)], 0.58-0.76 [m, 2H, NCH2CH(CHHCHH)], 0.83-0.93 [m, 1H,
NCH2CH(CH2CH2)], 0.96-1.07 [m, 1H, NCH2CH(CH2CH2)], 5.57 [s, 1H, C(5)H], 6.47-6.55 [m, 
2H, C(1 )H and C(2)H], 6.79-6.85 [m, 1H, ArH], 7.09-7.23 [m, 1H, ArH] and 7.27-7.32 [m, 1H, 
ArH]\ 13C NMR (67.8 MHz, CD3OD) 8 3.7 [NCH2CH(CH2CH2)], 4.2 [NCH2CH(CH2CH2)], 6.5 
[NCH2CH(CH2CH2)], 7.1 [NCH2CH(CH2CH2)], 11.5 [NCH2CH(CH2CH2)], 11.7 (CH3), 23.6 
[C(10)], 25.3 (CH2), 30.0 (CH2), 30.5 (CH2), 44.6 [C(16)], 47.6 (CH2), 47.9 [quaternary C(13)],
59.2 [C(18)], 63.9 [C(9)]t 73.9 [quaternary C(14)], 85.2 [C(5)], 110.3 (Ar), 114.2 (Ar), 118.5 (Ar),
119.7 (Ar), 120.9 (Ar), 122.7 (Ar), 122.9 (Ar), 127.4 (Ar), 128.4 (2 x Ar), 128.9 (Ar), 129.2 (Ar),
130.1 (2 x Ar), 130.6 (Ar), 132.8 (Ar), 138.3 (Ar), 138.5 (Ar), 142.4 (Ar), 145.1 (Ar) and 156.8 




NaHC03 (0.013 g, 0.15 mmol) was added to 17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy- 
5'-bis-BOC-(N'-4-aminobenzyl)guanidinylethyl-3,14-dihydroxyindolo-[2',3':6,7]morphinan (126) 
(0.030 g, 0.04 mmol) in a mixture of CHCI3 (2 ml) and H20  (1 ml). After cooling the reaction 
mixture in an ice bath, thiophosgene (0.006 g, 0.05 mmol) was added. The mixture was then
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warmed to RT and allowed to stir for 2 h. The organic layer was collected and the aqueous 
layer further extracted with CHCI3. The combined organic layers were then dried (Na2S04), 
concentrated and purified by preparative thin layer chromatography [CH3OH/CH2CI2 (70:30)], to 
give 17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-bis-BOC-(N'-4-isothiocyanatobenzyl)- 
guanidinylethyl-3,14-dihydroxyindolo-[2',3':6,7]morphinan (0.018 g, 0.02 mmol, 57%); Rf = 0.43 
[CH3OH/CH2CI2 (70:30)]; 1H NMR (400 MHz, CDCI3) 8 0.29-0.44 [m, 2H, NCH2CH(CHHCHH)], 
0.58-0.73 [m, 2H, NCH2CH(CHHCHH)], 0.96-1.04 [m, 1H, NCH2CH(CH2CH2)], 1.29 [s, 9H, 
C(Ctf3)3], 1.38 [s, 9H, C(CH3)3], 5.63 [s, 1H, C(5)H], 6.50 [d, J=8.2  Hz, 1H, C(1)HJ, 6.57 [d, 
J=8.2 Hz, 1H, C(2)H\, 6.73-6.81 (m, 1H, ArH) and 6.98-7.22 (m, 6 H, ArH)\ 13C NMR adequate 
spectra were not obtained due to poor solubility. We aim to remake these compounds and to 
run 13C NMR spectra in d6-DMSO; FAB+MS m/z 847 [(M+1)\ 100%] and 647 (100); HRMS 
(FAB) m/z 847.3877 (M +1)\ C47H55N6O7S requires 847.3853.
^-Cyclopropylmethyl-ey-didehydro^.Sa-epoxy-S’-bis-BOC-fN'^-isocyanatobenzylJguanidinyl- 
ethyl-3,14-dihydroxyindolo[2',3':6,7]morphinan (0.017 g, 0.02 mmol) was treated as described in 
general procedure G, to give 17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5'-(N'-4- 
isocyanatobenzylJguanidinylethyl-S.^-dihydroxyindoloP'.S'tfJlmorphinan (124) as the 
bistrifluoroacetic acid salt (0.015 g, 0 .02  mmol, 99%); mp. 154 °C; Rf = 0.16 [CH3OH/CH2CI2 
(30:70)]; IR vmax/cm (KBr) 3650-2850 (br, bonded OH and NH) and 1678 (br, C=N, NH and 
NH2); 1H NMR (400 MHz, CD3OD) 8 0.48-0.59 [m, 2H, NCH2CH(CHHCHH)], 0.73-0.92 [m, 2H, 
NCH2CH(CHHCHH)], 1.10-1.21 [m, 1H, NCH2CH(CH2CH2)], 5.75 [s, 1H, C(5)H\, 6.64 [d, J=8.2 
Hz, 1H, C(1)HJ, 6.67 [d, J=8.2 Hz, 1H, C(2)H], 6.84-6.90 (m, 1H, ArH) and 6.99-7.32 (m, 6 H, 
ArH)\ 13C adequate spectra were not obtained due to poor solubility. We aim to remake these 
compounds and to run 13C NMR spectra in d5-DMSO; FAB+MS m/z 647 [(M+1)+, 100%]; 




NaHC03  (0.020 g, 0.25 mmol) was added to 17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy- 
5,-bis-BOC-(N'-4-aminobenzyl)guanidinyl-3I14-dihydroxyindolo-[2',3,:6,7]morphinan (127) 
(0.048 g, 0.06 mmol) in a mixture of CHCI3 (3 ml) and H20  (1 ml). After cooling the reaction 
mixture in an ice bath, thiophosgene (0.009 g, 0.08 mmol) was added. The mixture was then 
warmed to RT and allowed to stir for 2 h. The organic layer was collected and the aqueous 
layer further extracted with CHCI3. The combined organic layers were then dried (Na2S0 4 ), 
concentrated and purified by preparative thin layer chromatography [CH3OH/CH2CI2 (70:30)], to 
give 17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-5,-bis-BOC-(N,-4-isothiocyanatobenzyl)- 
guanidinyl-3,14-dihydroxyindolo-[2',3':6,7]morphinan (125) (0.025 g, 0.03 mmol, 50%); Rf = 
0.40 [CH3OH/CH2CI2 (70:30)]; 1H NMR (400 MHz, CDCI3) 5 0.08-0.17 [m, 2H, 
NCH2CH(CHHCHH)], 0.48-0.57 [m, 2H, NCH2CH(CHHCHH)], 1.36 [s, 9H, C(CH3)3], 1.38 [s, 
9H, C(CH3)3], 5.67 [s, 1H, C(5)H|, 6.60-6.78 (m, 3H, ArH) and 7.03-7.54 (m, 6 H, ArH); 13C NMR 
adequate spectra were not obtained due to poor solubility. We aim to remake these compounds 
and to run 13C NMR spectra in d6-DMSO; FAB+MS m/z 819 [(M+1)\ 100%] and 719 (20).
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5.4 MOLECULAR MODELLING METHODS
This section contains a detailed description of the parameters used for the molecular modelling 
studies described in this thesis. The computational work was carried out under the guidance of 
Dr. Wolfgang Brandt, Martin-Luther Universiteit, Halle-Wittenberg, Halle (Saale), Germany.
5.4.1 Minimisation
The parameters used for the minimisation procedure were as follows:
Method: Powell Initial Optimisation: simplex
Termination: Gradient [0.05 kcal/(mol*A)]
Force Field: Tripos Charges: Gasteiger-Marsili
Non-bonded cutoff: 8.0
Dielectric Function: distance Dielectric constant: 4.0
RMS Displacement: 0.001
Min Energy Change: 0.05 Max Displacement: 0.01
At certain stages during the minimisation process, aggregates (atoms held fixed in their 
position) or constraints (distances between atoms maintained) were imposed on certain atoms. 
These were however removed before the final minimisation of the structures. One exception to 
this is the receptor. Whenever the receptor was minimised, either the backbone or the side 
chains were kept as aggregate. This was to ensure that the integrity of the receptor model was 
not jeopardised.
5.4.2 Molecular Dynamics
The molecule was heated to 100 K (Kelvin) for 10 000 fs (femtoseconds). The “dynamics 
history” was then replayed. A table was automatically generated, showing snap shots of the 
molecule at 1000 fs intervals. The molecule usually takes between 1000-2000 fs to equilibrate.
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The latter snap shots and final structure of the molecule can therefore be minimised (according 
to the parameters discussed above) in order to find the minimum structure. By heating the 
molecule, it is hoped that the energy of the molecule would not rest in a local minimum, but 
rather that energy barriers might be overcome and that the molecule might finally rest in a 
global minimum state.
5.4.3 Simulated Annealing
The molecules were heated to 700 K (Kelvin) in 2000 fs (femtoseconds) and then cooled to 100 
K in 2000 fs. This procedure was repeated 30 times. Analysis of the simulated annealing was 
run, generating a table with all the possible structures. The 30 structures with the lowest energy 
were automatically stored in a database (/'e. lowest one from each run). These structures were 
however not minimised. Subsequent minimisation (according to the above procedure) allowed 
the structure with the approximate global minimum to be identified.
5.5 PHARMACOLOGICAL METHODS ,
This section contains a detailed description of the pharmacological procedures used to evaluate 
the compounds whose synthesis is described in this thesis. The displacement binding assays 
and functional in vitro assays (GPI, MVD, GTPyS) were performed under the National Institute 
on Drug Abuse (NIDA) contract, at Stanford Research Institute, California, USA.
5.5.1 In Vitro Assay Methods
Binding
Receptor binding studies were conducted on human opioid receptors transfected into Chinese 
hamster ovary (CHO) cells. The p cell line is maintained in Ham’s F-12 medium supplemented 
with 10% fetal bovine serum and 400pg/ml GENETICIN (G418 sulphate). The 8 cell line is 
maintained in Ham’s F-12 medium supplemented with 10% fetal bovine serum and 500pg/ml
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hygromycin B. The k  cell line is maintained in Dulbecco’s minimal essential medium (DMEM) 
supplemented with 10% fetal bovine serum, 400pg/ml GENETICIN (G418 sulphate) and 0.1% 
penicillin/streptomycin. All cell lines are grown to full confluency, then harvested for membrane 
preparation. The membrane used for functional assays is prepared in buffer A (20mM HEPES, 
10mM MgCI2, and 100mM NaCI at pH 7.4) and the membrane for binding assays is prepared in 
50mM Tris buffer pH 7.7. Cells are harvested by scraping the plates with a rubber policeman 
and then centrifuged at 20000 x g for 20 minutes. The cell pellet is washed in buffer A or Tris, 
centrifuged at 20000 x g for another 20 minutes and finally suspended in a small amount of 
buffer to determine protein content. Membrane is aliquoted in small vials at a concentration of 
6mg/ml per vial and stored at -70°C and used as needed.
Routine binding assays were conducted using [3H] DAMGO, [3H] CI-DPDPE and [3H] U69593 to 
bind to p, 5 and k  receptors, respectively. For binding, cell membranes are incubated with the 
appropriate radioligand and unlabelled drug in a total volume of 200pl in 96-well plates, usually 
for 1 hour at 25°C. For routine experiments, membranes are incubated with the test 
compounds at concentrations ranging from 10'5 to 10'10M. After the incubation, samples are 
filtered through glass fibre filters by using a Tomtec cell harvester. Filters are dried overnight 
before radioactivity levels are determined. Non-specific binding is determined by using 1 .OpM 
of the unlabelled countepart of each radioligand.
Full characterization of compounds includes analysis of the data for IC50 values and Hill 
coefficients by using the program PRISM. Kj values are calculated using the Cheng Prusoff 
transformation:
Ki = ICso/(1+L/Kd)
where L is the radioligand concentration and Kd is the binding affinity of the radioligand, as 
determined previously by saturation analysis.
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Functional - [35S] GTPyS Assay
Membrane prepared as desribed above is incubated with [35S] GTPyS (50pM), GDP (usually 
10|iM), and the desired compound, in a total volume of 200jliI, for 60 minutes at 25°C. Samples 
are filtered over glass fibre filters and counted as described for the binding assays. A dose 
response curve with a prototypical full agonist (DAMGO, DPDPE, or U69593, for p ,  6  and k  
receptors, respectively) is conducted in each experiment to identify full and partial agonist 
compounds.
High affinity compounds that demonstrate no agonist activity are tested as antagonists. For 
each compound a full Schild analysis is conducted, utilizing a full agonist dose response curve 
in the presence of at least three concentrations of the antagonist. pA2 values and Schild slopes 
are determined using a statistical program designed for these experiments. The equilibrium 
dissociation constant (Ke) is calculated from the following equation:
Ke = a / DR -  1
where “a” is the nanomolar concentration of antagonist and DR is the virtual shift of the agonist 
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SCHEMATIC REPRESENTATION OF THE 3 OPIOID RECEPTOR TYPES202
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PROCEDURE USED FOR MODELLING THE k-OPIOID RECEPTOR
Using the known amino acid sequence of the kappa opioid receptor and the SYBYL package, 
COMPOSER,184 the sequence of the kappa receptor was matched to homologous sequences 
in Bovine Rhodopsin (Brookhaven Protein Database, 1F88), as well as to a model of the 5- 
opioid receptor previously determined by Brandt.189 Often this matching can be improved 
manually because of differing lengths of non-conserved regions in the proteins. COMPOSER 
then copies the structure of these conserved regions from the known receptor. The 
Brookhaven Protein Database is searched for sections which are similar in both sequence 
and length, to those which do not match the known receptor, and these are then used to 
propose the structure of the non-conserved portion of the protein. For the kappa receptor, the 
presence of the disulphide bond between extracellular loops 1 and 2 is well documented.203 
From the loop search, only those sequences in which the two cysteine molecules are in 
appropriate positions for the formation of a disulphide bridge can therefore be considered.
All minimisations were performed using the Tripos Force Field, Gasteiger-Marsili charges and 
a distance dependent dielectric function, with a dielectric constant of 4.0. The termination 
gradient was set at 0.05 kcal/mol with a minimum energy change of 0.05. The receptor 
structure was minimised and evaluated using the program, ProCheck.185 This program 
determines whether the amino acid backbone and side chains are in feasible orientations 
(with respect to bond lengths, chirality, planarity, bond angles, torsion angles, etc).
The model was further validated by docking known K-selective agonists and antagonists into 
the receptor, and comparing the interactions of the receptor/ligand complex to site directed 







Fig. 27 Representation of the modelled K-opioid receptor showing extracellular loops, 
transmembrane regions and intracellular loops.
183
APPENDIX D
PROCHECK ANALYSIS OF THE RECEPTOR
Omega Phi C ' - N - C a -C'
Psi N - C a - C ' - N
Chi1 N - C a - C b - C c
Chi2 Ca - Cb - Cc - Cd
Omega Ca - C' - N - Ca












Residues in most favoured regions [A,B,L] 201 75.6%
Residues in additional allowed regions [a,b,l,p] 57 21.4%
Residues in generously allowed regions [~a,~b,~l,~p] 7 2.6%
Residues in disallowed regions 1 0.4%
Number of non-glycine and non-proline residues 266 100.0%
Number of end-residues (excl. Gly and Pro) 2
Number of glycine residues (shown as triangles) 9
Number of proline residues 9
Total number of residues 286
Based on an analysis of 118 structures of resolution of at least 2.0 Angstroms 
and R-factor no greater than 20%, a good quality model would be expected 
to have over 90% in the most favoured regions.
185










Numbers o f residues are shown in brackets. Those in unfavourable conformations (score < -4.00) are labelled.
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Numbers of residues are shown in brackets. Those in unfavourable conformations (score < -4.00) are labelled.








L y s ( l l )  M et (9) Phe (19)
^  1--------------------------  1--------- 360-i---------1------------------ r™--------
------i*
















Numbers of residues are shown in brackets. Those in unfavourable conformations (score < -4.00) are labelled.
























































b. Peptide bond planarity - om ega angle sda. Ramachandran plot quality assessment
1 0 1.5 2.0 2.5 3.0 3.5 4 .0
Resolution (Angstroms)
d. Alpha carbon tetrahedral distortion
1 0  1.5 2.0 2.5 3.0 3.5 4.0
Resolution (Angstroms)
c. Measure o f bad non-bonded interactions
1.5 2.0 2.5 3.0 3.5 4.0
Resolution (Angstroms)
e. Hydrogen bond energies
Resolution (Angstroms) 
f. Overall G-factor
Resolution (Angstroms) Resolution (Angstroms)
Plot statistics
Comparison values No. of 
No. of Parameter Typical Band band widths
iata pts value value width from meanStereochemical parameter
Main-chain parameters
nb42 1
a. %-tage residues in A, B, L
b. Omega angle st dev
c. Bad contacts /1 0 0  residues
d. Zeta angle st dev




























































b. C h i-l transa. C hi-l gauche minus
Resolution (Angstrom s)
d. C hi-l pooled standard deviation
Resolution (Angstroms)
c. C hi-l gauche plus
1.5 2.0 2.5 3.0 3.5
Resolution (Angstroms)Resolution (Angstroms)
e. Standard deviation o f  Chi-2 trans angle
Resolution (Angstroms)
Plot statistics
Comparison values No. of 
No. of Parameter Typical Band band widths










a. C h i-l gauche minus st dev 45 16.0 18.1 6.5 -0.3 Inside
b. C h i-l trans st dev 100 15.0 19.0 5.3 -0.8 Inside
c. C h i-l gauche plus st dev 106 13.4 17.5 4.9 -0.8 Inside
d. C h i-l pooled st dev 251 14.7 18.2 4.8 -0.7 Inside
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Residue number Highlighted residues than are those 
that deviate by more than 2 . 0  st. devs. from ideal
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Black bars > 2.0 st. devs. from mean.
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Black bars > 2.0 st. devs. from mean. 4 or ► signifies data points o ff the graph in the direction shown.
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JLA« 6  121
Black bars > 2.0 st. devs. from mean.
Solid and dashed lines represent the mean and standard deviation values as per Engh &  Huber small-molecule data.
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RMS distances from planarity
Page 1
ARG
°o1)o am ao2 aoi 004
nb42 1
ASN ASP
aoi 002 003 004 001 002 003 00
GLN GLU HIS
°0.00 0.01 002 003 004001 002 003 0 S4 OOl 0 H2 0.03 0.04
PHE TRP TYR
0.00 0.01 ^  O.O* 0.1)3 0.0.00 0.01 0.02 0.03 0.0430 0.01
Histograms showing RMS distances o f planar atoms from best-fit plane.
Black bars indicate large deviations from planarity: RMS dist > 0.03 for rings, and > 0.02 otherwise.





M ain -cha in  bond angles
CB HO.] c  CB 109.1 C CA H6-2 N CB H0.I C CB H0.1 C N >105 CB
10.2 ' N ^ d ^ ' / 13.2 N^1203^/^i<>.2 NV y 9 ^ ^ / 'l4.3
CA CA (2 CA CA CA
Lys 89 Val 108 Met 112 Glu 209 Cys 210 Cys 210
CB HO.l C 
\ ^ 2 a ^ n i . 7
CA
Leu 269




9ICB $ $ <>1 CB ■ CB 1 CB ' CB 1 CB
0.043 0.111 0.069 0.082 0.044 0.078


















Sidechains with RMS dist. from planarity > 0.04A for rings, or > 0.03A otherwise. Value shown is RMS dist.
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APPENDIX E
FULL ASSIGNMENT OF A TYPICAL NMR
5’-Cyanomethyl-17-cyclopropylmethyl-6,7-didehydro-4,5a-epoxy-3,14-dihydroxyindolo- 
P'.S'iejlmorphinan (75)
1H NMR (300 MHz, CDCI3) 6 0.18-0.23 [m, 2H, NCH2CH(CHHCHH)], 0.57-0.65 [m, 2H, 
NCH2CH(CHHCHH)], 0.89-0.97 [m, 1H, NCH2CH(CH2CH2)], 1.16-1.19 [m, 2H, CH2CN], 1.73- 
1.80 [m, 1H, C(8)HaHb], 2.28-2.38 [m, 1H, C(16)tfaHb], 2.45-2.52 [m, 1H, C(8)HaHb], 2.61-2.66 
[m, 2H, C(18)H2], 2.78-2.84 [m, 1H, C(16)HaHb], 2.88-2.90 [m, 2H, C(15)H2], 3.11-3.17 [m, 
1H, C(10)HaHb], 3.44-3.46 [m, 1H, C(9)H], 3.76-3.78 [m, 1H, C(10)HaHb), 5.62 [s, 1H, C(5)H], 
6.54 [d, J=8.2 Hz, 1H, C(1 )H], 6.62 [d, J=8.2 Hz, 1H, C(2)H\, 6.97 [d, J=8.6 Hz, 1H, C(6’)H], 
7.23 [d, J=8.6 Hz, 1H, C(7')H] and 7.28-7.32 [m, 1H, C(4’)H]; 13C NMR (CDCI3) 5 3.8 
[NCH2CH(CH2CH2)], 4.3 [NCH2CH(CH2CH2)], 9.2 [NCH2CH(CH2CH2)], 23.5 [C(10)]> 24.9 
(CH2CN), 28.9 [C(15)], 31.4 [C(8)], 44.1 [C(16>], 49.9 [quaternary C(13)], 59.5 [C(18)], 62.5 
[C(9)], 73.1 [quaternary C(14)], 84.9 [C(5)], 112.2 [C(7’)], 117.4 (CN), 118.3 [C(2)], 119.1 
[C(4’)J, 119.3 [C(1)], 120.2 [C(5’)], 122.3 [C(6’)], 124.5 [quaternary C(11)], 128.1 [C(9’)], 128.2 
[C(7)]p 130.7 [quaternary C(12)], 130.9 [C(8’)], 137.0 [quaternary C(3)], 139.9 [quaternary 
C(6)], and 143.5 [quaternary C(4)].
Fig. 4 Possible positions of NH groups able to form hydrogen bonds with Glu 297
Fig. 5 Ionic interactions and hydrogen bonds between naltrindole and the K-opioid receptor




Fig. 7 Hydrophobic interactions between alkyl amides (130-132) and the K-receptor
Fig 8 Hydrophobic interactions between aromatic amides (60-63) and the K-receptor (clockwise from top left 60, 61,63,62)
Fig.10 Ionic interactions and H-bonds between propyl reverse amidine (72) and the K-receptor
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Fig. 13 Hydrophobic interactions between amines (76, 98) and the K-receptor
Fig. 17 Hydrophobic interactions between norBNI (40) and the K-receptor

Fig. 23 Ionic interactions and H-bonds between urea (87) and the p-receptor
Fig. 25 Ionic interactions and H-bonds between urea (86) and the ^-receptor
